



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Board Meeting

February 12, 2014

NOTE: Pursuant to the Open Meetings Law at La. R.S. 42:16, the Board may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



NOTICE IS HEREBY GIVEN that a meeting of the Board has been ordered and called for 10:00 a.m. on Wednesday, February 12, 2014 at the Board office, for the purpose to wit:

AGENDA

NOTE: This agenda is tentative until 24 hours in advance of the meeting, at which time the most recent revision becomes official.

Revised 02-07-2014

1. Call to Order
2. Invocation & Pledge of Allegiance
3. Quorum Call
4. Call for Additional Agenda Items
5. Consideration of Minutes
6. Report on Action Items
7. Confirmation of Acts
8. Opportunity for Public Comment
9. Committee Reports
 - A. Finance – Mr. Pitre
 - Consideration of Interim Report for Fiscal Year 2013-2014
 - B. Application Review – Mr. Soileau
 - Consideration of Committee Recommendations re Applications
 - C. Reciprocity – Ms. Hall
 - Consideration of Committee Recommendations re Applications
 - D. Violations – Mr. Bond
 - Consideration of Proposed Voluntary Consent Agreements
 - E. Impairment – Mr. Rabb
 - Consideration of Committee Recommendations re Applications
 - F. Reinstatement – Ms. Melancon
 - Consideration of Committee Recommendations re Applications
 - G. Tripartite – Mr. Burch
 - H. Regulation Revision – Mr. McKay
 - Consideration of Regulatory Proposal 2014-A ~ PMP Delegates
 - Consideration of Regulatory Proposal 2014-B ~ Veterinarian Exclusion from PMP
 - Consideration of Legislative Proposal 2014-A ~ CDS Schedule Update
 - Consideration of Legislative Proposal 2014-B ~ PMP Data Reporting
 - I. Executive – Mr. Aron
 - Consideration of Proposed Contracts & Agreements
10. Staff Reports
 - J. Prescription Monitoring Program – Mr. Fontenot
 - K. General Counsel – Mr. Finalet
 - Consideration of Proposed Voluntary Surrenders and Consent Agreements
 - L. Executive Director – Mr. Broussard
11. Announcements
12. Recess

NOTE: Pursuant to the Open Meetings Law at La. R.S. 42:16, the Board may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.

Acronyms

AACP	American Association of Colleges of Pharmacy
AAPS	American Association of Pharmaceutical Scientists
AAPT	American Association of Pharmacy Technicians
ACA	American College of Apothecaries
ACCME	Accreditation Council for Continuing Medical Education
ACCP	American College of Clinical Pharmacy
ACE	Advisory Committee on Examinations (NABP)
ACPE	Accreditation Council for Pharmacy Education
ADA	American Dental Association
ADC	automated dispensing cabinet
ADS	automated dispensing system
AFDO	Association of Food & Drug Officials
AFPE	American Foundation for Pharmaceutical Education
AIHP	American Institute of the History of Pharmacy
AMA	American Medical Association
AMCP	Academy of Managed Care Pharmacy
AMS	automated medication system
APEC	Australian Pharmacy Examining Council
APhA	American Pharmacists Association
APPE	advanced pharmacy practice experience
ASAE	American Society of Association Executives
ASAP	American Society for Automation in Pharmacy
ASCP	American Society of Consultant Pharmacists
ASHP	American Society of Health-System Pharmacists
ASPL	American Society for Pharmacy Law
AVMA	American Veterinary Medical Association
AWARxE	NABP consumer protection program
BNDD	Bureau of Narcotics and Dangerous Drugs
BPS	Board of Pharmacy Specialties
CAC	Citizen Advocacy Center
CCAPP	Canadian Council for Accreditation of Pharmacy Programs
CCGP	Commission for Certification in Geriatric Pharmacy
CDC	Centers for Disease Control and Prevention
CDER	Center for Drug Evaluation and Research
CDTM	collaborative drug therapy management
CDS	controlled dangerous substances
CE	continuing education
CFR	Code of Federal Regulations
CHPA	Consumer Healthcare Products Association
CLEAR	Council on Licensure, Enforcement and Regulation
CMI	consumer medication information
CMS	Centers for Medicare and Medicaid Services
CPD	continuing professional development
CPhA	Canadian Pharmacists Association
CPSC	Consumer Product Safety Commission
DEA	Drug Enforcement Administration
DEQ	La. Department of Environmental Quality
DHH	La. Department of Health and Hospitals
DME	durable medical equipment

DMEPOS	durable medical equipment, prosthetics, orthotics, and supplies
DNV	Det Norske Veritas (Norwegian accreditation organization)
DSM	disease state management
EDK	emergency drug kit
ELTP	Electronic Licensure Transfer Program (NABP)
EPA	Federal Environmental Protection Agency
EPCS	Electronic Prescribing of Controlled Substances (DEA)
ETS	Educational Testing Service
EU	European Union
ExCPT	Examination for the Certification of Pharmacy Technicians
FARB	Federation of Associations of Regulatory Boards
FBI	Federal Bureau of Investigation
FD&C	Federal Food, Drug & Cosmetic Act
FDA	Federal Food & Drug Administration
FIP	Federation Internationale Pharmaceutique
FMI	Food Marketing Institute
FPGEC	Foreign Pharmacy Graduate Examination Committee (NABP)
FPGEE	Foreign Pharmacy Graduate Equivalency Examination (NABP)
FSBPT	Federation of State Boards of Physical Therapy
FSMB	Federation of State Medical Boards
FRC	Foreign Pharmacy Graduate Equivalency Examination Review Committee (NABP)
FTC	Federal Trade Commission
GPhA	Generic Pharmaceutical Association
GPO	US Government Printing Office
gTLD	generic top level domain (Internet addresses)
HCFA	Health Care Financing Administration
HDMA	Healthcare Distribution Management Association
HIPAA	Health Insurance Portability and Accountability Act (of 1996)
HIPDB	Healthcare Integrity and Protection Data Bank
HMO	health maintenance organization
IACP	International Academy of Compounding Pharmacists
ICANN	Internet Corporation for Assigned Numbers and Names
ICPT	Institute for the Certification of Pharmacy Technicians
IDOI	Internet Drug Outlet Identification (NABP)
INEOA	International Narcotic Enforcement Officers Association
IOM	Institute of Medicine
IPPE	introductory pharmacy practice experience
ISMP	Institute for Safe Medication Practices
JCPP	Joint Commission of Pharmacy Practitioners
LAMP	Louisiana Academy of Medical Psychologists
LANP	Louisiana Association of Nurse Practitioners
LAPA	Louisiana Academy of Physician Assistants
LBP	Louisiana Board of Pharmacy
LDA	Louisiana Dental Association
LIPA	Louisiana Independent Pharmacies Association
LPA	Louisiana Pharmacists Association
LPTA	Louisiana Physical Therapy Association
LPTB	Louisiana Physical Therapy Board
LSBD	Louisiana State Board of Dentistry
LSBME	Louisiana State Board of Medical Examiners
LSBN	Louisiana State Board of Nursing

LSBOE	Louisiana State Board of Optometry Examiners
LSBPNE	Louisiana State Board of Practical Nurse Examiners
LSBVM	Louisiana State Board of Veterinary Medicine
LSBWDD	Louisiana State Board of Wholesale Drug Distributors
LSHP	Louisiana Society of Health-System Pharmacists
LSMS	Louisiana State Medical Society
LSNA	Louisiana State Nurses Association
LTC	long term care
LTCF	long term care facility
LVMA	Louisiana Veterinary Medical Association
MPJE	Multistate Pharmacy Jurisprudence Examination (NABP)
MRC	MPJE Review Committee (NABP)
NABP	National Association of Boards of Pharmacy
NABP-F	National Association of Boards of Pharmacy Foundation
NABPLAW	National Association of Boards of Pharmacy – Law Database
NACDS	National Association of Chain Drug Stores
NAMSDL	National Alliance for Model State Drug Laws
NAPLEX	North American Pharmacist Licensure Examination (NABP)
NAPRA	National Association of Pharmacy Regulatory Authorities (Canada)
NASCSA	National Association of State Controlled Substance Authorities
NASPA	National Alliance of State Pharmacy Associations
NASPER	National All Schedules Prescription Electronic Reporting Act
NCC MERP	National Coordinating Council for Medication Error Reporting and Prevention
NCPA	National Community Pharmacists Association
NCPDP	National Council for Prescription Drug Programs
NCPIE	National Council on Patient Information and Education
NCPO	National Conference of Pharmaceutical Organizations
NCSBN	National Council of State Boards of Nursing
NCVHS	National Committee on Vital and Health Statistics
NDC	National Drug Code
NDMA	Nonprescription Drug Manufacturing Association
NIPCO	National Institute for Pharmacist Care Outcomes
NISPC	National Institute for Standards in Pharmacist Credentialing
NOCA	National Organization for Competency Assurance
NPA	National Pharmacy Association
NPC	National Pharmaceutical Council
NPDB	National Practitioner Data Bank
NPTA	National Pharmacy Technician Association
NRC	NAPLEX Review Committee (NABP) Federal Nuclear Regulatory Commission
OAL	Optometry Association of Louisiana
OBRA	Omnibus Budget Reconciliation Act
OIG	Office of Inspector General
ONDPCP	Office of National Drug Control Policy
ONDD	Office of Narcotics and Dangerous Drugs
OSHA	Occupational Safety and Health Administration
PARE	Pharmacy Assessment, Remediation and Evaluation (NABP)
PBM	pharmacy benefit management
PCAB	Pharmacy Compounding Accreditation Board
PCCA	Professional Compounding Centers of America
PCMA	Pharmaceutical Care Management Association

PCOA	Pharmacy Curriculum Outcomes Assessment (NABP)
PDMA	Prescription Drug Marketing Act
PEBC	Pharmacy Examining Board of Canada
PhRMA	Pharmaceutical Research and Manufacturers of America
PMP	Prescription Monitoring Program
PMP-i	Prescription Monitoring Program Interconnect (NABP)
PTCB	Pharmacy Technician Certification Board
PTCE	Pharmacy Technician Certification Examination
PTEC	Pharmacy Technician Educators Council
RFID/EPC	Radio Frequency Identification / Electronic Product Code
SAMSHA	Federal Substance Abuse & Mental Health Services Administration
TJC	The Joint Commission
TOEFL	Test of English as a Foreign Language
TOEFL iBT	Test of English as a Foreign Language Internet-based Test
TSE	Test of Spoken English
URAC	Utilization Review Accreditation Commission
USP	United States Pharmacopeia / United States Pharmacopeial Convention
USP DI	US Pharmacopeia Dispensing Information
USP-NF	US Pharmacopeia – National Formulary
VAWD	Verified-Accredited Wholesale Distributors (NABP)
Vet-VIPPS	Veterinary-Verified Internet Pharmacy Practice Sites (NABP)
VIPPS	Verified Internet Pharmacy Practice Sites (NABP)
WHO	World Health Organization
WHPA	World Health Professions Alliance



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Minutes

Regular Meeting

Wednesday, November 6, 2013 at 10:00 a.m.

Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700

Administrative Hearing

Thursday, November 7, 2013 at 8:30 a.m.

Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700

Table of Contents

<u>Agenda Item No.</u>	<u>Description</u>	<u>Page No.</u>
<i>Wednesday, November 6, 2013</i>		
1.	Call to Order	4
2.	Invocation & Pledge of Allegiance	4
3.	Quorum Call	4
4.	Call for Additional Agenda Items	5
5.	Consideration of Minutes	5
6.	Report on Action Items	5
7.	Confirmation of Acts	5
8.	Opportunity for Public Comment	6
9.	Election of Officers	6
10.	Committee Reports	
	A. Finance	6
	B. Application Review	7
	C. Reciprocity	7
	D. Violations	10
	E. Impairment	7
	F. Reinstatement	12
	G. Tripartite	13
	H. Regulation Revision	13
	I. Executive	14
11.	Staff Reports	
	J. Prescription Monitoring Program	15
	K. General Counsel	16
	L. Executive Director	17
12.	Request for Opinion – Return of Dispensed Prescriptions to Clinic Pharmacy (David Raines Community Health Center Pharmacy)	6
13.	Request for Consideration of New Rule to Prohibit Physician Ownership of Pharmacies (The Picard Group)	10
14.	Announcements	18
15.	Recess	18

Table of Contents

<u>Agenda Item No.</u>	<u>Description</u>	<u>Page No.</u>
<i>Thursday, November 7, 2013</i>		
A.	Call to Order	19
B.	Invocation & Pledge of Allegiance	19
C.	Quorum Call	19
D.	Call for Additional Agenda Items	19
E.	Opportunity for Public Comment	19
	Appearances	19
F.	Formal Hearings	21
G.	Report of Violations Committee	10
H.	Report of General Counsel	16
I.	Adjourn	23

A regular meeting of the Louisiana Board of Pharmacy was held on Wednesday, November 6, 2013 in the Boardroom of the Board's office, located at 3388 Brentwood Drive in Baton Rouge, Louisiana. The meeting was held pursuant to public notice, each member received notice, and notice was properly posted.

1. Call to Order

Mr. Carl Aron, President, called the meeting to order at 10:25 a.m.

2. Invocation & Pledge

Mr. Aron called upon Mr. Brian Bond, and he delivered the invocation. Dr. Deborah Simonson then led the group in the recitation of the Pledge of Allegiance.

3. Quorum Call

Mr. Aron then called upon the Secretary, Mr. Bond, to call the roll.

Members Present:

Mr. Carl W. Aron
Mr. Brian A. Bond
Mr. Clovis S. Burch
Mr. Ryan M. Dartez
Ms. Jacqueline L. Hall
Mr. Richard M. Indovina
Mr. Marty R. McKay (late arrival)
Ms. Chris B. Melancon
Ms. Diane G. Milano
Mr. Ronald E. Moore
Mr. Blake P. Pitre
Mr. T. Morris Rabb
Ms. Pamela G. Reed
Mr. Don L. Resweber
Dr. Deborah H. Simonson
Mr. Richard A. Soileau
Mr. Rhonny K. Valentine (late arrival)

Staff Present:

Mr. Malcolm J. Broussard, Executive Director
Mr. Carlos M. Finalet, III, General Counsel
Mr. M. Joseph Fontenot, Assistant Executive Director
Mr. Cary D. Aaron, Pharmacist Compliance Officer
Mr. Stephen L. Collins, Pharmacist Compliance Officer
Mr. Huey J. Savoie, Pharmacist Compliance Officer

Guests:

Ms. Rosamaend Oglesbee – CVS Pharmacies
Mr. David Ruckman – Target Pharmacies
Ms. Mary Staples – NACDS
Mr. Reginald Abrams – David Raines Community Health Center Pharmacy

Mr. Cyrus Miller – Albertson’s Pharmacies
Ms. Susie Murphy – David Raines Community Health Center Pharmacy
Mr. Willie White, III – David Raines Community Health Center Pharmacy
Mr. Carl Gulino – Wal-Mart Stores
Ms. Patricea Angelle – Prescription Compounds
Mr. Danny Donato – Omnicare
Ms. Berkley Durbin – MedicineLouisiana
Ms. Crystal Carter – La Pharmacists Association
Ms. Michelle Dunmiles – Walgreens Pharmacies
Ms. Rebecca LaRochelle – Walgreens Pharmacies
Mr. Bud Courson – Courson Nickel
Mr. Randal Johnson – La. Independent Pharmacies Association
Mr. Greg Waddell – La. State Medical Society
Mr. Max Huff – The Wellness Corner
Mr. Devin Richardson – Wal-Mart Stores
Mr. Eric Vidrine – Professional Arts Pharmacy
Mr. Bradley Howard – Brown & Fortunato

Mr. Bond certified 15 of the 17 members were present, constituting a quorum for the conduct of official business.

4. Call for Additional Agenda Items

Mr. Aron asked if there were any additional agenda items, but none were offered. Mr. Aron then requested authority from the Board to reorder the agenda as necessary for the purpose of adjusting the sequence of various reports or guests. There were no objections to that request.

5. Consideration of Minutes

Mr. Aron reminded the members they had received the draft minutes from the Regular Board Meeting on August 14, 2013, and the Administrative Hearing on August 15, 2013, both of which were held in Baton Rouge, Louisiana. With no objections, he waived the reading thereof. Hearing no requests for amendment or any objection to their approval, Mr. Aron declared the minutes were approved as presented. Mr. Bond reminded the members to sign the Minute Book.

6. Report on Action Items

Mr. Broussard directed the members to the report of the annual legislative audit in their meeting binder. He also provided an update on the three regulatory proposals discussed at the August 27 public hearing, as well as the re-publication of the emergency rule relative to compounding for prescriber use on September 27.

7. Confirmation of Acts

Pursuant to Mr. Aron’s declaration that the officers, committees, and executive director had attended to the business of the Board since the last meeting in accordance with policies and procedures previously approved by the Board, Mr. Burch moved,

Resolved, that the actions taken and decisions made by the Board officers, Board committees, and Executive Director in the general

conduct and transactions of Board business since August 15, 2013 are approved, adopted, and ratified by the entire Board.

The motion was adopted after a unanimous vote in the affirmative.

8. *Opportunity for Public Comment*

Mr. Aron reminded the members and guests the Open Meetings Law requires all public bodies to provide an opportunity for public comment at all meetings and for each agenda item upon which a vote is to be taken. He solicited general comments on non-agenda items from the guests present, and no comments were offered.

9. *Election of Officers*

Mr. Aron reminded the members of their duty to elect officers for the Board during the final Board meeting of the calendar year. He then conducted the election, and the following members assumed their respective offices immediately:

- President – Carl W. Aron
- First Vice President – T. Morris Rabb
- Second Vice President – Marty R. McKay
- Third Vice President – Chris B. Melancon
- Secretary – Brian A. Bond

At this point, Mr. Aron re-ordered the agenda to consider the request for an opinion.

12. *Request for Opinion: Return of Dispensed Prescriptions to Clinic Pharmacy (David Raines Community Health Center Pharmacy [DRCHC])*

Mr. Aron recognized the representatives from the pharmacy: Ms. Susie Murphy, PIC, Mr. Willie White, CEO, and Mr. Reginald Abrams, attorney. Mr. Aron directed the members to the information in their meeting binders, more specifically the most recent inspection report, a copy of the relevant pharmacy policy, and the letter from Ms. Murphy. During the presentation, Ms. Murphy indicated the policy previously provided to the Board had been recently updated, and she circulated a copy of that current version of the policy. The representatives responded to questions from the members. Following a short discussion among the members, Mr. Rabb moved,

Resolved, that the Board approve *DRCHC Pharmacy Policy No. 11-09 ~ Patient Prescription Delivery to Satellite Sites (August 30, 2013)*.

The motion was adopted after a unanimous vote in the affirmative.

At this point, Mr. Aron declared a brief recess. It was noted the Board recessed at 11:25 a.m. and then reconvened at 11:35 a.m. Mr. Aron then resumed the posted agenda.

10. *Committee Reports*

A. *Finance Committee*

Mr. Aron called upon Mr. Pitre for the committee report. Mr. Pitre directed the members to the two documents in their meeting binders:

- *Interim Report for Fiscal Year 2013-2014*
- *Proposed Budget for Fiscal Year 2014-2015*

Mr. Pitre reviewed the current financial report which included data for the first quarter ending September 30, 2013. He responded to questions from the members and tendered the report for information only. He then directed the members to the proposed budget for the following fiscal year. He reported the committee had met the previous day to review the staff proposal in detail before voting to recommend the approval of the proposed budget as presented. He then moved,

Resolved, that the Board approve and adopt the Proposed Budget for Fiscal Year 2014-2015 as presented.

The motion was adopted after a unanimous vote in the affirmative.

Finally, Mr. Pitre expressed his appreciation to the other members of the committee for their work the previous day.

B. Application Review Committee.

Mr. Aron called upon Mr. Soileau for the committee report. Mr. Soileau indicated the committee had not met since the last Board meeting and their next meeting was scheduled for the following week, on November 12.

C. Reciprocity Committee

Mr. Aron called upon Ms. Hall for the committee report. She reported the committee interviewed 24 applicants in the interim since the previous board meeting, and in conformance with the policies and procedures previously approved by the board, had authorized the issuance of pharmacist licenses for those applicants. She noted their names were recorded on the posted committee meeting agenda for that day. She then reported the committee interviewed an additional 23 applicants earlier that day, and their names were also listed on the posted committee agenda, a copy of which was in the meeting binder. She then moved for the Board to approve all 23 applicants for pharmacist licensure by reciprocity. The motion was adopted after a unanimous vote in the affirmative.

Ms. Hall closed her report with appreciation to her fellow committee members for their work earlier that day.

At this point, Mr. Aron re-ordered the agenda to consider the report from the Impairment Committee.

E. Impairment Committee

Mr. Aron called upon Mr. Rabb for the committee report. Mr. Rabb reported the committee met the previous day to consider 13 referrals from staff. Mr. Rabb then presented the following files for Board action.

Scott Nolan Gewin (PST.017104) Mr. Rabb moved to accept the voluntary surrender of the credential. The motion was adopted after a unanimous vote in the affirmative. The Board accepted the voluntary surrender of the credential, resulting in active suspension of the license for an indefinite period of time, effective September 30, 2013.

Sharon Renee Barnes Michael (PST.017155) Mr. Rabb moved to accept the voluntary surrender of the credential. The motion was adopted after a unanimous vote in the affirmative. The Board accepted the voluntary surrender of the credential, resulting in active suspension of the license for an indefinite period of time, effective October 3, 2013.

Randi Lea Cassidy (CPT.010273) Mr. Rabb moved to accept the voluntary surrender of the credential. The motion was adopted after a unanimous vote in the affirmative. The Board accepted the voluntary surrender of the credential, resulting in active suspension of the certificate for an indefinite period of time, effective October 15, 2013.

Noel Gerard Faucheux (PST.011765) Mr. Rabb moved to accept the voluntary surrender of the credential. The motion was adopted after a unanimous vote in the affirmative. The Board accepted the voluntary surrender of the credential, resulting in active suspension of the license for an indefinite period of time, effective October 24, 2013.

William Francis McCarthy, Jr. (PST.013008) Mr. Rabb moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board granted the respondent's request for reinstatement of the previously suspended license, converted the duration of the suspensive period from an indefinite term to a term of five years and suspended the execution of the suspension, then placed the license on probation for five years, effective November 6, 2013, subject to certain terms enumerated in the consent agreement.

Lanny Joseph Richard (PST.011807) Mr. Rabb moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board granted the respondent's request for reinstatement of the previously suspended license, converted the duration of the suspensive period from an indefinite term to a term of five years and suspended the execution of the suspension, then placed the license on probation for five years, effective November 6, 2013, subject to certain terms enumerated in the consent agreement.

Edwin Paul Domingue, Jr. (PST.010459) Mr. Rabb moved to deny the respondent's request for termination of all probationary restrictions. The motion was adopted after a unanimous vote in the affirmative. The Board denied the respondent's request for termination of all probationary restrictions.

LaShunda Renee Williams (CPT.006933) Mr. Rabb moved to grant respondent's request for termination of all probationary restrictions. The motion was adopted after a unanimous vote in the affirmative. The Board removed all probationary restrictions and restored the certificate to active and unrestricted status.

David Collins Evans (PST.014181) Mr. Rabb moved to deny the respondent's request for modification of previously imposed probationary terms. The motion was adopted after a unanimous vote in the affirmative. The Board denied the respondent's request for modification of previously imposed probationary terms.

Steve Larry Wilson, Jr. (PST.015952) Mr. Rabb moved to grant the request for termination of all probationary restrictions. The motion was adopted after a unanimous vote in the affirmative. The Board removed all probationary restrictions and restored the license to active and unrestricted status.

Matthew Paul Dixon (Applicant for Pharmacist License by Reciprocity) Mr. Rabb moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board approved the application for licensure by reciprocity, authorized the issuance of a pharmacist license, suspended the license for five years and suspended the execution of the suspension, and then placed the license on probation for five years, effective November 6, 2013, subject to certain terms enumerated in the consent agreement.

John David May (Applicant for Pharmacist License by Reciprocity) Mr. Rabb moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board approved the application for licensure by reciprocity, authorized the issuance of a pharmacist license, suspended the license for five years and suspended the execution of the suspension, and then placed the license on probation for five years effective November 6, 2013, subject to certain terms enumerated in the consent agreement.

Mr. Rabb informed the members of the results of a recent audit for compliance with probationary restrictions, in particular attendance at AA/NA meetings. For the 20% of pharmacists who failed to document their compliance with the requirements, Mr. Rabb directed each of the respondents to complete the Begin Recovery educational program as operated by Dr. Douglas Cook within six months of the assignment. He suggested the propriety of a standard proposed voluntary consent agreement to be offered to anyone in the future who fails the same type of compliance audit. He then moved,

Resolved, that the Board's administrative officers be authorized to offer a standard proposed voluntary consent agreement to any person on probation who fails a compliance audit of AA/NA meeting attendance; and further, the standard proposed voluntary consent agreement would include the following terms: (1) the issuance of a Letter of Warning; (2) the assessment of a \$250 administrative hearing fee; and (3) a requirement to complete the Begin Recovery educational program as operated by Dr. Douglas

Cook within six months of the assignment date; and further, all such standard proposed voluntary consent agreements accepted by respondents shall be presented to the Board for its approval.

The motion was adopted after a unanimous vote in the affirmative.

Mr. Rabb closed his report with appreciation to his fellow committee members for their work the previous day.

At this point, Mr. Aron declared a luncheon recess. It was noted the Board recessed at 12:10 p.m. and reconvened in open session at 12:55 p.m. Mr. Aron re-ordered the agenda to consider the request for a new rule.

13. Request for Consideration of New Rule to Prohibit Physician Ownership of Pharmacies (The Picard Group)

Mr. Aron recognized Mr. Eric Vidrine and Mr. Bradley Howard, an attorney with Brown & Fortunato, a firm specializing in health care law. Mr. Howard distributed a binder to the members and reviewed the contents therein. He then presented a proposal to prohibit a physician from sending prescriptions to a pharmacy in which he holds a financial interest and requested the development and promulgation of a new rule to that effect. Following a brief discussion, Mr. Resweber moved to refer the topic to the Regulation Revision Committee for its consideration and development of a regulatory proposal. The motion was adopted after a unanimous vote in the affirmative. Mr. Aron referred the request to the Board's Regulation Revision Committee for its consideration.

At this point, Mr. Aron re-ordered the agenda to receive the remainder of the committee reports. It was noted that Mr. Valentine arrived at approximately 1:50 p.m.

10. Committee Reports

D. Violations Committee

Mr. Aron called upon Mr. Bond for the committee report. Mr. Bond reported the committee held an informal conference on August 28-29 to consider their posted agenda which included 8 pharmacists, 3 pharmacy technicians, 4 pharmacy technician candidates and 9 pharmacy permits. Following their interviews and deliberations, the committee took no action on ten cases.

Without objection from the members, Mr. Aron reordered the agenda to consider the proposed voluntary consent agreements originally scheduled for presentation by the Violations Committee during the following day's administrative hearing.

Thursday, November 7, 2013

G. Report of Violations Committee

Mr. Bond presented the following matters for the Board's consideration.

Robert Blake Vidrine (PST.010232) Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board suspended the license for an

indefinite period of time, and further, assessed a fine of \$5,000 plus administrative costs, and further, conditioned the acceptance of any future application for reinstatement of the license upon certain conditions itemized in the consent agreement.

Louisiana CVS Pharmacy, LLC d/b/a CVS Pharmacy No. 7224 (PHY.006153) Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board assessed a fine of \$5,000 plus administrative costs.

Louisiana CVS Pharmacy, LLC d/b/a CVS Pharmacy No. 5432 (PHY.005782) Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board assessed a fine of \$2,500 plus administrative and investigative costs.

Brent Michael Cantrelle (PST.018704) Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board assessed a fine of \$1,500 plus administrative costs.

Barry Joseph Robichaux (PST.010309) Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board extended the active suspension already in place (from a previous unrelated matter earlier in the year) for an indefinite period of time, and further, assessed a fine of \$1,500 plus administrative costs.

Emma Harris Porter (CPT.001663) Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board suspended the certificate for an indefinite period of time, effective August 26, 2013, and further, imposed a permanent prohibition on the acceptance of any future application for reinstatement of the certificate.

Louisiana CVS Pharmacy, LLC d/b/a CVS Pharmacy No. 5331 (PHY.005773) Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board assessed a fine of \$10,000 plus administrative costs.

Louisiana CVS Pharmacy LLC, d/b/a CVS Pharmacy No. 5396 (PHY.005963) Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board assessed a fine of \$10,000 plus administrative costs.

Louisiana CVS Pharmacy, LLC d/b/a CVS Pharmacy No. 4743 (PHY.006485) Mr. Bond moved to approve the proposed voluntary consent

agreement. The motion was adopted after a unanimous vote in the affirmative. The Board assessed a fine of \$10,000 plus administrative costs.

Louisiana CVS Pharmacy, LLC d/b/a CVS Pharmacy No. 5360 (PHY.005774) Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board assessed a fine of \$10,000 plus administrative costs.

Chris Youree Kalstone (PST.010973) Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board issued a Letter of Warning and requested its publication in the Board's quarterly newsletter, and further, assessed a fine of \$2,500 plus administrative and investigative costs.

Michael Glenn Harlton (PTC.020106) Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board revoked the registration.

Mr. Bond indicated the committee was scheduled to meet again on December 11-12, the docket for which listed 11 pharmacists, 5 pharmacy technicians, one pharmacy technician candidates, 13 pharmacy permits, and one DME permit.

He then closed his report with appreciation to the other committee members for their ongoing efforts.

At this point, Mr. Aron resumed the posted agenda and called for the next committee report.

Wednesday, November 6, 2013

F. Reinstatement Committee

Mr. Aron called upon Ms. Melancon for the committee report. She reported the committee had met the previous day to consider six referrals from the staff. She then presented the following files for Board action.

Catina Elizabeth Wyre (CPT.003792) Ms. Melancon moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board granted the respondent's request for reinstatement of the previously lapsed certificate, contingent upon the satisfaction of certain conditions identified in the consent agreement.

Desiree LaRita Craig-Francis (CPT.004513) Ms. Melancon moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board granted the respondent's request for reinstatement of the previously lapsed certificate, contingent upon the satisfaction of certain conditions identified in the consent agreement.

Harold Scott Otwell (PST.015945) Ms. Melancon moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board granted the respondent's request for reinstatement of the previously lapsed license, contingent upon the satisfaction of certain conditions identified in the consent agreement.

Kiana Johnson Middlebrooks (CPT.005442) Ms. Melancon moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board granted the respondent's request for reinstatement of the previously lapsed certificate, contingent upon the satisfaction of certain conditions identified in the consent agreement.

Debbie Jean Spoonhour (PST.017524) Ms. Melancon moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board granted the respondent's request for reinstatement of the previously lapsed license, contingent upon the satisfaction of certain conditions identified in the consent agreement.

April Rhiannon Muth (CPT.004096) Ms. Melancon moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board granted the respondent's request for reinstatement of the previously lapsed certificate, contingent upon the satisfaction of certain conditions identified in the consent agreement.

Ms. Melancon closed her report with appreciation to the other committee members for their work the previous day.

G. Tripartite Committee

Mr. Aron noted the committee had not met since the last Board meeting.

At this point, Mr. Aron declared a brief recess. It was noted the members recessed at 2:20 p.m. and reconvened in open session at 2:40 p.m.

H. Regulation Revision Committee

Since Mr. McKay had not yet arrived at the meeting, Mr. Aron requested Mr. Broussard to provide the committee's report. Mr. Broussard reported the committee had not met since the previous Board meeting but that their next meeting was scheduled for the following week, on November 13.

Mr. Broussard reminded the members the Board conducted a public hearing on August 27 to receive comments and testimony on three separate regulatory projects. He reported the project relative to preferential licensing for military personnel elicited no comments or testimony, and further, that the project relative to penal pharmacy permit revision had elicited one comment and request for non-substantive amendment, to which the Board agreed, and further, that both of those projects had been submitted to the legislative oversight committee and were scheduled for publication as final rules in the

November 2013 edition of the Louisiana Register.

Mr. Broussard then reported the project relative to collaborative drug therapy management had elicited several comments and testimonials at the public hearing. He directed the members to a compilation of the comments and testimony in their meeting binder. He then reminded them of their duty to consider the comments and testimony and then determine whether any changes to the original proposal were necessary, and secondly, to provide guidance to the staff for the required responses to the commentators.

Mr. Broussard then led the discussion guiding the members through each of the submissions listed in the compilation. Following their review and deliberations, the members determined that no changes to the original proposal were necessary, and further, they provided guidance to staff on how to respond to each of the commentators.

It was noted that Mr. McKay arrived at the meeting at 3:05 p.m.

Finally, Mr. McKay expressed his appreciation to the other members of the committee for their ongoing efforts.

I. Executive Committee

Mr. Aron informed the members the committee had met the previous day to consider the matters on their posted agenda. With respect to the current policy on salary administration for the office staff, Mr. Aron indicated the committee reviewed a proposed revision to that policy and he called upon Mr. Rabb for the committee's recommendation. Mr. Rabb moved to approve the proposed revision, Policy No. II.A.6 – Flexible Special Entrance Rates for Salaries. The motion was adopted after a unanimous vote in the affirmative.

With respect to the office's administrative operations, the committee reviewed the new legislation relative to non-resident pharmacies as well as the current administrative procedures. He informed the members the committee had directed staff to solicit a proposal from the National Association of Boards of Pharmacy (NABP) for the inspection of non-resident pharmacies and then refer that proposal to the Board for its consideration. The committee also requested the insertion of an article in the January 2014 edition of the Board's newsletter advising all pharmacies that the renewal of a pharmacy permit for Calendar Year 2015 and beyond will require the date of the most recent inspection to be less than three years prior to the date of the renewal application. The committee also requested that the criminal background check requirement be applied to all applicants for pharmacy permits.

With respect to the administrative operations relative to the processing of applications for pharmacist licensure by reciprocity, the committee reviewed staff research on the number of states still requiring mandatory interviews for all reciprocity applicants. There are seven states, including Louisiana, that still require mandatory interviews for all applicants. Another 15 states reserve the right to require an interview based on information contained within the application. Mr. Aron requested discussion among the members as to

whether they wished to retain the mandatory requirement for a face-to-face interview. Several members suggested the Board should reserve the right to require an interview but that perhaps it was not necessary for a mandatory interview for all applicants. Mr. Aron referred the matter to the Reciprocity Committee and requested their assistance on the development of a proposed policy revision relative to mandatory interviews for reciprocity applicants.

Finally, Mr. Aron completed his report with appreciation to his fellow officers for their ongoing efforts.

11. Staff Reports

J. Prescription Monitoring Program

Mr. Aron called upon Mr. Fontenot for the report. He directed the members to the quarterly statistical report in their meeting binder. He reported on the number of prescription transactions reported to the database, and the number of prescribers and dispensers who had acquired access privileges. He also reported on the number of queries made by those prescribers and dispensers, as well as law enforcement and regulatory agencies.

He reminded the members about the 2009 change in the PMP law that authorized the Board to issue waivers to the duty to report data to the program. He then directed the members to a list of 15 pharmacies requesting such a waiver. Ms. Melancon moved,

Resolved, to authorize the issuance of PMP reporting waivers to:

- > PHY.005250-NR – Cystic Fibrosis Services;
 - > PHY.006125-HOS – Promise Hospital Pharmacy;
 - > PHY.006472-NR – Advanced Pharmacy;
 - > PHY.006567-NR – Henry Schein Animal Health Supply;
 - > PHY.006585-IR – HPC Biologicals;
 - > PHY.006615-NR – JCB Laboratories;
 - > PHY.006630-NR – Amber Pharmacy;
 - > PHY.006665-NR – QPHARxMACY;
 - > PHY.006685-HOS – LSU Health Baton Rouge – Surgical Center Pharmacy;
 - > PHY.006696-NRN – Cardinal Health 414;
 - > PHY.006706-NR – Advantage Pharmacy;
 - > PHY.006737-NR – EntrustTx;
 - > PHY.006744-HOS – Our Lady of the Lake Outpatient Infusion Pharmacy at Picardy;
 - > PHY.006728-HOS – University Medical Center Management Corporation (Interim LSU Hospital); and
 - > PHY.006608-NR – VetRxDirect,
- once they have executed the standard consent agreement for that purpose.

The motion was adopted after a unanimous vote in the affirmative.

Finally, Mr. Fontenot indicated the completion of his report.

K. Report of General Counsel

Without objection from the members, Mr. Aron reordered the agenda to consider the proposed voluntary consent agreements originally scheduled for presentation by Mr. Finalet during the following day's administrative hearing.

Thursday, November 7, 2013

H. Report of General Counsel

Mr. Finalet presented the following matters for the Board's consideration.

Tony Xavier Neustadler (PTC.019472) Mr. McKay moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board revoked the registration, and further, issued a permanent prohibition on the acceptance of any future application for the reinstatement of the registration or for any other credential issued by the Board.

Jade Mychel Schultz (CPT.008106) Mr. McKay moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board revoked the certificate, and further, issued a permanent prohibition on the acceptance of any future application for the reinstatement of the certificate or for any other credential issued by the Board.

LaToya Michelle Franklin (CPT.007151) Mr. McKay moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board revoked the certificate, and further, issued a permanent prohibition on the acceptance of any future application for the reinstatement of the certificate or for any other credential issued by the Board.

Edozie Chukwudinma Okereke (CDS.025714-DPM) Mr. McKay moved to suspend the CDS license based on the suspension of his medical license. The motion was adopted after a unanimous vote in the affirmative. The Board suspended the CDS license for an indefinite period of time effective July 15, 2013.

Randy Wayne Head (CDS.024040-MD) Mr. McKay moved to suspend the CDS license based on the suspension of his medical license. The motion was adopted after a unanimous vote in the affirmative. The Board suspended the CDS license for an indefinite period of time effective September 4, 2013.

Barbara Ann Noguchi (CDS.023751-MD) Mr. McKay moved to suspend the CDS license based on the suspension of her medical license. The motion was adopted after a unanimous vote in the

affirmative. The Board suspended the CDS license for an indefinite period of time effective August 19, 2013.

Donald Peter Auzine, II (CDS.028735-MD) Mr. McKay moved to revoke the CDS license based on the revocation of his medical license. The motion was adopted after a unanimous vote in the affirmative. The Board revoked the CDS license effective August 19, 2013.

Linda Camille Bunch (CDS.016907-MD) Mr. McKay moved to suspend the CDS license based on the suspension of her medical license. The motion was adopted after a unanimous vote in the affirmative. The Board suspended the CDS license for an indefinite period of time effective September 18, 2013.

Don Francis Peterson (CDS.019052-MD) Mr. McKay moved to suspend the CDS license based on the voluntary surrender of his federal registration to the U.S. Drug Enforcement Administration. The motion was adopted after a unanimous vote in the affirmative. The Board suspended the CDS license for an indefinite period of time effective October 23, 2013.

At this point, Mr. Aron resumed the posted agenda, still within the Report of the General Counsel.

Wednesday, November 6, 2013

Mr. Finalet then reported on the status of the pending litigation, as well as an article in a recent edition of the state pharmacy association journal.

Finally, Mr. Finalet indicated the completion of his report.

L. Report of Executive Director

Mr. Aron called upon Mr. Broussard for the report. Mr. Broussard directed the members to his report which was posted in the Boardroom Library prior to the meeting; it was also included in the meeting binder. He reviewed the following topics:

- Meeting Activity
- Reports
 - Census Reports – Credentials & Compliance Divisions
 - Production Reports – Credentials Division
 - Exceptions Report
 - Annual Audit Report from Legislative Auditor
- Examinations
 - MPJE
 - NAPLEX
 - PTCB
- Operations
 - Credentials Division

Compliance Division
Administrative Division

- State Activities
 - 2013 Legislature
 - Board of Nursing
 - Board of Medical Examiners
- National Activities
 - National Association of Boards of Pharmacy (NABP)
 - NABP-AACP District 6 Annual Meeting
 - MALTAGON
- International Activities
 - International Pharmaceutical Federation (FIP)
 - World Health Professions Alliance (WHPA)

14. *Announcements*

Mr. Aron informed the members of recent accomplishments by Mr. Joe Fontenot, Assistant Executive Director. Having completed his one year term as Secretary of the Alliance of States with Prescription Monitoring Programs (ASPMP), he was elected to a one year term as Vice President of that organization during their recent annual meeting in October. During the annual meeting of the National Association of State Controlled Substance Authorities (NASCSA), which was also held in October, Mr. Fontenot was elected to a two year term as a member of the Executive Committee. Finally, he continues to represent Louisiana on the Prescription Monitoring Program (PMP) Work Group at the National Association of Boards of Pharmacy (NABP). In reciting Mr. Fontenot's accomplishments, Mr. Aron indicated his national service benefits the Louisiana Board of Pharmacy and its Prescription Monitoring Program and expressed his appreciation to Mr. Fontenot. The members expressed their appreciation with a round of applause.

Mr. Aron directed the members to the announcements in their meeting binder, which included the tentative dates for the board meetings in Calendar Year 2014.

15. *Recess*

Having completed the tasks itemized on the posted agenda, with no further business pending before the Board, and without objection, Mr. Aron recessed the meeting at 3:50 p.m.

* * * * *

An Administrative Hearing was convened on Thursday, November 7, 2013 in the Boardroom of the Board's office, located at 3388 Brentwood Drive in Baton Rouge, Louisiana. The hearing was held pursuant to public notice, each member received notice, each respondent received notice (unless specifically stated otherwise in the official transcript), and notice was properly posted.

A. Call to Order

Mr. Aron called the meeting to order at 8:20 a.m.

B. Invocation & Pledge of Allegiance

Mr. Aron called upon Mr. Bond for the invocation, then Mr. Valentine led the group in the recitation of the Pledge of Allegiance

C. Quorum Call

Mr. Aron called upon Secretary Bond and he called the roll. After doing so, he certified 14 of the 17 members were present, constituting a quorum for the conduct of official business. Ms. Melancon, Mr. Rabb, and Ms. Reed were absent.

D. Call for Additional Agenda Items

Mr. Aron asked if there were any additional agenda items; none were requested. At his request, the members granted Mr. Aron authority to re-order the agenda with respect to the sequence of cases, witnesses, and other items of business.

E. Opportunity for Public Comment

Mr. Aron reminded the members and guests the Open Meetings Law requires all public bodies to provide an opportunity for public comment at all meetings and prior to the vote on each agenda item. He solicited comments from the guests, but none were offered.

Appearances

Mr. Aron declared the Administrative Hearing in session, and then served as the Hearing Officer. Mr. Carlos Finalet served as the Prosecuting Attorney, Ms. Susan Erkle was the Official Recorder, and Mr. Malcolm Broussard served as the Hearing Clerk. Without objection, Mr. Aron waived the reading of the posted agenda and instead directed the insertion thereof into these minutes. The posted agenda is re-created here.

A G E N D A

NOTE: This agenda is tentative until 24 hours in advance of the meeting, at which time the most recent revision becomes official.

Revised 10-28-2013

A. Call to Order

B. Invocation & Pledge of Allegiance

C. Quorum Call

D. Call for Additional Agenda Items

E. Opportunity for Public Comment

F. Formal Hearings

01. CPT.004539 – Charlene Marie Fletcher

Case No. 13-0235

02. CPT.008519 – Javondra Marie Raby

Case No. 13-0143

G. Report of Violations Committee – Consideration of Voluntary Consent Agreements

03.	PST.010232 – Robert Blake Vidrine	Case No. 13-0024
04.	PHY.006153 – Louisiana CVS Pharmacy, LLC d/b/a CVS Pharmacy No. 7224	Case No. 13-0133
05.	PHY.005782 – Louisiana CVS Pharmacy, LLC d/b/a CVS Pharmacy No. 5432	Case No. 13-0056
+		
06.	PST.018704 – Brent Michael Cantrelle	Case No. 13-0157
+		
07.	PST.010309 – Barry Joseph Robichaux	Case No. 13-0170
08.	CPT.001663 – Emma Harris Porter	Case No. 12-0156
09.	PHY.005773 – Louisiana CVS Pharmacy, LLC d/b/a CVS Pharmacy No. 5331	Case No. 13-0262
10.	PHY.005963 – Louisiana CVS Pharmacy, LLC d/b/a CVS Pharmacy No. 5396	Case No. 13-0263
11.	PHY.006485 – Louisiana CVS Pharmacy, LLC d/b/a CVS Pharmacy No. 4743	Case No. 13-0264
12.	PHY.005774 – Louisiana CVS Pharmacy, LLC d/b/a CVS Pharmacy No. 5360	Case No. 13-0265
13.	PST.010973 – Chris Youree Kalstone	Case No. 12-0292
14.	PTC.020106 – Michael Glenn Harlton	Case No. 13-0178

H. Report of General Counsel

Consideration of Voluntary Consent Agreements

15.	PTC.019472 – Tony Xavier Neustadter	Case No. 13-0296
16.	CPT.008106 – Jade Mychel Schultz	Case No. 13-0305
17.	CPT.007151 – LaToya Michelle Franklin	Case No. 13-0346

Consideration of Voluntary Surrenders

Consideration of CDS Licenses for Disciplined Practitioners

18.	CDS.025714-DPM – Edozie Chukwudinma Okereke	Case No. 13-0272
19.	CDS.024040-MD – Randy Wayne Head	Case No. 13-0408
20.	CDS.023751-MD – Barbara Ann Noguchi	Case No. 13-0409
21.	CDS.028735-MD – Donald Peter Auzine, II	Case No. 13-0410
22.	CDS.016907-MD – Linda Camille Bunch	Case No. 13-0417
23.	CDS.019052-MD – Don Francis Peterson	Case No. 13-0428

I. Adjourn

F. Formal Hearings

Mr. Aron excused Mr. Bond and Mr. Burch from participating on the Board's hearing panel for these hearings due to their prior knowledge of the cases, which were previously considered by the Violations Committee. Mr. Aron called upon Mr. Finalet and he presented the following cases to the members of the Board's hearing panel for its consideration.

Javondra Marie Raby (CPT.008519) Mr. Finalet appeared for the Board and noted the absence of the respondent. After verifying the respondent's absence, Mr. Aron ruled the hearing would continue as scheduled in the form of a default proceeding. Mr. Finalet presented an opening statement, no witnesses and five exhibits. He then offered a closing statement, proffered proposed findings of fact, conclusions of law and board order, and then tendered the matter to the hearing panel for its consideration. Mr. McKay moved to enter into executive session for the purpose of deliberating the disciplinary matter and discussing the respondent's professional competency. The motion was adopted after a unanimous roll call vote in the affirmative.

It was noted the hearing panel entered into executive session at 8:30 a.m. and then returned to open session at 8:45 a.m.

Ms. Hall moved,

Resolved, that the Board's hearing panel, having heard the testimony and considered the evidence, accept the Findings of Fact as proposed by the Prosecuting Attorney and modify them by amending Item 3 to correct a typographical error and adopt the amended findings as our own, and then enter them into the hearing record.

The motion was adopted after a unanimous vote in the affirmative. Ms. Hall then moved,

Resolved, that the Board's hearing panel accept the Conclusions of Law as proposed by the Prosecuting Attorney, adopt them as our own, and then enter them into the hearing record.

The motion was adopted after a unanimous vote in the affirmative. Ms. Hall then moved,

Resolved, that the hearing panel enter the following order at this time:

It is ordered, adjudged, and decreed that Louisiana Pharmacy Technician Certificate No. 8519, held by Javondra Marie Raby, shall be and is hereby revoked, effective on the entry of this order; and further, the respondent shall pay the following assessments:

- (1) A fine of \$5,000;
- (2) The administrative hearing fee of \$250; and
- (3) The investigative and hearing costs, including the costs

of the prosecuting attorney and the official recorder; and

It is further ordered, the acceptance of any future application for the reinstatement of this certificate, or any application for any other credential issued by the Board, shall be conditioned upon the satisfaction of the following terms:

- (1) Respondent shall have paid all assessments levied herein; and
- (2) Respondent shall have no legal or disciplinary matters pending against her in any jurisdiction.

The motion was adopted after a unanimous vote in the affirmative.

Charlene Marie Fletcher (CPT.004539) Mr. Finalet appeared for the Board and noted the absence of the respondent. After verifying the respondent's absence, Mr. Aron ruled the hearing would continue as scheduled in the form of a default proceeding. Mr. Finalet presented an opening statement, no witnesses and four exhibits. He then offered a closing statement, proffered proposed findings of fact, conclusions of law and board order, and then tendered the matter to the hearing panel for its consideration. Mr. Moore moved to enter into executive session for the purpose of deliberating the disciplinary matter and discussing the respondent's professional competency. The motion was adopted after a unanimous roll call vote in the affirmative.

It was noted the hearing panel entered into executive session at 9:00 a.m. and then returned to open session at 9:10 a.m.

Ms. Hall moved,

Resolved, that the Board's hearing panel, having heard the testimony and considered the evidence, accept the Findings of Fact as proposed by the Prosecuting Attorney, adopt them as our own, and then enter them into the hearing record.

The motion was adopted after a unanimous vote in the affirmative. Ms. Hall then moved,

Resolved, that the Board's hearing panel accept the Conclusions of Law as proposed by the Prosecuting Attorney, adopt them as our own, and then enter them into the hearing record.

The motion was adopted after a unanimous vote in the affirmative. Ms. Hall then moved,

Resolved, that the Board's hearing panel enter the following order at this time:

It is ordered, adjudged, and decreed that Louisiana Pharmacy Technician Certificate No. 4539, held by Charlene Marie Fletcher, shall be and is hereby revoked, effective on the entry of this order; and further, the respondent shall pay the following assessments:

- (1) A fine of \$5,000;
- (2) The administrative hearing fee of \$250; and

- (3) The investigative and hearing costs, including the costs of the prosecuting attorney and the official recorder; and

It is further ordered, the acceptance of any future application for the reinstatement of this certificate, or any application for any other credential issued by the Board, shall be conditioned upon the satisfaction of the following terms:

- (1) Respondent shall have paid all assessments levied herein; and
- (2) Respondent shall have no legal or disciplinary matters pending against her in any jurisdiction.

The motion was adopted after a unanimous vote in the affirmative.

Mr. Finalet indicated completion of the formal hearings.

I. Adjourn

Mr. Pitre moved to adjourn. Having completed the tasks itemized on the posted agenda, with no further business pending before the Board, and without objection, Mr. Aron adjourned the hearing at 9:15 a.m.

Respectfully submitted,

Brian A. Bond
Secretary



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Finance Committee

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Finance Committee

Interim Report Fiscal Year 2013-2014

February 12, 2014

Blake P. Pitre
Chair

Louisiana Board of Pharmacy
 FY 2013-2014
 Statement of Assets, Liabilities, Equity

FY 12-13
 Q4 06/30/2013

FY 13-14
 Q2 12/31/2013

ASSETS

> Current Assets

* Cash

General Operations

Whitney Bank

147,965

160,272

Iberia Bank

906,642

1,654,649

PMP Operations

Whitney Bank

12,167

0

Iberia Bank

484,309

0

Hurricane Relief Fund - Whitney Bank

83,054

83,096

Reserve Funds

General Account

1,467,662

504,716

OPEB Account

0

970,866

* Total Cash

3,101,799

3,373,599

* Prepaid Expenses

18,695

0

* Total Prepaid Expenses

18,695

0

* Accounts Receivable

4,685

0

* Total Accounts Receivable

4,685

0

Total Current Assets

3,125,179

3,373,599

> Fixed Assets

Land: Lot 5-A, Towne Center Business Park

709,080

709,080

Land: Lot 1-A-2, Leonard Place Subdivision

295,860

295,860

Office Building - 3388 Brentwood Drive

1,049,655

1,052,255

Office Equipment

190,669

195,597

Furniture

144,510

146,280

Software: Licensure & Website

408,560

408,560

Accumulated Depreciation

(533,294)

(605,343)

Total Fixed Assets

2,265,040

2,202,289

TOTAL ASSETS

5,390,219

5,575,888

LIABILITIES

> Current Liabilities

Accrued salaries and benefits

67,036

0

Unemployment taxes payable

57

19

State taxes withheld

3,423

4,730

State retirement withheld

0

0

Accounts payable

4,319

0

Interest payable

5,555

0

Compensated absences (ST)

51,306

51,306

Building Loan @ Iberia Bank (ST)

71,150

71,150

Total Current Liabilities

202,846

127,205

Louisiana Board of Pharmacy
 FY 2013-2014
 Statement of Assets, Liabilities, Equity

FY 12-13
 Q4 06/30/2013

FY 13-14
 Q2 12/31/2013

> Long Term Liabilities		
Compensated absences (LT)	75,562	75,562
Other Post Employment Benefits (OPEB) Payable	929,700	925,404
Building Loan @ Iberia Bank (LT)	<u>961,058</u>	<u>925,965</u>
<i>Total Long Term Liabilities</i>	<i>1,966,320</i>	<i>1,926,931</i>
 TOTAL LIABILITIES	 2,169,166	 2,054,136
 <u>EQUITY</u>		
Fund Balance - designated	178,905	178,905
Fund Balance @ 06-30-2013	1,525,136	1,841,269
Invested in Fixed Assets	1,232,833	1,205,175
Net Income/Loss	<u>284,179</u>	<u>296,403</u>
TOTAL EQUITY	3,221,053	3,521,752
 <u>TOTAL LIABILITIES & EQUITY</u>	 <u>5,390,219</u>	 <u>5,575,888</u>

Louisiana Board of Pharmacy
 FY 2013-2014
 Statement of Revenue, Expenses, and Budget Performance

	Revenue		
	FY 12-13 Q4 06/30/2013	FY 13-14 Q2 12/31/2013	FY 13-14 Budget (A#1)
<i>Licenses & Permits</i>			
Pharmacist Renewals	737,100	737,025	737,000
New Pharmacist Licensing Fee	140,100	58,200	140,100
Technician Renewals	295,950	11,250	296,000
Technician Candidate Registrations	33,275	17,875	35,000
Lapsed Credential Fees	43,200	17,400	42,000
Student Registrations	2,560	2,190	3,000
Permits - Pharmacies	251,500	248,575	250,000
Permits - CDS	426,980	178,470	430,000
Permits - Emergency Drug Kits	12,500	1,450	12,500
Permits - Automated Medication Systems	13,500	3,750	13,500
Permits - Durable Medical Equipment	25,500	57,000	25,500
<i>Examinations</i>			
Reciprocity	40,650	23,850	40,000
Technicians	63,000	32,100	63,000
<i>Penalties</i>			
Licenses and Certificates	7,630	2,575	7,500
Permits	11,482	7,162	11,000
<i>Administrative Fees</i>			
Documents: Copies and Certification Fees	3,712	3,751	3,500
Duplicate Credentials	4,205	1,660	4,000
Silver Certificates	400	200	500
Original Certificates	8,700	7,125	10,000
NSF Fees	475	250	500
Handling & Mailing Fees	83	36	150
<i>Sale of Goods & Services</i>			
Law Books	5,960	1,305	6,000
Official Lists of Licensees	6,150	3,000	6,000
USCPSC Inspection Fee	2,250	1,650	2,250
<i>Enforcement Actions</i>			
Hearing Fees	22,250	9,750	24,000
Fines	160,081	72,000	160,000
Investigative Costs	44,133	3,369	45,000
<i>Prescription Monitoring Program</i>			
Assessments	447,650	185,750	448,000
Grants	40,035	0	0
<i>Miscellaneous</i>			
	918	250	1,000
TOTAL REVENUE	2,851,929	1,688,968	2,817,000

Louisiana Board of Pharmacy
 FY 2013-2014
 Statement of Revenue, Expenses, and Budget Performance

		Expenses		
		FY 12-13 Q4 06/30/2013	FY 13-14 Q2 12/31/2013	FY 13-14 Budget (A#1)
<i>Operations</i>	Rentals - Office & Equipment	5,509	(4,880)	18,000
	Equipment Maintenance	2,873	2,387	4,000
	Telephone	14,952	5,562	15,000
	Printing	50,742	29,490	47,500
	Postage	43,007	34,607	40,000
	Civil Service Assessment	3,748	4,236	4,000
	Office Insurance (ORM)	8,927	6,272	9,000
	Dues & Subscriptions	28,417	10,786	20,000
	Office Supply Expenses	18,417	8,606	20,000
	Trust Fund Fees	0	0	0
	Financial Service Charges	42,460	26,964	50,000
	Depreciation of Fixed Assets	136,782	72,049	135,000
	Interest Payments on Building Loan	68,025	26,612	68,000
	Office Meeting Expenses	863	0	1,000
	Utilities	9,563	3,723	10,000
	Miscellaneous	14	0	0
	<i>Acquisitions</i>	13,187	345	2,500
<i>Personal Services</i>	Salaries	975,927	574,478	1,096,000
	Payroll Taxes (FICA + FUTA)	18,552	10,384	22,500
	Retirement Contributions	279,473	177,303	341,000
	Health Insurance (SEGBP)	112,525	60,588	126,000
	Other Post Employment Benefits (OPEB)	84,798	0	85,000
	Board Member Per Diem	30,975	15,600	31,000
<i>Professional Services</i>	Accounting	21,086	14,425	22,000
	Legal	24,593	11,126	25,000
	Information Systems	89,684	82,896	98,000
	Property Management	18,496	7,012	35,000
	Temp. Labor	16,015	11,603	20,000
	Prescription Monitoring Program	323,814	150,291	360,500
<i>Staff Expenses</i>	ED - Travel	4,145	1,964	0
	GC - Travel	5,495	12	0
	CO - Travel	6,600	3,240	7,000
	CO - Rental Cars & Fuel	6,307	5,808	10,000
	CO - Education	7,039	6,110	6,000
	House Staff - Travel	50	0	0
	Mileage	29,501	6,604	25,000
<i>Board Expenses</i>	Meeting Expenses	15,207	8,662	15,000
	Committee Expenses	8,282	2,747	8,000
	Conventions	15,950	11,880	15,000
	Mileage	15,443	5,834	15,000
	President's Expenses	7,626	5,590	10,000
TOTAL EXPENSES		2,565,069	1,400,916	2,817,000

Louisiana Board of Pharmacy
 FY 2013-2014
 Summary of Income Fund Balance Changes

Summary

	FY 12-13 Q4 06/30/2013	FY 13-14 Q2 12/31/2013	FY 13-14 Budget (A#1)
Income Statement			
Total Revenue	2,851,929	1,688,968	2,817,000
Total Expenses	2,565,069	1,400,916	2,817,000
Net Ordinary Income	286,860	288,052	0
Other Income & Expenses			
Investment	(2,726)	8,351	0
Disposl of assets	46	0	0
Net Income	284,180	296,403	0

	FY 12-13 Q4 06/30/2013	FY 13-14 Q2 12/31/2013	FY 13-14 Budget (A#1)
Fund Balance			
Beginning Fund Balance	2,936,874	3,221,054	3,221,054
Total Income	2,849,249	1,697,319	2,817,000
Total Expenses	2,565,069	1,400,916	2,817,000
Ending Fund Balance	3,221,054	3,517,457	3,221,054
Reservations of Fund Balance	750,000	2,162,000	2,162,000
Unreserved Fund Balance	2,471,054	1,355,457	1,059,054

Notes on Reservation of Fund Balance

FY 12-13	Continuing Payroll Obligation	150,000
	Homeland Maintenance	100,000
	Debt Service	<u>500,000</u>
	TOTAL	750,000

FY 13-14	Other Post Employment Benefits Payable	929,700
	Debt Service Payable	1,032,300
	Continuing Payroll Obligations	150,000
	Homeland Maintenance	<u>50,000</u>
	TOTAL	2,162,000

Louisiana Board of Pharmacy
FY 2013-2014
Schedule A - Prescription Monitoring Program

Revenue

		FY 12-13 Q4 06/30/2013	FY 13-14 Q2 12/31/2013	FY 13-14 Budget (A#1)
4620	Grants	40,035	0	
4640	Appropriations, State Government	0		
4660	Assessments	447,650	185,750	448,000
4680	Miscellaneous Revenue	0		
4600	TOTAL REVENUE	487,685	185,750	448,000

Louisiana Board of Pharmacy
FY 2013-2014
Schedule A - Prescription Monitoring Program
Expenses

		FY 12-13 Q4 06/30/2013	FY 13-14 Q2 12/31/2013	FY 13-14 Budget (A#1)
5610	Operations			
5611	Office rent	10,000	10,000	10,000
5612	Equipment rent	0	0	0
5613	Equipment maintenance	0	0	0
5614	Telephone	1,827	689	3,000
5615	Internet access fees	2,500	2,500	2,500
5616	Printing	230	0	1,000
5617	Postage	2,010	414	4,000
5618	Office supplies	1,267	0	2,000
5619	Office meeting expenses	0	0	0
5620	Dues and subscriptions	6,490	750	7,000
5621	Financial service fees	0	0	0
5622	Utilities	0	500	2,000
5623	Miscellaneous	122	0	0
5630	Acquisitions			
5632	Furniture	2,063	0	0
5634	Equipment	195	0	0
5640	Personal Services			
5641	Salaries	139,023	45,261	147,100
5642	Payroll Taxes	2,812	656	3,000
5643	Retirement contributions	36,490	13,918	45,800
5644	Health insurance premiums	6,373	1,621	17,000
5650	Professional Services			
5652	Software Maintenance / Support	33,063	20,917	33,100
	Software Enhancements	0	0	0
	Educational Program Develop.	0	0	0
5654	Data collection	49,332	32,888	49,500
5656	Hosting fees	28,104	18,737	28,000
	PMP Interconnect	0	0	0
5660	Staff Expenses			
5661	Manager travel	1,863	1,427	5,000
5662	Manager mileage	50	0	500
5663	Staff travel	0	0	0
5664	Staff mileage	0	13	0
5670	Advisory Council Expenses	0	0	0
5680	Miscellaneous Expenses	0	0	0
5600	TOTAL EXPENSES	323,814	150,291	360,500
	<i>Net Profit/Loss</i>	163,871	2,096	87,500

Louisiana Board of Pharmacy
 FY 2013-2014
 Schedule B - Hurricane Katrina/Rita Pharmacy Relief Fund

Statement of Assets, Liabilities & Equity

	FY 12-13 Q4 06/30/2013	FY 13-14 Q2 12/31/2013
ASSETS		
Current Assets		
Hancock Bank - Checking Account	<u>83,054</u>	<u>83,096</u>
<u>TOTAL ASSETS</u>	<u>83,054</u>	<u>83,096</u>
LIABILITIES		
Current Liabilities	0	0
EQUITY		
Retained Earnings	82,970	83,054
Net Income	<u>84</u>	<u>42</u>
<u>TOTAL LIABILITIES & EQUITY</u>	<u>83,054</u>	<u>83,096</u>

Statement of Receipts & Disbursements

	FY 12-13 Q4 06/30/2013	FY 13-14 Q2 12/31/2013
RECEIPTS		
FEMA - Funds for payment of claims	8,920,812	8,920,812
FEMA - Administrative allowance	81,103	81,103
Pharmacies - reversal of claims	430,138	430,138
Interest income	<u>21,979</u>	<u>22,021</u>
<u>TOTAL RECEIPTS</u>	<u>9,454,032</u>	<u>9,454,074</u>
DISBURSEMENTS		
Claims paid to pharmacies	8,920,812	8,920,812
Reversed claim funds returned	430,138	430,138
Reversed administrative allowance returned	7,338	7,338
Interest earned on reversed admin. allowance returned	<u>12,690</u>	<u>12,690</u>
<u>TOTAL DISBURSEMENTS</u>	<u>9,370,978</u>	<u>9,370,978</u>
FUND BALANCE	<u>83,054</u>	<u>83,096</u>

Note: These funds are held in an account separate and apart from the Board's operating funds. Further, all recordkeeping is kept separate from the Board's general fund records. At the conclusion of the audit exposure period, any funds remaining will be transferred to the Board's operating account.

Louisiana Board of Pharmacy
FY 2013-2014
Summary of Board Actions

Date	Action
12/11/2012	Original Budget - Finance Committee Approval
12/12/2012	Original Budget - Board Approval
8/13/2013	Budget Amendment #1 - Finance Committee Approval
8/14/2013	Budget Amendment #1 - Board Approval
	Budget Amendment #2 - Finance Committee Approval
	Budget Amendment #2 - Board Approval
	Acceptance of Final Report

Account Number: H5E-049797
 Statement Period: 12/01/2013 - 12/31/2013

Valuation at a Glance

	This Period
Beginning Account Value	\$1,477,779.36
Cash Deposits	105,103.65
Cash Withdrawals	-105,103.65
Dividends/Interest	0.81
Change in Account Value*	-973,217.93
Ending Account Value	\$504,562.24
Estimated Annual Income	\$21.51


* Change in Account Value includes the value of free receives/delivers.

LOUISIANA BOARD OF PHARMACY
 3388 BRENTWOOD DR
 BATON ROUGE LA 70809 - 1700

Your Account Executive:
 JOSEPH BARRECA, JR.
 (504) 310-7364

Asset Allocation

Cash, Money Funds, and Bank Deposits	105,104.11	21%
Fixed Income	399,458.13	79%
Account Total (Pie Chart)	\$504,562.24	100%



Client Service Information

Your Account Executive: X57

JOSEPH BARRECA, JR.
IBERIA FINANCIAL SERVICES
200 W. CONGRESS STREET 1ST FLOOR
LAFAYETTE LA 70501

Contact Information

Telephone Number: (504) 310-7364

Your Account Information

Tax Lot Default Disposition Method

Default Method for Mutual Funds: AVERAGE COST (USING FIRST IN FIRST OUT)

Default Method for Stocks in a Dividend Reinvestment Plan: FIRST IN FIRST OUT

Default Method for all Other Securities: FIRST IN FIRST OUT

Copies of Statement Sent

KOLDER, CHAMPAGNE, SLAVEN & CO

At your request copies of this statement have been sent to the above.

Electronic Delivery

You have not selected any account communications for electronic delivery. To register and turn off paper communications, log in to your account or contact your Account Executive for more information.

Activity Summary (All amounts shown are in base currency: USD)

	This Period	Year-to-Date		This Period	Year-to-Date
Credits					
Securities Bought	0.00	0.00	Securities Bought	0.00	-534,933.12
Total Securities	\$0.00	\$0.00	Total Securities	\$0.00	-\$534,933.12
Dividends and Interest	\$0.81	\$9,541.12	Dividends and Interest	\$0.00	\$0.00
Distributions	\$0.00	\$220,000.00	Distributions	\$0.00	\$0.00
Cash			Cash		
Withdrawals	0.00	0.00	Withdrawals	-105,103.65	-105,103.65
Deposits	105,103.65	245,103.65	Deposits	0.00	0.00
Total Cash	\$105,103.65	\$245,103.65	Total Cash	-\$105,103.65	-\$105,103.65
Total Credits	\$105,104.46	\$474,644.77	Total Debits	-\$105,103.65	-\$640,036.77

Brokerage Account Statement

Statement Period: 12/01/2013 - 12/31/2013

Transactions in Date Sequence

Process/ Settlement Date	Activity Type	Description	Quantity	Price	Accrued Interest	Amount	Ccy
12/13/13	CUSTOMER AUTHORIZED TRANSFER	TRANS TO H5E-077160				-105,103.65	USD
12/13/13	USD999997 CUSTOMER AUTHORIZED TRANSFER	TRANS FRM H5E-077160				105,103.65	USD
12/13/13	USD999997 CUSTOMER AUTHORIZED TRANSFER	ALLY BANK MIDVALE UTAH CTF DEP ACT/365 1.000% 05/26/15 B/E DTD 05/23/12 TRANS TO H5E-077160	-120,000.000			0.00	USD
12/13/13	02005QF57 CUSTOMER AUTHORIZED TRANSFER	BANK OF THE WEST INSTL CTF DEP PROGRAM BOOK ENTRY INSTL CTF DEP 0.000% 12/28/16 B/E DTD 12/28/11 TRANS TO H5E-077160	-89,000.000			0.00	USD
12/13/13	06426XGL2 CUSTOMER AUTHORIZED TRANSFER	BANK OF THE WEST INSTL CTF DEP PROGRAM BOOK ENTRY INSTL CTF DEP 0.000% 12/28/16 B/E DTD 12/28/11 TRANS FRM H5E-077160	89,000.000			0.00	USD
12/13/13	06426XGL2 CUSTOMER AUTHORIZED TRANSFER	BANK OF THE WEST INSTL CTF DEP PROGRAM BOOK ENTRY INSTL CTF DEP 0.000% 04/30/18 B/E DTD 04/29/13 TRANS TO H5E-077160	-155,000.000			0.00	USD
12/13/13	06740AA41 CUSTOMER AUTHORIZED TRANSFER	BARCLAYS BK DEL WILMINGTON CTF DEP ACT/365 ANNUALLY LKD TO S&P 500 0.000% 07/30/18 B/E DTD 07/31/13 TRANS TO H5E-077160	-85,000.000			0.00	USD
12/13/13	06740AA41 CUSTOMER AUTHORIZED TRANSFER	BARCLAYS BK DEL WILMINGTON CTF DEP ACT/365 ANNUALLY LKD TO S&P 500 0.000% 07/30/18 B/E DTD 07/31/13 TRANS FRM H5E-077160	85,000.000			0.00	USD
12/13/13	06740ATS8 CUSTOMER AUTHORIZED TRANSFER	BARCLAYS BK DEL WILMINGTON CTF DEP ACT/365 ZERO CPN LKD PERFORM OF A BSKT 0.000% 05/30/17 B/E DTD 05/31/12 TRANS TO H5E-077160	-83,000.000			0.00	USD
12/13/13	06740AYS2 CUSTOMER AUTHORIZED TRANSFER	BARCLAYS BK DEL WILMINGTON CTF DEP ACT/365 0.000% 04/27/18 B/E DTD 04/30/13 TRANS TO H5E-077160	-160,000.000			0.00	USD
12/13/13	254671BG4 CUSTOMER AUTHORIZED TRANSFER	DISCOVER BK GREENWOOD DEL CTF DEP ACT/365 1.250% 05/23/16 B/E DTD 05/23/12 TRANS TO H5E-077160	-120,000.000			0.00	USD

Transactions in Date Sequence (continued)

Process/ Settlement Date	Activity Type	Description	Quantity	Price	Accrued Interest	Amount	CTY
12/13/13	MONEY MARKET FUND INCOME RECEIVED	GENERAL MNY MKT CL B INCOME REDEEMED				0.35	USD
12/13/13	370990Z28 CUSTOMER AUTHORIZED TRANSFER	GOLDMAN SACHS BK USA NEW YORK CTF DEP ACT/365 1.800% 05/23/17 B/E DTD 05/23/12 TRANS TO H5E-077160	-120,000.000			0.00	USD
12/13/13	38143ASV8 CUSTOMER AUTHORIZED TRANSFER	HUNTINGTON NATL BK COLUMBUS OHIO CTF DEP ACT/365 0.500% 05/27/14 B/E DTD 05/25/12 TRANS TO H5E-077160	-120,000.000			0.00	USD
12/13/13	446438PP2 CUSTOMER AUTHORIZED TRANSFER	IBERIABANK LAFAYETTE LA CTF DEP ACT/365 0.000% 05/31/16 B/E DTD 05/31/11 TRANS TO H5E-077160	-10,000.000			0.00	USD
12/13/13	45083AAV4 CUSTOMER AUTHORIZED TRANSFER	IBERIABANK LAFAYETTE LA CTF DEP ACT/365 0.000% 05/31/16 B/E DTD 05/31/11 TRANS FRM H5E-077160	10,000.000			0.00	USD
12/13/13	45083AAV4 CUSTOMER AUTHORIZED TRANSFER	JPMORGAN CHASE BK NA COLUMBUS OHIO CTF DEP DTD 07/31/2013 ACT/365 AT-MATURITY 0.000% 07/31/18 B/E DTD 07/31/13 TRANS TO H5E-077160	-125,000.000			0.00	USD
12/13/13	48124JS41 CUSTOMER AUTHORIZED TRANSFER	UNION BK N A SAN FRANCISCO CALIF CTF DEP ACT/365 0.000% 12/30/15 B/E DTD 12/30/11 TRANS TO H5E-077160	-88,000.000			0.00	USD
12/13/13	90521AHP6 CUSTOMER AUTHORIZED TRANSFER	UNION BK N A SAN FRANCISCO CALIF CTF DEP ACT/365 0.000% 12/30/15 B/E DTD 12/30/11 TRANS FRM H5E-077160	88,000.000			0.00	USD
12/13/13	90521AHP6 CUSTOMER AUTHORIZED TRANSFER	UNION BK N A SAN FRANCISCO CALIF CTF DEP ACT/365 0.000% 12/29/14 B/E DTD 12/28/11 TRANS TO H5E-077160	-88,000.000			0.00	USD
12/13/13	90521AHS0 CUSTOMER AUTHORIZED TRANSFER	UNION BK N A SAN FRANCISCO CALIF CTF DEP ACT/365 0.000% 12/29/14 B/E DTD 12/28/11 TRANS FRM H5E-077160	88,000.000			0.00	USD
12/13/13	90521AHS0 CUSTOMER AUTHORIZED TRANSFER	UNITED STATES TREAS NTS INFLATION INDEXED NOTES TIPS 1.250% 07/15/20 B/E DTD 07/15/10 TRANS TO H5E-077160	-25,000.000			0.00	USD
12/13/13	912828NM8 CUSTOMER AUTHORIZED TRANSFER	UNITED STATES TREAS NTS INFLATION INDEXED NOTES TIPS 1.250% 07/15/20 B/E DTD 07/15/10 TRANS FRM H5E-077160	25,000.000			0.00	USD
12/31/13	MONEY MARKET FUND INCOME RECEIVED	GENERAL MNY MKT CL B				0.46	USD
370990Z28							
Total Value of Transactions						\$0.00	\$0.81

The price and quantity displayed may have been rounded.

Not Guaranteed by the Bank. Not FDIC Insured. Not a Deposit.

Statement Period: 12/01/2013 - 12/31/2013

Portfolio Holdings

Description	Quantity	Opening Balance	Closing Balance	Accrued Income	Income This Year	30-Day Yield
Cash, Money Funds, and Bank Deposits 21.00% of Portfolio						
Cash Balance		115.00	0.00			
Money Market						
GENERAL MNY MKT FUND CL B	105,104.110	104,988.30	105,104.11	0.00	21.51	0.01%
Total Money Market		\$104,988.30	\$105,104.11	\$0.00	\$21.51	
Total Cash, Money Funds, and Bank Deposits		\$105,103.30	\$105,104.11	\$0.00	\$21.51	

Description	Quantity	Market Price	Market Value	Accrued Interest	Estimated Yield
Fixed Income 79.00% of Portfolio (In Maturity Date Sequence)					
Certificates of Deposit					
UNION BK N A SAN FRANCISCO CALIF CTF DEP ACT/365 0.000% 12/29/14 B/E DTD 12/28/11 Security Identifier: 90521AHSO	88,000.000	105.0800	92,470.40	0.00	
UNION BK N A SAN FRANCISCO CALIF CTF DEP ACT/365 0.000% 12/30/15 B/E DTD 12/30/11 INTEREST PAYABLE AT MATURITY Security Identifier: 90521AHP6	88,000.000	111.1400	97,803.20	0.00	
IBERIA/BANK LAFAYETTE LA CTF DEP ACT/365 0.000% 05/31/16 B/E DTD 05/31/11 1ST CPN DTE 11/29/11 CPN PMT SEMI ANNUAL ON MAY 31 AND NOV 31 Security Identifier: 45083AAV4	10,000.000	102.0900	10,209.00	0.00	
BANK OF THE WEST INSTL CTF DEP PROGRAM BOOK ENTRY INSTL CTF DEP 0.000% 12/28/16 B/E DTD 12/28/11 1ST CPN DTE 12/28/12 CPN PMT ANNUALLY ON DEC 28 Security Identifier: 06426XCL2	89,000.000	96.8900	86,232.10	0.00	

Portfolio Holdings (continued)

Description	Quantity	Market Price	Market Value	Accrued Interest	Estimated Yield
Fixed Income (continued)					
Certificates of Deposit (continued)					
BARCLAYS BK DEL WILMINGTON CTF DEP ACT/365 ANNUALLY LKD TO S&P 500 0.000% 07/30/18 B/E DTD 07/31/13 1ST CPN DTE 07/30/14 CPN PMT ANNUALLY ON JUL 30 Security Identifier: 06740AAA41	85,000.000	98.9400	84,099.00	0.00	
Total Certificates of Deposit:	360,000.000		\$370,813.70	\$0.00	
U.S. Treasury Securities					
UNITED STATES TREAS NTS INFLATION INDEXED NOTES TIPS 1.250% 07/15/20 B/E DTD 07/15/10 Moody Rating AAA Security Identifier: 912828NMRB Factor: 1.07098000 Effective Date: 12/31/13 Current Face Value: 26,774,500	25,000.000 26,774,500	106.9840	28,644.43	153.70	
Total U.S. Treasury Securities:	25,000.000		\$28,644.43	\$153.70	
Total Current Face Value:	385,000.000		\$399,458.13	\$153.70	
Total Fixed Income:			\$504,562.24	\$153.70	\$21.51

⁶ The Current Face value represents the outstanding principal balance of the underlying security. The Current Face value is determined by multiplying the current factor times the original face amount of the security. Factors may change over time and are obtained from sources we believe to be reliable.

Portfolio Holdings Disclosures

Pricing

This section includes the net market value of the securities in your account on a settlement date basis, including short positions, at the close of the statement period. The market prices have been obtained from sources which we believe to be reliable. Pershing may not use the closing price of the particular exchange or marketplace where your position was purchased as the "Market Price." Securities for which a price is not available are marked "N/A" and are omitted from the Total.

The estimated annual income (EAI) and estimated current yield (ECY) figures are estimates and for informational purposes only. These figures are not considered to be a forecast or guarantee of future results. These figures are computed using information from providers believed to be reliable; however, no assurance can be made as to the accuracy. Since interest and dividend rates are subject to change at any time, and may be affected by current and future economic, political, and business conditions, they should not be relied on for making investment, trading, or tax decisions. These figures assume that the position quantities, interest and dividend rates, and prices remain constant. A capital gain or return of principal may be included in the figures for certain securities, thereby overstating them. Refer to www.pershing.com/business_continuity.html for specific details as to formulas used to calculate the figures. Accrued interest represents interest earned but not yet received. Refer to THE AS OF PRICE DATE ONLY APPEARS WHEN THE PRICE DATE DOES NOT EQUAL THE STATEMENT DATE.

Statement Period: 12/01/2013 - 12/31/2013

Portfolio Holdings Disclosures (continued)

Reinvestment

The dollar amount of Mutual Fund distributions, Money Market Fund dividend income, Bank Deposit interest income, or dividends for other securities shown on your Statement may have been reinvested. You will not receive confirmation of these reinvestments. Upon written request to your financial institution, information pertaining to these transactions, including the time of execution and the name of the person from whom your security was purchased. In dividend reinvestment transactions, Pershing acts as your agent and receives payment for order flow.

Option Disclosure

Information with respect to commissions and other charges incurred in connection with the execution of option transactions has been included in confirmations previously furnished to you. A summary of this information is available to you promptly upon your written request directed to your introducing firm. In order to assist your introducing firm in maintaining current background and financial information concerning your option accounts, please promptly advise them in writing of any material change in your investment objectives or financial situation. Expiring options which are valuable are exercised automatically pursuant to the exercise by exception procedure of the Options Clearing Corporation. Additional information regarding this procedure is available upon written request to your introducing firm.

Certificates of Deposit

Please be advised that the secondary market for CDs is generally illiquid; the actual value of CDs may be different from their purchase price; and a significant loss of principal could result if your CDs are sold prior to maturity. In the event that the CDs listed above do not indicate a market valuation, an accurate market value could not be determined. In the event that a price is listed above for your CDs, Pershing has obtained a price from sources deemed to be reliable or has priced your CDs using a matrix formula. Prices are estimates and the actual value you may obtain for your CD may be different if you elect to sell your CD in the secondary market.

Foreign Currency Transactions

Pershing may execute foreign currency transactions as principal for your account. Pershing may automatically convert foreign currency to or from U.S. dollars for dividends and similar corporate action transactions unless you instruct your financial organization otherwise. Pershing's currency conversion rate will not exceed the highest interbank conversion rate identified from customary banking sources on the conversion date or the prior business day, increased by up to 1%, unless a particular rate is required by applicable law. Your financial organization may also increase the currency conversion rate. This conversion rate may differ from rates in effect on the date you executed a transaction, incurred a charge, or received a credit. Transactions converted by agents (such as depositories) will be billed at the rates such agents use.

Proxy Vote

Securities not fully paid for in your margin account may be lent by Pershing to itself or others in accordance with the terms outlined in the Margin Agreement. The right to vote your shares held on margin may be reduced by the amount of shares on loan. The Proxy Voting Instruction Form sent to you may reflect a smaller number of shares entitled to vote than the number of shares in your margin account.

Money Market Fund Detail

Date	Activity Type	Description	Amount	Balance
Sweep Money Market Fund				
GENERAL MINY MKT FUND CL B				
Account Number: 0000671452 Current Yield: 0.01% Activity Ending: 12/31/13				
11/30/13	Opening Balance		104,988.30	104,988.30
12/02/13	Deposit		115.00	105,103.30
12/13/13	Withdrawal	MONEY FUND PURCHASE	-105,103.30	0.00
12/13/13	Withdrawal	MONEY FUND REDEMPTION	-0.35	-0.35
12/13/13	Deposit	SHARES REDEEMED	0.35	0.00
12/16/13	Deposit	ACCRUED DIVIDEND CREDIT		105,103.65
		MONEY FUND PURCHASE		

Money Market Fund Detail (continued)

Date	Activity Type	Description	Amount	Balance
Sweep Money Market Fund (continued)				
GENERAL MNY MKT FUND CL B (continued)				
12/31/13	Deposit			105,104.11
12/31/13	Closing Balance	INCOME REINVEST	0.46	\$105,104.11
Total All Money Market Funds				\$105,104.11

Messages

Although a money market mutual fund seeks to preserve the value of your investment at \$1 per share, it is possible to lose money by investing in a money market mutual fund. Shares of a money market mutual fund or the balance of a bank deposit product held in your brokerage account may be liquidated upon request with the proceeds credited to your brokerage account. Please see the money market mutual fund's prospectus or the bank deposit product's disclosure document or contact your investment professional for additional information.

Important Information and Disclosures

The Role of Pershing

- Pershing carries your account as clearing broker pursuant to a clearing agreement with your financial institution. Pershing may accept from your financial institution without inquiry or investigation (i) orders for the purchase and sale of securities and other property and (ii) any other instructions concerning your account. Pershing is not responsible or liable for any acts or omissions of your financial institution or its employees and it does not supervise them. Pershing provides no investment advice nor does it assess the suitability of any transaction or order. Pershing acts as the agent of your financial institution and you agree that you will not hold Pershing or any person controlling or under common control with it liable for any investment losses incurred by you.
- Pershing performs several key functions at the direction of your financial institution. It acts as custodian for funds and securities you may deposit with it directly or through your financial institution or that it receives as the result of securities transactions it processes.
- Your financial institution is responsible for adherence to the securities laws, regulations and rules which apply to it regarding its own operations and the supervision of your account, its sales representatives and other personnel. Your financial institution is also responsible for approving the opening of accounts and obtaining account documents; the acceptance and, in certain instances, execution of securities orders; the assessment of the suitability of those transactions, where applicable; the rendering of investment advice, if any, to you and in general, for the ongoing relationship that it has with you.
- Inquiries concerning the positions and balances in your account may be directed to the Pershing Customer Service Department at (201) 413-3333. All other inquiries regarding your account or activity should be directed to your financial institution. Your financial organization's contact information can be found on the first page of this statement.
- For a description of other functions performed by Pershing please consult the Disclosure Statement provided to you upon the opening of your account. This notice is not meant as a definitive enumeration of every possible circumstance, but as a general disclosure. If you have any questions regarding this notice or if you would like additional copies of the Disclosure Statement, please contact your financial institution.
- Pershing is a member of the Securities Investor Protection Corporation (SIPC[®]). Please note that SIPC does not protect against loss due to market fluctuation. In addition to SIPC protection, Pershing provides coverage in excess of SIPC limits. For more detailed information please visit: www.pershing.com/strength_stability.html.
- This statement will be deemed conclusive. You are advised to report any inaccuracy or discrepancy (including unauthorized trading), to your financial organization and Pershing, within ten days after receipt of this statement. Please be advised that any oral communication should be re-confirmed in writing to further protect your rights, including your rights under the Securities Investor Protection Act.
- Your financial organization's contact information can be found on the first page of this statement. Pershing's contact information is as follows: Pershing LLC; Legal Department; One Pershing Plaza, Jersey City, New Jersey 07399; (201) 413-3330. Errors and Omissions excepted.

Important Arbitration Disclosures

- All parties to this agreement are giving up the right to sue each other in court, including the right to a trial by jury, except as provided by the rules of the arbitration forum in which a claim is filed.
- Arbitration awards are generally final and binding; a party's ability to have a court reverse or modify an arbitration award is very limited.
- The ability of the parties to obtain documents, witness statements and other discovery is generally more limited in arbitration than in court proceedings.
- The arbitrators do not have to explain the reason(s) for their award, unless, in an eligible case, a joint request for an explained decision has been submitted by all parties to the panel at least 20 days prior to the first scheduled hearing date.
- The panel of arbitrators will typically include a minority of arbitrators who were or are affiliated with the securities industry.
- The rules of some arbitration forums may impose time limits for bringing a claim in arbitration. In some cases, a claim that is ineligible for arbitration may be brought in court.

Statement Period: 12/01/2013 - 12/31/2013

Important Information and Disclosures (continued)

Important Arbitration Disclosures (continued)

- The rules of the arbitration forum in which the claim is filed, and any amendments thereto, shall be incorporated into this agreement.

Important Arbitration Agreement

Any controversy between you and Pershing LLC shall be submitted to arbitration before the Financial Industry Regulatory Authority. No person shall bring a putative or certified class action to arbitration, nor seek to enforce any predispute arbitration agreement against any person who has initiated in court a putative class action, who is a member of a putative class who has not opted out of the class with respect to any claims encompassed by the putative class action until: (i) the class certification is denied; (ii) the class is decertified; or (iii) the client is excluded from the class by the court. Such forbearance to enforce an agreement to arbitrate shall not constitute a waiver of any rights under this agreement except to the extent stated herein. The laws of the State of New York govern.

Pershing's contact information is as follows: Pershing LLC; Legal Department; One Pershing Plaza; Jersey City, New Jersey 07399; (201) 413-3330.

Brokerage Account Statement

Account Number: H5E-077160
 Statement Period: 12/12/2013 - 12/31/2013

Valuation at a Glance

	This Period
Beginning Account Value	\$0.00
Cash Deposits	105,103.65
Cash Withdrawals	-105,103.65
Change in Account Value*	970,301.20
Ending Account Value	\$970,301.20
Estimated Annual Income	\$5,460.00

* Change in Account Value includes the value of free receives/delivers.

LA BD OF PHARMACY OPEB RES ACT
 3388 BRENTWOOD DRIVE
 BATON ROUGE LA 70809 - 1700

Your Account Executive:
 JOSEPH BARRECA, JR.
 (504) 310-7364

Asset Allocation

	This Period	% Allocation
Fixed Income	970,301.20	100%
Account Total	\$970,301.20	100%

Your Account is 100% Invested in Fixed Income.

Client Service Information

Your Account Executive: X57
 JOSEPH BARRECA, JR.
 IBERIA FINANCIAL SERVICES
 200 W. CONGRESS STREET 1ST FLOOR
 LAFAYETTE LA 70501

Contact Information

Telephone Number: (504) 310-7364

Your Account Information

Tax Lot Default Disposition Method

Default Method for Mutual Funds: AVERAGE COST (USING FIRST IN FIRST OUT)

Default Method for Stocks in a Dividend Reinvestment Plan: FIRST IN FIRST OUT

Default Method for all Other Securities: FIRST IN FIRST OUT

Copies of Statement Sent

KODLER, CHAMPAGNE, SLAVEN & CO

At your request copies of this statement have been sent to the above.

Electronic Delivery

You have not selected any account communications for electronic delivery. To register and turn off paper communications, log in to your account or contact your Account Executive for more information.

Activity Summary (All amounts shown are in base currency: USD)

	This Period	Year-to-Date		This Period	Year-to-Date
Credits					
Cash			Debits		
Withdrawals	0.00	0.00	Withdrawals	-105,103.65	-105,103.65
Deposits	105,103.65	105,103.65	Deposits	0.00	0.00
Total Cash	\$105,103.65	\$105,103.65	Total Cash	-\$105,103.65	-\$105,103.65
Total Credits	\$105,103.65	\$105,103.65	Total Debits	-\$105,103.65	-\$105,103.65

Transactions in Date Sequence

Process/ Settlement Date	Activity Type	Description	Quantity	Price	Accrued Interest	Amount	CCY
12/13/13	CUSTOMER AUTHORIZED TRANSFER	TRANS FRM H5E-049797				105,103.65	USD
12/13/13	USD999997 CUSTOMER AUTHORIZED TRANSFER	TRANS TO H5E-049797				-105,103.65	USD
12/13/13	USD999997 CUSTOMER AUTHORIZED TRANSFER	ALLY BANK MIDVALE UTAH CTF DEP ACT/365 1.0000% 05/26/15 B/E DTD 05/23/12 TRANS FRM H5E-049797	120,000.000			0.00	USD

Statement Period: 12/12/2013 - 12/31/2013

Transactions in Date Sequence (continued)

Process/ Settlement Date	Activity Type	Description	Quantity	Price	Accrued Interest	Amount	CCY
12/13/13	CUSTOMER AUTHORIZED TRANSFER 06426XCL2	BANK OF THE WEST INSTL CTF DEP PROGRAM BOOK ENTRY INSTL CTF DEP 0.000% 12/28/16 B/E DTD 12/28/11 TRANS FRM H5E-049797	89,000.000			0.00	USD
12/13/13	CUSTOMER AUTHORIZED TRANSFER 06426XCL2	BANK OF THE WEST INSTL CTF DEP PROGRAM BOOK ENTRY INSTL CTF DEP 0.000% 12/28/16 B/E DTD 12/28/11 TRANS TO H5E-049797	-89,000.000			0.00	USD
12/13/13	CUSTOMER AUTHORIZED TRANSFER 06426XGLB	BANK OF THE WEST INSTL CTF DEP PROGRAM BOOK ENTRY INSTL CTF DEP 0.000% 04/30/18 B/E DTD 04/29/13 TRANS FRM H5E-049797	155,000.000			0.00	USD
12/13/13	CUSTOMER AUTHORIZED TRANSFER 06740AA41	BARCLAYS BK DEL WILMINGTON CTF DEP ACT/365 ANNUALLY LKD TO S&P 500 0.000% 07/30/18 B/E DTD 07/31/13 TRANS FRM H5E-049797	85,000.000			0.00	USD
12/13/13	CUSTOMER AUTHORIZED TRANSFER 06740AA41	BARCLAYS BK DEL WILMINGTON CTF DEP ACT/365 ANNUALLY LKD TO S&P 500 0.000% 07/30/18 B/E DTD 07/31/13 TRANS TO H5E-049797	-85,000.000			0.00	USD
12/13/13	CUSTOMER AUTHORIZED TRANSFER 06740ATS8	BARCLAYS BK DEL WILMINGTON CTF DEP ACT/365 ZERO CPN LKD PERFORM OF A BSKT 0.000% 05/30/17 B/E DTD 05/31/12 TRANS FRM H5E-049797	83,000.000			0.00	USD
12/13/13	CUSTOMER AUTHORIZED TRANSFER 06740AYS2	BARCLAYS BK DEL WILMINGTON CTF DEP ACT/365 0.000% 04/27/18 B/E DTD 04/30/13 TRANS FRM H5E-049797	160,000.000			0.00	USD
12/13/13	CUSTOMER AUTHORIZED TRANSFER 254671BG4	DISCOVER BK GREENWOOD DEL CTF DEP ACT/365 1.250% 05/23/16 B/E DTD 05/23/12 TRANS FRM H5E-049797	120,000.000			0.00	USD
12/13/13	CUSTOMER AUTHORIZED TRANSFER 38143ASV8	GOLDMAN SACHS BK USA NEW YORK CTF DEP ACT/365 1.800% 05/23/17 B/E DTD 05/23/12 TRANS FRM H5E-049797	120,000.000			0.00	USD
12/13/13	CUSTOMER AUTHORIZED TRANSFER 44643BP2	HUNTINGTON NATL BK COLUMBUS OHIO CTF DEP ACT/365 0.500% 05/27/14 B/E DTD 05/25/12 TRANS FRM H5E-049797	120,000.000			0.00	USD
12/13/13	CUSTOMER AUTHORIZED TRANSFER 45083AAV4	IBERIABANK LAFAYETTE LA CTF DEP ACT/365 0.000% 05/31/16 B/E DTD 05/31/11 TRANS FRM H5E-049797	10,000.000			0.00	USD

Transactions in Date Sequence (continued)

Process/ Settlement Date	Activity Type	Description	Quantity	Price	Accrued Interest	Amount	CTY
12/13/13	CUSTOMER AUTHORIZED TRANSFER 45083AAV4	IBERIABANK LAFAYETTE LA CTF DEP ACT/365 0.000% 05/31/16 B/E DTD 05/31/11 TRANS TO H5E-049797	-10,000,000			0.00	USD
12/13/13	CUSTOMER AUTHORIZED TRANSFER 48124JS41	JPMORGAN CHASE BK NA COLUMBUS OHIO CTF DEP DTD 07/31/2013 ACT/365 AT-MATURITY 0.000% 07/31/18 B/E DTD 07/31/13 TRANS FRM H5E-049797	125,000,000			0.00	USD
12/13/13	CUSTOMER AUTHORIZED TRANSFER 90521AHP6	UNION BK N A SAN FRANCISCO CALIF CTF DEP ACT/365 0.000% 12/30/15 B/E DTD 12/30/11 TRANS FRM H5E-049797	88,000,000			0.00	USD
12/13/13	CUSTOMER AUTHORIZED TRANSFER 90521AHP6	UNION BK N A SAN FRANCISCO CALIF CTF DEP ACT/365 0.000% 12/30/15 B/E DTD 12/30/11 TRANS TO H5E-049797	-88,000,000			0.00	USD
12/13/13	CUSTOMER AUTHORIZED TRANSFER 90521AHS0	UNION BK N A SAN FRANCISCO CALIF CTF DEP ACT/365 0.000% 12/29/14 B/E DTD 12/28/11 TRANS FRM H5E-049797	88,000,000			0.00	USD
12/13/13	CUSTOMER AUTHORIZED TRANSFER 90521AHS0	UNION BK N A SAN FRANCISCO CALIF CTF DEP ACT/365 0.000% 12/29/14 B/E DTD 12/28/11 TRANS TO H5E-049797	-88,000,000			0.00	USD
12/13/13	CUSTOMER AUTHORIZED TRANSFER 912828NM8	UNITED STATES TREAS NTS INFLATION INDEXED NOTES TIPS 1.250% 07/15/20 B/E DTD 07/15/10 TRANS FRM H5E-049797	25,000,000			0.00	USD
12/13/13	CUSTOMER AUTHORIZED TRANSFER 912828NM8	UNITED STATES TREAS NTS INFLATION INDEXED NOTES TIPS 1.250% 07/15/20 B/E DTD 07/15/10 TRANS TO H5E-049797	-25,000,000			0.00	USD
Total Value of Transactions						\$0.00	

The price and quantity displayed may have been rounded.

Portfolio Holdings

Description	Quantity	Market Price	Market Value	Accrued Interest	Estimated Annual Income	Estimated Yield
Fixed Income 100.00% of Portfolio (In Maturity Date Sequence)						
Certificates of Deposit						
HUNTINGTON NATL BK COLUMBUS OHIO CTF DEP ACT/365 0.500% 05/27/14 B/E DTD 05/25/12 1ST CPN DTE 11/25/12 CPN PMT SEMI ANNUAL ON MAY 25 AND NOV 25 Security Identifier: 446438PP2	120,000,000	100.1710	120,205.20	59.18	600.00	0.49%

Brokerage Account Statement

Statement Period: 12/12/2013 - 12/31/2013

Portfolio Holdings (continued)

Description	Quantity	Market Price	Market Value	Accrued Interest	Estimated Annual Income	Estimated Yield
Fixed Income (continued)						
Certificates of Deposit (continued)						
ALLY BANK MIDVALE UTAH CTF DEP ACT/365 1.000% 05/26/15 B/E DTD 05/23/12 1ST CPN DTE 11/23/12 CPN PMT SEMI ANNUAL ON MAY 23 AND NOV 23 Security Identifier: 02005QF57	120,000.000	100.5920	120,710.40	124.93	1,200.00	0.99%
DISCOVER BK GREENWOOD DEL CTF DEP ACT/365 1.250% 05/23/16 B/E DTD 05/23/12 1ST CPN DTE 11/23/12 CPN PMT SEMI ANNUAL ON MAY 23 AND NOV 23 Security Identifier: 254671BG4	120,000.000	100.7090	120,850.80	156.16	1,500.00	1.24%
GOLDMAN SACHS BK USA NEW YORK CTF DEP ACT/365 1.800% 05/23/17 B/E DTD 05/23/12 1ST CPN DTE 11/23/12 CPN PMT SEMI ANNUAL ON MAY 23 AND NOV 23 Security Identifier: 38143ASV8	120,000.000	101.1260	121,351.20	224.88	2,160.00	1.77%
BARCLAYS BK DEL WILMINGTON CTF DEP ACT/365 ZERO CPN LKD PERFORM OF A BSKT 0.000% 05/30/17 B/E DTD 05/31/12 1ST CPN DTE 05/31/13 CPN PMT ANNUALLY ON MAY 31 Security Identifier: 06740ATS8	83,000.000	93.9200	77,953.60	0.00	0.00	
BARCLAYS BK DEL WILMINGTON CTF DEP ACT/365 0.000% 04/27/18 B/E DTD 04/30/13 1ST CPN DTE 04/29/14 CPN PMT ANNUALLY ON APR 27 Security Identifier: 06740AYS2	160,000.000	90.5800	144,928.00	0.00	0.00	
BANK OF THE WEST INSTL CTF DEP PROGRAM BOOK ENTRY INSTL CTF DEP 0.000% 04/30/18 B/E DTD 04/29/13 1ST CPN DTE 04/29/14 CPN PMT ANNUALLY ON APR 29 Security Identifier: 06426XGL8	155,000.000	94.3400	146,227.00	0.00	0.00	

Portfolio Holdings (continued)

Description	Quantity	Market Price	Market Value	Accrued Interest	Estimated Annual Income	Estimated Yield
Fixed Income (continued)						
Certificates of Deposit (continued)						
JPMORGAN CHASE BK NA COLUMBUS OHIO CTF DEP DTD 07/31/2013 ACT/365 AT-MATURITY 0.000% 07/31/18 B/E DTD 07/31/13 Security Identifier: 48124ISA1	125,000,000	94.4600	118,075.00	0.00		
Total Certificates of Deposit:	1,003,000,000		\$970,301.20	\$565.15	\$5,460.00	
Total Fixed Income:	1,003,000,000		\$970,301.20	\$565.15	\$5,460.00	

Total Portfolio Holdings

Market Value	Accrued Interest	Estimated Annual Income
\$970,301.20	\$565.15	\$5,460.00

Portfolio Holdings Disclosures

Pricing

This section includes the net market value of the securities in your account on a settlement date basis, including short positions, at the close of the statement period. The market prices have been obtained from sources which we believe to be reliable. Pershing may not use the closing price of the particular exchange or marketplace where your position was purchased as the "Market Price." Securities for which a price is not available are marked "N/A" and are omitted from the Total.

The estimated annual income (EAI) and estimated current yield (ECY) figures are estimates and for informational purposes only. These figures are not considered to be a forecast or guarantee of future results. These figures are computed using information from providers believed to be reliable; however, no assurance can be made as to the accuracy. Since interest and dividend rates are subject to change at any time, and may be affected by current and future economic, political, and business conditions, they should not be relied on for making investment, trading, or tax decisions. These figures assume that the position quantities, interest and dividend rates, and prices remain constant. A capital gain or return of principal may be included in the figures for certain securities, thereby overstating them. Refer to www.pershing.com/business_continuity.html for specific details as to formulas used to calculate the figures. Accrued interest represents interest earned but not yet received.

THE AS OF PRICE DATE ONLY APPEARS WHEN THE PRICE DATE DOES NOT EQUAL THE STATEMENT DATE.

Reinvestment

The dollar amount of Mutual Fund distributions, Money Market Fund dividend income, Bank Deposit interest income, or dividends for other securities shown on your Statement may have been reinvested. You will not receive confirmation of these reinvestments. Upon written request to your financial institution, information pertaining to these transactions, including the time of execution and the name of the person from whom your security was purchased. In dividend reinvestment transactions, Pershing acts as your agent and receives payment for order flow.

Option Disclosure

Information with respect to commissions and other charges incurred in connection with the execution of option transactions has been included in confirmations previously furnished to you. A summary of this information is available to you promptly upon your written request directed to your introducing firm. In order to assist your introducing firm in maintaining current background and financial information concerning your option accounts, please promptly advise them in writing of any material change in your investment objectives or financial situation. Expiring options which are valuable are exercised automatically pursuant to the exercise by exception procedure of the Options Clearing Corporation. Additional information regarding this procedure is available upon written request to your introducing firm.

Certificates of Deposit

Please be advised that the secondary market for CDs is generally illiquid; the actual value of CDs may be different from their purchase price; and a significant loss of principal could result if your CDs are sold prior to maturity. In the event that the CDs listed above do not indicate a market valuation, an accurate market value could not be determined. In the event that a price is listed above for your CDs, Pershing has obtained a price from sources deemed to be reliable or has priced your CDs using a matrix formula. Prices are estimates and the actual value you may obtain for your CD may be different if you elect to sell your CD in the secondary market.

Foreign Currency Transactions

Pershing may execute foreign currency transactions as principal for your account. Pershing may automatically convert foreign currency to or from U.S. dollars for dividends and similar corporate action

Statement Period: 12/12/2013 - 12/31/2013

Portfolio Holdings Disclosures (continued)

Foreign Currency Transactions (continued)

transactions unless you instruct your financial organization otherwise. Pershing's currency conversion rate will not exceed the highest interbank conversion rate identified from customary banking sources on the conversion date or the prior business day, increased by up to 1%, unless a particular rate is required by applicable law. Your financial organization may also increase the currency conversion rate. This conversion rate may differ from rates in effect on the date you executed a transaction, incurred a charge, or received a credit. Transactions converted by agents (such as depositories) will be billed at the rates such agents use.

Proxy Vote

Securities not fully paid for in your margin account may be lent by Pershing to itself or others in accordance with the terms outlined in the Margin Agreement. The right to vote your shares held on margin may be reduced by the amount of shares on loan. The Proxy Voting Instruction Form sent to you may reflect a smaller number of shares entitled to vote than the number of shares in your margin account.

Messages

Although a money market mutual fund seeks to preserve the value of your investment at \$1 per share, it is possible to lose money by investing in a money market mutual fund. Shares of a money market mutual fund or the balance of a bank deposit product held in your brokerage account may be liquidated upon request with the proceeds credited to your brokerage account. Please see the money market mutual fund's prospectus or the bank deposit product's disclosure document or contact your investment professional for additional information.

Important Information and Disclosures

The Role of Pershing

- Pershing carries your account as clearing broker pursuant to a clearing agreement with your financial institution. Pershing may accept from your financial institution without inquiry or investigation (i) orders for the purchase and sale of securities and other property and (ii) any other instructions concerning your account. Pershing is not responsible or liable for any acts or omissions of your financial institution or its employees and it does not supervise them. Pershing provides no investment advice nor does it assess the suitability of any transaction or order. Pershing acts as the agent of your financial institution and you agree that you will not hold Pershing or any person controlling or under common control with it liable for any investment losses incurred by you.
- Pershing performs several key functions at the direction of your financial institution. It acts as custodian for funds and securities you may deposit with it directly or through your financial institution or that it receives as the result of securities transactions it processes.
- Your financial institution is responsible for adherence to the securities laws, regulations and rules which apply to it regarding its own operations and the supervision of your account, its sales representatives and other personnel. Your financial institution is also responsible for approving the opening of accounts and obtaining account documents; the acceptance and, in certain instances, execution of securities orders; the assessment of the suitability of those transactions, where applicable; the rendering of investment advice, if any, to you and in general, for the ongoing relationship that it has with you.
- Inquiries concerning the positions and balances in your account may be directed to the Pershing Customer Service Department at (201) 413-3333. All other inquiries regarding your account or activity should be directed to your financial institution. Your financial organization's contact information can be found on the first page of this statement.
- For a description of other functions performed by Pershing please consult the Disclosure Statement provided to you upon the opening of your account. This notice is not meant as a definitive enumeration of every possible circumstance, but as a general disclosure. If you have any questions regarding this notice or if you would like additional copies of the Disclosure Statement, please contact your financial institution.
- Pershing is a member of the Securities Investor Protection Corporation (SIPC[®]). Please note that SIPC does not protect against loss due to market fluctuation. In addition to SIPC protection, Pershing provides coverage in excess of SIPC limits. For more detailed information please visit: www.pershing.com/strength_stability.html.
- This statement will be deemed conclusive. You are advised to report any inaccuracy or discrepancy (including unauthorized trading), to your financial organization and Pershing, within ten days after receipt of this statement. Please be advised that any oral communication should be re-confirmed in writing to further protect your rights, including your rights under the Securities Investor Protection Act.
- Your financial organization's contact information can be found on the first page of this statement. Pershing's contact information is as follows: Pershing LLC; Legal Department; One Pershing Plaza; Jersey City, New Jersey 07399; (201) 413-3330. Errors and Omissions excepted.

Important Information and Disclosures (continued)

Important Arbitration Disclosures

- All parties to this agreement are giving up the right to sue each other in court, including the right to a trial by jury, except as provided by the rules of the arbitration forum in which a claim is filed.
- Arbitration awards are generally final and binding; a party's ability to have a court reverse or modify an arbitration award is very limited.
- The ability of the parties to obtain documents, witness statements and other discovery is generally more limited in arbitration than in court proceedings.
- The arbitrators do not have to explain the reason(s) for their award, unless, in an eligible case, a joint request for an explained decision has been submitted by all parties to the panel at least 20 days prior to the first scheduled hearing date.
- The panel of arbitrators will typically include a minority of arbitrators who were or are affiliated with the securities industry.
- The rules of some arbitration forums may impose time limits for bringing a claim in arbitration. In some cases, a claim that is ineligible for arbitration may be brought in court.
- The rules of the arbitration forum in which the claim is filed, and any amendments thereto, shall be incorporated into this agreement.

Important Arbitration Agreement

Any controversy between you and Pershing LLC shall be submitted to arbitration before the Financial Industry Regulatory Authority. No person shall bring a putative or certified class action to arbitration, nor seek to enforce any predispute arbitration agreement against any person who has initiated in court a putative class action, who is a member of a putative class who has not opted out of the class with respect to any claims encompassed by the putative class action unit; (i) the class certification is denied; (ii) the class is decertified; or (iii) the client is excluded from the class by the court. Such forbearance to enforce an agreement to arbitrate shall not constitute a waiver of any rights under this agreement except to the extent stated herein. The laws of the State of New York govern.

Pershing's contact information is as follows: Pershing LLC; Legal Department; One Pershing Plaza; Jersey City, New Jersey 07399; (201) 413-3330.



TERMS AND CONDITIONS

TRANSACTIONS

• ALL ORDERS AND TRANSACTIONS SHALL BE SOLELY FOR YOUR ACCOUNT AND RISK SHALL BE SUBJECT TO THE CONSTITUTION, RULES, REGULATIONS, CUSTOMS, USAGES, RULINGS AND INTERPRETATIONS OF THE EXCHANGE OR MARKET AND THE CLEARING FACILITY, IF ANY, WHERE THE TRANSACTIONS ARE EXECUTED AND/OR SETTLED, OR IF APPLICABLE, OF THE FINANCIAL INDUSTRY REGULATORY AUTHORITY AND TO ALL APPLICABLE LAWS AND REGULATIONS.

• TITLE TO SECURITIES SOLD TO YOU, WHERE PERSHING HAS ACTED AS PRINCIPAL, SHALL REMAIN WITH PERSHING UNTIL THE ENTIRE PURCHASE PRICE IS RECEIVED OR UNTIL THE SETTLEMENT DATE, WHICHEVER IS LATER. YOU MAY HAVE RECEIVED CONFIRMATIONS FOR TRANSACTIONS WHICH DO NOT APPEAR ON YOUR STATEMENT. IF SO, THE TRANSACTIONS WILL APPEAR ON YOUR NEXT PERIODIC STATEMENT. SUCH TRANSACTIONS MUST BE CONSIDERED BY YOU WHEN COMPUTING THE VALUE OF YOUR ACCOUNT. THIS IS ESPECIALLY TRUE IF YOU HAVE WRITTEN OPTIONS WHICH HAVE BEEN EXERCISED.

FREE CREDIT BALANCES: ANY FREE CREDIT BALANCE CARRIED FOR YOUR ACCOUNT REPRESENTS FUNDS PAYABLE UPON DEMAND WHICH, ALTHOUGH PROPERLY ACCOUNTED FOR ON PERSHING'S BOOKS OF RECORD, ARE NOT SEGREGATED AND MAY BE USED IN THE CONDUCT OF ITS BUSINESS.

DEBIT BALANCES: INTEREST CHARGED ON DEBIT BALANCES IN YOUR ACCOUNT APPEARS ON THE STATEMENT. THE RATE OF INTEREST AND PERIOD COVERED ARE INDICATED. THE RATE MAY CHANGE FROM TIME TO TIME DUE TO FLUCTUATIONS IN MONEY RATES OR OTHER REASONS. INTEREST IS COMPUTED AS DESCRIBED IN MATERIAL PREVIOUSLY FURNISHED TO YOU. PLEASE CONTACT YOUR FINANCIAL INSTITUTION IF YOU DESIRE ADDITIONAL COPIES.

MARGIN INFORMATION: IF YOU MAINTAIN A MARGIN ACCOUNT, THIS IS A COMBINED STATEMENT OF YOUR GENERAL ACCOUNT AND A SPECIAL MEMORANDUM ACCOUNT MAINTAINED FOR YOU UNDER REGULATION T OF THE BOARD OF GOVERNORS OF THE FEDERAL RESERVE SYSTEM. THE PERMANENT RECORD OF THE SEPARATE ACCOUNT AS REQUIRED BY REGULATION T IS AVAILABLE FOR YOUR INSPECTION UPON REQUEST.

TAX INFORMATION

• AFTER YEAR END, PERSHING IS REQUIRED TO PROVIDE TAX INFORMATION TO THE INTERNAL REVENUE SERVICE AND OTHER GOVERNMENTAL AUTHORITIES. AT THAT TIME PERSHING WILL PROVIDE THAT INFORMATION ON THE ANNUAL TAX INFORMATION STATEMENT TO YOU; USE THAT STATEMENT TO PREPARE YOUR TAX FILINGS. THE TAX STATEMENT ALSO INCLUDES OTHER USEFUL INFORMATION TO ASSIST IN ACCUMULATING THE DATA TO PREPARE YOUR TAX RETURNS.

• DIVIDENDS, INTEREST AND OTHER DISTRIBUTIONS SHOWN ON THIS STATEMENT WERE CLASSIFIED AS TAXABLE OR NON-TAXABLE BASED ON CERTAIN INFORMATION KNOWN AS OF THE DISTRIBUTION DATE. THIS CLASSIFICATION IS SUBJECT TO CHANGE AND IS SOLELY INTENDED FOR USE AS GENERAL INFORMATION.

• PERSHING DOES NOT PROVIDE TAX, INVESTMENT OR LEGAL ADVISORY SERVICES AND NO ONE ASSOCIATED WITH PERSHING IS AUTHORIZED TO RENDER SUCH ADVICE. DO NOT RELY UPON ANY SUCH ADVICE. IF GIVEN, INVESTORS ARE ENCOURAGED TO CONSULT THEIR TAX ADVISORS TO DETERMINE THE APPROPRIATE TAX TREATMENT OF THEIR BUSINESS.

GENERAL INFORMATION

• WHENEVER YOU ARE INDEBTED TO PERSHING LLC ("PERSHING") FOR ANY AMOUNT, ALL SECURITIES HELD BY IT FOR YOU IN ANY ACCOUNT IN WHICH YOU HAVE ANY INTEREST SHALL SECURE ALL YOUR LIABILITIES TO PERSHING, AND PERSHING MAY IN ITS DISCRETION AT ANY TIME, WITHOUT TENDER, DEMAND OR NOTICE TO YOU, CLOSE OR REDUCE ANY OR ALL OF YOUR ACCOUNTS BY PUBLIC OR PRIVATE SALE OR PURCHASE OR BOTH OF ALL OR ANY SECURITIES CARRIED IN SUCH ACCOUNTS; ANY BALANCE REMAINING DUE PERSHING TO BE PROMPTLY PAID BY YOU.

• WHENEVER YOU ARE INDEBTED TO PERSHING FOR ANY AMOUNT, ALL SECURITIES CARRIED FOR YOUR ACCOUNT ARE OR MAY BE, WITHOUT FURTHER NOTICE TO YOU, LOANED OR PLEDGED BY PERSHING, EITHER SEPARATELY OR UNDER CIRCUMSTANCES WHICH WILL PERMIT THE COMINGLING THEREOF, WITH OTHER SECURITIES FOR ANY AMOUNT LESS THAN EQUAL TO OR GREATER THAN YOUR LIABILITIES TO PERSHING, BUT NOT UNDER CIRCUMSTANCES FOR AN AMOUNT PROHIBITED BY LAW.

• PERSHING MAY TRADE FOR ITS OWN ACCOUNT AS A MARKET MAKER, SPECIALIST, ODD LOT DEALER, BLOCK POSITIONER, ARBITRAGEUR OR INVESTOR. CONSEQUENTLY, AT THE TIME OF ANY TRANSACTION YOU MAY MAKE, PERSHING MAY HAVE A POSITION IN SUCH SECURITIES, WHICH POSITION MAY BE PARTIALLY OR COMPLETELY HEDGED.

• IF AVERAGE PRICE TRANSACTION IS INDICATED ON THE FRONT OF THIS STATEMENT YOUR FINANCIAL INSTITUTION OR PERSHING MAY HAVE ACTED AS PRINCIPAL. AGENT OR BOTH. DETAILS AVAILABLE UPON REQUEST.

• A FINANCIAL STATEMENT OF PERSHING IS AVAILABLE FOR YOUR PERSONAL INSPECTION AT PERSHING'S OFFICES. A COPY OF IT WILL BE MAILED UPON YOUR WRITTEN REQUEST OR YOU CAN VIEW IT ONLINE AT WWW.PERSHING.COM.

• FOR BUSINESS CONTINUITY AND ADDITIONAL DISCLOSURES: WWW.PERSHING.COM/BUSINESS_CONTINUITY.HTML

• THIS STATEMENT SHOULD BE RETAINED FOR YOUR RECORDS.

PAYMENT FOR ORDER FLOW AND ORDER ROUTING POLICIES DISCLOSURES [REGULATION NMS—RULE 607(A)(1)-(2)]

PERSHING SENDS CERTAIN EQUITY ORDERS TO EXCHANGES, ELECTRONIC COMMUNICATION NETWORKS, OR BROKER-DEALERS DURING NORMAL BUSINESS HOURS AND DURING EXTENDED TRADING SESSIONS. CERTAIN OF THESE VENUES PROVIDE PAYMENTS TO PERSHING OR CHARGE ACCESS FEES TO PERSHING DEPENDING UPON THE CHARACTERISTICS OF THE ORDER AND ANY SUBSEQUENT EXECUTION. IN ADDITION PERSHING MAY EXECUTE CERTAIN EQUITY ORDERS AS PRINCIPAL. THE DETAILS OF THESE PAYMENTS AND FEES ARE AVAILABLE UPON WRITTEN REQUEST. PERSHING RECEIVES PAYMENTS FOR DIRECTING LISTED OPTIONS ORDER FLOW TO CERTAIN OPTION EXCHANGES. COMPENSATION IS GENERALLY IN THE FORM OF A PER OPTION CONTRACT CASH PAYMENT.

BEST EXECUTION: NOTWITHSTANDING THE PREVIOUS PARAGRAPH REGARDING PAYMENT FOR ORDER FLOW, PERSHING SELECTS CERTAIN MARKET CENTERS TO PROVIDE EXECUTION OF OVER-THE-COUNTER AND EXCHANGE LISTED SECURITIES TRANSACTIONS WHICH AGREE TO ACCEPT ORDERS, TRANSMITTED ELECTRONICALLY UP TO A SPECIFIED SIZE, AND TO EXECUTE THEM AT OR BETTER THAN THE NATIONAL BEST BID OR OFFER (NBBO). ON CERTAIN LARGER ORDERS, OR IF THE DESIGNATED MARKET CENTERS DO NOT MAKE A MARKET IN THE SUBJECT SECURITY, PERSHING DIRECTLY CONTACTS MARKET CENTERS TO OBTAIN AN EXECUTION; THE DESIGNATED MARKET CENTERS TO WHICH ORDERS ARE AUTOMATICALLY ROUTED ARE SELECTED BASED ON THE CONSISTENT HIGH QUALITY OF THEIR EXECUTIONS IN ONE OR MORE MARKET SEGMENTS AND THEIR ABILITY TO PROVIDE OPPORTUNITIES FOR EXECUTION AT PRICES SUPERIOR TO THE NBBO. PERSHING ALSO REGULARLY REVIEWS REPORTS FOR QUALITY OF EXECUTION PURPOSES.

WRAP ACCOUNT CUSTOMERS WHO ELECTED NOT TO RECEIVE IMMEDIATE CONFIRMATION OF TRANSACTIONS
THE FOLLOWING TERMS AND CONDITIONS ARE APPLICABLE ONLY IF YOUR ACCOUNT IS AN INVESTMENT ADVISORY ACCOUNT AND THE TRANSACTION CONFIRMATIONS ARE NOT SENT TO YOU (SENT ONLY TO YOUR FIDUCIARY) PURSUANT TO YOUR INSTRUCTION:

WRAP ACCOUNT TRANSACTIONS

- THE FOLLOWING INFORMATION WILL BE FURNISHED TO YOU UPON REQUEST TO YOUR FINANCIAL INSTITUTION (INTRODUCING FIRM) WITH RESPECT TO ANY TRANSACTION FOR WHICH A CONFIRMATION WAS NOT SENT TO YOU: THE MARKET UPON WHICH ANY TRANSACTION WAS EXECUTED; THE TIME OF DAY THAT ANY TRANSACTION WAS EXECUTED; THE NAME OF THE PERSON FROM WHOM ANY SECURITY WAS PURCHASED OR TO WHOM SUCH SECURITY WAS SOLD; THE SOURCE AND AMOUNT OF OTHER COMMISSIONS RECEIVED IN CONNECTION WITH ANY TRANSACTION; AND A COPY OF THE TRANSACTION CONFIRMATION.
- YOUR INTRODUCING FIRM EFFECTED EACH TRANSACTION FOR WHICH A CONFIRMATION WAS NOT SENT TO YOU AS YOUR AGENT.

• IN CONNECTION WITH EACH EQUITY SECURITY AND CERTAIN OTHER SECURITIES SOLD, YOUR INTRODUCING FIRM CHARGES TO YOU, AND REMITS TO A REGULATORY ORGANIZATION OR NATIONAL SECURITIES EXCHANGE, A "TRANS. FEE." PERSHING CALCULATES THIS FEE BASED ON AMOUNTS PAID BY YOUR INTRODUCING FIRM TO THE APPLICABLE REGULATORY ORGANIZATION OR NATIONAL SECURITIES EXCHANGE. THIS, IN TURN, IS BASED ON THE VALUE OF THE APPLICABLE SECURITIES SOLD. TO DETERMINE THE EXACT AMOUNT OF THIS FEE WITH RESPECT TO ANY TRANSACTION, PLEASE CONTACT YOUR INTRODUCING FIRM.

• IF ANY TRANSACTION INVOLVES AN ASSET-BACKED SECURITY, INCLUDING A MUNICIPAL COLLATERALIZED MORTGAGE OBLIGATION, WHICH REPRESENTS AN INTEREST IN OR IS SECURED BY A POOL OF RECEIVABLES OR OTHER FINANCIAL ASSETS THAT ARE SUBJECT CONTINUOUSLY TO PREPAYMENT, THEN THE ACTUAL YIELD OF SUCH SECURITY MAY VARY ACCORDING TO THE RATE AT WHICH THE UNDERLYING RECEIVABLES OR OTHER FINANCIAL ASSETS ARE PREPAID. INFORMATION CONCERNING THE FACTORS THAT AFFECT YIELD (INCLUDING AT A MINIMUM ESTIMATED YIELD, WEIGHTED AVERAGE LIFE, AND THE PREPAYMENT ASSUMPTIONS OF UNDERLYING YIELD) WILL BE FURNISHED TO YOU UPON REQUEST TO YOUR INTRODUCING FIRM.

WRAP ACCOUNT ORDER FLOW: YOUR INTRODUCING FIRM DOES NOT RECEIVE ANY PAYMENT FOR ORDER FLOW FOR ANY TRANSACTION FOR WHICH A CONFIRMATION WAS NOT SENT TO YOU.

WRAP ACCOUNT CALL FEATURES: CALL FEATURES MAY EXIST FOR SECURITIES. CALL FEATURES FOR FIXED INCOME SECURITIES MAY AFFECT YIELD. COMPLETE INFORMATION WILL BE PROVIDED UPON REQUEST.

WRAP ACCOUNT RATINGS: THE RATINGS THAT APPEAR IN THE DESCRIPTION OF SOME FIXED INCOME SECURITIES HAVE BEEN OBTAINED FROM RATINGS SERVICES WHICH PERSHING BELIEVES TO BE RELIABLE; HOWEVER, PERSHING CANNOT GUARANTEE THEIR ACCURACY. SECURITIES FOR WHICH A RATING IS NOT AVAILABLE ARE MARKED "UNRATED".

IF ANY OF THE ABOVE TERMS AND CONDITIONS ARE UNACCEPTABLE TO YOU, PLEASE NOTIFY PERSHING IMMEDIATELY IN WRITING BY CERTIFIED MAIL TO ONE PERSHING PLAZA, JERSEY CITY, NJ 07309, ATTN: LEGAL DEPT

Go paperless ASK ABOUT E DELIVERY
Boind Excellent
DALBAR BA LLC COMMUNICATIONS
FXCHLFINCE
Clearing through Pershing LLC, a wholly owned subsidiary
of The Bank of New York Mellon Corporation (BNY Mellon)
Pershing LLC, member FINRA, NYSE, SIPC



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Application Review Committee

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Reciprocity Committee

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



NOTICE IS HEREBY GIVEN that a meeting of the Reciprocity Committee has been ordered and called for 7:15 a.m. on Wednesday, February 12, 2014 at the Board office, for the purpose to wit:

AGENDA

NOTE: This agenda is tentative until 24 hours in advance of the meeting, at which time the most recent revision becomes official.

Revised 02-11-2014

- A. Call to Order
- B. Quorum Call
- C. Call for Additional Agenda Items
- D. Opportunity for Public Comment
- E. Review of Committee Policies & Procedures
- F. Activity since last Board Meeting

<u>Applicant</u>	<u>Interviewer</u>	<u>Result</u>
Jennifer Lynne Olsen (TX)	Ms. Reed	PST.020415 issued 12-19-2013
Wilburn Turner Davis, III (FL)	Ms. Reed	PST.020416 issued 12-19-2013
Jason Scott Doenges (OH)	Ms. Reed	PST.020417 issued 12-23-2013
Jean Marie Bremer (TX)	Ms. Reed	PST.020427 issued 01-02-2014
Richard Lynn Dobbs (OK)	Ms. Reed	PST.020428 issued 01-02-2014
Dona Thuy Phan (TX)	Ms. Reed	PST.020429 issued 01-02-2014
Rhiannon Michelle Hatton (MA)	Ms. Reed	PST.020430 issued 01-02-2014
Silas Alan Raymond (FL)	Ms. Reed	PST.020431 issued 01-02-2014
Natalie Durr Jackson (AL)	Ms. Reed	PST.020432 issued 01-02-2014
Sarah Marie Braley (MA)	Ms. Reed	PST.020433 issued 01-02-2014
Christine Kay Coopman (AZ)	Ms. Reed	PST.020434 issued 01-02-2014
LeShay Nicole Wesson (NC)	Ms. Reed	PST.020435 issued 01-02-2014
Johnny Ray Garcia, Jr. (NM)	Ms. Reed	PST.020436 issued 01-02-2014
Kevin Alan Long (GA)	Ms. Reed	PST.020437 issued 01-02-2014
Thomas Ryan Bostwick (MI)	Ms. Reed	PST.020438 issued 01-02-2014
Melissa Antoinette Brandt (VA)	Ms. Reed	PST.020439 issued 01-02-2014
William Christopher Pierce (MS)	Ms. Reed	PST.020440 issued 01-02-2014
Carie Donna Hatch (IA)	Ms. Reed	PST.020441 issued 01-02-2014
Leah Siobhan Smith (GA)	Ms. Reed	PST.020442 issued 01-02-2014
Matthew Ronald Garvin (AZ)	Ms. Reed	PST.020443 issued 01-02-2014
Allen Frank Scorsatto (AZ)	Ms. Reed	PST.020445 issued 01-16-2014
Safiya Khurshid (NY)	Ms. Reed	PST.020446 issued 01-16-2014
Tri Minh Nguyen (TX)	Ms. Reed	PST.020447 issued 01-16-2014
Pete Cangialosi (NV)	Ms. Reed	PST.020448 issued 01-16-2014
David Marten Miller (NJ)	Ms. Reed	PST.020449 issued 01-16-2014
Sameh Refaat Ramzy Garas (MI)	Ms. Reed	PST.020450 issued 01-16-2014
Thomas Leo Beranek (NV)	Ms. Reed	PST.020451 issued 01-16-2014
Tracy Renee McGee (TN)	Ms. Reed	PST.020452 issued 01-16-2014
Sally L. Chia (NV)	Ms. Reed	PST.020453 issued 01-16-2014
Mary Louise Glenn (IL)	Ms. Reed	PST.020454 issued 01-16-2014
Sabeen Hasni (NJ)	Ms. Reed	PST.020455 issued 01-16-2014
Conroy St. Christopher Whitely (FL)	Ms. Reed	PST.020456 issued 01-16-2014
Valerie Fay Rentfro (TX)	Ms. Reed	PST.020457 issued 01-16-2014
Michael Allen Kondik (OH)	Ms. Reed	PST.020458 issued 01-16-2014

NOTE: Pursuant to the Open Meetings Law at La. R.S. 42:16, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.

Pamela Jane Williams (OH)	Ms. Reed	PST.020459 issued 01-16-2014
Madhavi Padigala (NJ)	Ms. Reed	PST.020460 issued 01-16-2014
Bruce Allen Strike (IA)	Ms. Reed	PST.020461 issued 01-16-2014
Wollansa Almaz Boschulte (MI)	Ms. Reed	PST.020462 issued 01-16-2014
Angela Martin Harris (AL)	Ms. Reed	PST.020463 issued 01-16-2014

G. Appearances for Interview

1. Deborah Denise Allen (TX)
2. Jocelyn Leigh Anstine (OK)
3. Patrick Daniel Baker (PA)
4. Joseph Anthony Cassaccia, Jr. (AL)
5. Timothy Ka-Ming Cheung (FL)
6. Atta-ekarim Chowdhry (OR)
7. Maximiliano Garcia, Jr. (TX)**
8. Robert Allen Hatcher (AL)
9. Kristy Michelle Humber (AL)
10. Kelly Michael Kain (MT)
11. William Joseph Kottmer (AZ)
12. William Kenneth McAuliff (NE)**
13. Ingrid Maria Michael (MA)
14. Shrouq Kamel Qaisi (AL)
15. Anthony James Ricciardone (AL)
16. Harold D. Ross (IN)
17. Dennis Philip Soffin (NJ)
18. Anthony Robert Stricker (WA)
19. Walter Joseph Valentine (NJ)
20. John Shibi Varghese (NJ)
21. Craig Matthew Woodruff (FL)

** Must meet with full committee

H. Adjourn

NOTE: Pursuant to the Open Meetings Law at La. R.S. 42:16, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.

2
3 Title: Reciprocity Committee

Policy No. I.B.4.a

4
5 Approved: 11-09-2010

Revised:

6
7
8 1. The statutory authority for the Reciprocity Committee is RS 37:1203.

9
10 2. The regulatory authority for the Reciprocity Committee is LAC 46:LIII.109.

11
12 3. ~~After all other requirements for reciprocity have been completed, the applicant shall apply for an opportunity for the interview examination.~~

13
14
15 The licensing manager shall review all applications for pharmacist licensure by reciprocity as well as any other information acquired from other sources about the applicant. When the application and all supporting materials are complete and demonstrate compliance with the licensure requirements, the licensing manager shall issue the license.

16
17
18
19
20
21 4. ~~Board members shall receive advance notification of reciprocity applicants prior to the interview examination.~~

22
23
24 In the event the application or other information includes evidence of prior disciplinary history or other legal issues, the licensing manager shall refer the file to an administrative officer. Following the administrative officer's review of the file, the administrative officer may approve issuance of the license, or in the alternative, may refer the application to the full committee for its consideration.

25
26
27
28
29
30 5. ~~The date for the reciprocity interview will be determined by Board staff in consultation with both the reciprocity candidate and the interviewer(s).~~

31
32
33 In the event the committee has pending applications on its docket, the full committee shall interview the applicant and develop a recommendation to the Board relative to the fitness for licensure of the applicant.

34
35
36
37 a. In the event the application is complete except for the report from the criminal background check, that shall not automatically delay the consideration of the application by the committee; provided, however, the issuance of the license shall require receipt and favorable review of that report.

38
39
40
41
42
43 6. ~~If the candidate requests an interview date prior to the next regular meeting of the Reciprocity Committee, the staff (in consultation with the committee chair) shall use the following order of precedence in facilitating the arrangements:~~

44
45
46
47 a. ~~If a member of the Reciprocity Committee is scheduled to be in the Board office for official business, that member shall conduct the interview.~~

50
51 Title: Reciprocity Committee

Policy No. I.B.4.a

52
53 Approved: 11-09-2010

Revised:




54
55
56 ~~b. If a member of the Reciprocity Committee is not available, but another~~
57 ~~Board member is scheduled to be in the Board office for official business,~~
58 ~~that member shall conduct the interview.~~

59
60 ~~c. If no Board member is available, the Executive Director shall conduct the~~
61 ~~interview.~~

62
63 ~~d. If no interviewer is available through the options stated herein, the~~
64 ~~Reciprocity Committee Chair shall appoint a member of the Reciprocity~~
65 ~~Committee or another Board member to conduct the interview.~~

66
67 7 6. During the Board meeting following any interview examination, the Reciprocity
68 Committee shall submit to the Board for ratification the results of all reciprocity
69 interview examinations.



70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95

Revision History

105 08-15-2001

Original policy approved.

107 05-05-2004

Updated the regulatory citation in Article 2.

109 02-17-2005

Inserted Article 3.

111 11-14-2007

Deleted Article 3, in compliance with Act 164 of 2006 Legislature.

113 11-09-2010

Inserted Sub-Article 5.a

DRAFT



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Violations Committee

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Impairment Committee

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



NOTICE IS HEREBY GIVEN that a meeting of the Impairment Committee has been ordered and called for 1:00 p.m. on Tuesday, February 11, 2014 at the Board office, for the purpose to wit:

AGENDA

NOTE: This agenda is tentative until 24 hours in advance of the meeting, at which time the most recent revision becomes official.

Revised 02-10-2014

1. Call to Order
2. Quorum Call
3. Call for Additional Agenda Items
4. Opportunity for Public Comment
5. Review of Docket
 - A. *For Acceptance of Voluntary Surrenders of Credentials*
 - i. Case No. 13-0436 ~ PST.013660 – Kimm Rogers
 - ii. Case No. 13-0471 ~ CPT.010910 – Lauren Ashley Guess
 - iii. Case No. 13-0306 ~ PNT.046513 – Hoa Thi Pham
 - iv. Case No. 13-0442 ~ PST.018354 – Randy Wayne Owers
 - B. *Petitions For Reinstatement of Suspended Credentials*
 - i. Case No. 14-0012 ~ PST.011765 – Noel Gerard Fauchoux
 - ii. Case No. 14-0013 ~ CPT.010273 – Randi Lea Cassidy
 - C. *Petitions for Modification of Previous Orders*
 - i. Case No. 14-0014 ~ PST.014181 – David Collins Evans
 - ii. Case No. 14-0015 ~ PST.015620 – Douglas Christopher Montecino
 - D. *Applications for Pharmacist Licensure by Reciprocity*
 - i. Case No. 13-0464 ~ PST Applicant – Irish Elaine Lytle
 - E. *Appearances for Informal Conference*
 - i. Case No. 13-0491 ~ PST.011293 – Leon Jacob Barker
 - ii. Case No. 13-0484 ~ PTC Applicant - Tyler Addison Brantmeyer
 - F. *Appearances for Guidance*
 - i. Case No. 13-0473 ~ PST.015703 – Delery Jude Matherne, Jr.
 - ii. Case No. 14-0011 ~ PST.020284 – Elizabeth Farrell Heard
6. Adjourn

NOTE: Pursuant to the Open Meetings Law at La. R.S. 42:16, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17..



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Reinstatement Committee

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ Email: info@pharmacy.la.gov



NOTICE IS HEREBY GIVEN that a meeting of the Reinstatement Committee has been ordered and called for 9:00 a.m. on Tuesday, February 11, 2014 at the Board office, for the purpose to wit:

AGENDA

NOTE: This agenda is tentative until 24 hours in advance of the meeting, at which time the most recent revision becomes official.

Revised 02-07-2014

1. Call to Order
2. Quorum Call
3. Call for Additional Agenda Items
4. Opportunity for Public Comment
5. Review of Committee Policies & Procedures
6. Docket
 - A. *Petitions for Reinstatement (suspended + lapsed > 5 years + chair's discretion)*
 - i. Case No. 13-0439 ~ PST.011145 – Louis Charles Gambina
 - ii. Case No. 14-0001 ~ CPT.004353 – Tabitha Anne Norman
 - iii. Case No. 14-0016 ~ PST.015886 – Giselle Natasha Munroe
 - B. *Petitions for Modification of Previous Orders*
 - i. Case No. 14-0002 ~ PST.017793 – Charles Fredrick Bruce
 - ii. Case No. 14-0010 ~ PST.014226 – Patrick Glen Andrus
 - C. *Petitions for Return of Inactive Licenses to Active Status*
 - D. *CDS Petitions for Reinstatement (lapsed > 5 years, appearance not required)*
 - i. CDS.030394.MD – Uzvalatha Ganji
 - ii. CDS.024984.MD – Marleece Sherman Barber
 - iii. CDS.031358.APN – Gretchen Mercer Deeves
 - iv. CDS.025669.MD – Bradley Setser
 - v. CDS.030316-MD – John E. Britt
 - E. *Reinstatement of CDS Licenses Previously Suspended Secondary to Action by Another Agency*
 - i. CDS.027003.MD – Marcelo Granado Polanco
 - ii. CDS.033924.MD – Karen Lynn Paul
 - iii. CDS.030002.MD – Dana Lynn Rice

NOTE: Pursuant to the Open Meetings Law at La. R.S. 42:16, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.

F. Discretionary Approvals by Committee Chair (lapsed > 1 year but < 5 years)

- i. CDS.035384.MD – Adela Marie Narcisse
- ii. CDS.033435.MD – Lemuel Newton
- iii. CDS.035113.APN – Charisse V. Conner
- iv. CDS.036932.DVM – Gregory Richard Schmidt
- v. CPT.009240 – Kristen Marie Vasquez
- vi. CDS.040883.PA – Nikki B. Porter
- vii. CDS.024948.MD – John Kevin Jackson
- viii. CDS.012719.MD – Greg A. Robicheaux
- ix. CDS.033575.DPM – Nickyla M. Harris-Ray
- x. CDS.018631.MD – Vincent Gray Valentine
- xi. CDS.037103.MD – Anitha Christopher
- xii. CDS.026179.MD – Teresa Elena Klainer
- xiii. CDS.036005.DDS – Joe David Flowers
- xiv. CPT.005260 – Tiffany Marie Gardner
- xv. CDS.038340.MD – Tesfay Julien Tekle
- xvi. CDS.035801.MD – Shantan G. Reddy
- xvii. PST.017521 – JoAnn Hanna Estephan
- xviii. CDS.038375.DVM – Emelie S. McLellan
- xix. CDS.024147.MD – Richard Scribner
- xx. CDS.035113.APN – Charisse V. Conner
- xxi. CDS.039900.MD – Katherine E. Smith
- xxii. CDS.028427.MD – Fred B. Gaupp
- xxiii. CDS.034419.MD – Michael J. Bates
- xxiv. CDS.020180.MD – Mark Evan Freeman
- xxv. CDS.025827.MD – Robert J. Browning

G. Staff Approvals by Board Policy (lapsed < 1 year)

- i. CPT.009389 – Ty'Ana Lynell Nelson
- ii. DME.000205 – Omega Medical Health Systems
- iii. CDS.020712.MD – Michael Henry Armani
- iv. CDS.023043.MD – James Monroe Rhorer
- v. CDS.024021.MD – Susan Louise Vaught
- vi. CDS.016344.DDS – Leonard Charles Breda, III
- vii. CDS.040931.MD – Katherine D. Dela Rosa
- viii. CDS.034798.HOS – LSU-HCSD De Paul Campus
- ix. CDS.035960.MD – Vladimir Zuzukin
- x. CDS.012777.MD – Gloria Miranda-Fernandez
- xi. CDS.040999.MD – James S. Lee
- xii. CDS.034810.MD – Marjorie Nathan Person
- xiii. CDS.036200.MD – Sohail Khan
- xiv. CDS.038350.APN – Andrea Delaune Plauche'
- xv. CDS.017409.MD – Charles Gilbert Rogers, Jr.
- xvi. CDS.038299.MD – Charles Arthur Roberts
- xvii. CDS.038319.MD – John Allen Woods, Jr.
- xviii. CDS.035566.DVM – Jessica Ann Leto
- xix. CDS.038317.OD – Laurie A. Sicard
- xx. CDS.037099.MD – Syeda S. Munir
- xxi. CDS.021430.MD – Pamela Marie Conley
- xxii. CDS.018484.DDS – Francis Rinaudo

NOTE: Pursuant to the Open Meetings Law at La. R.S. 42:16, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.

- xxiii. CDS.027182.MD – Jacqueline Slaughter Langie
- xxiv. CDS.042219.DDS – Keleigh J. Quimby
- xxv. CDS.032778.APN – Aimee Bourgeois Daigle
- xxvi. CDS.042388.MD – Ross Michael Doize
- xxvii. CDS.015770.MD – Debra Katherine Deprato
- xxviii. CDS.041012.APN – Jocelyn Shereen Beasley
- xxix. CDS.031792.DVM – Cynthia Alana Benbow
- xxx. CDS.017337.MD – Patricia Treloar Peairs
- xxxi. CDS.008860.MD – Cesar Ronaldo Funes
- xxxii. CDS.027681.MD – Amy E. Sheeder
- xxxiii. CDS.037113.MD – Jay Kennedy Kolls
- xxxiv. CPT.008099 – Jessica Anne Entremont
- xxxv. AMS.010484.X – Walgreens #04998
- xxxvi. PST.019356 – Doug Frederick Cammann
- xxxvii. CDS.037866.DDS – Francis S. Sicard
- xxxviii. CDS.028060.MD – Rosalind Annette Cropper
- xxxix. CDS.042335.MEX – North Oaks Primary Care – Independence
 - xl. CDS.037080.MD – Charles H. Baughman
 - xli. CDS.042498.APN – Emily M. Davis
 - xl.ii. CPT.010420 – British Roshanna Foster
 - xl.iii. CPT.006440 – Nedra Parker Allen
 - xl.iv. CDS.019410.EMS – American Medical Response
 - xl.v. CDS.030960.MD – Bryan Wayne Barrett
 - xl.vi. CDS.035908.DVM – Charlotte A. Milazzo
 - xl.vii. CDS.041093.DDS – Van Dien Nguyen
 - xl.viii. CDS.042326.DVM – Erin McCarty Davezac
 - xl.ix. CDS.007942.MD – Robyn Easton Tyler
 - I. CDS.034955.MD – Leonet Lacayo
 - li. CDS.031765.DET – Brad W. Rogers
 - lii. CDS.025054.MD – Brian K. Granger
 - liii. CDS.030095.MD – Andrew Rogers Marsh
 - liv. CDS.042378.APN – Michelle Meynard Comboy
 - lv. CDS.042519.APN – Donald Blake Smith
 - lvi. CDS.018840.MD – Mark Allen Sands
 - lvii. CDS.033895.MD – James E. Hines, III
 - lviii. CDS.037214.DDS – Yvondia M. Scott
 - lix. CDS.042516.MD – Carina Daisy Curnow
 - lx. CDS.042207.MD – Kelly M. Johnson
 - lxi. CDS.042430.MD – Timothy Donald McShurley
 - lxii. CDS.018570.ASC – Outpatient Eye Surgery Center Inc.
 - lxiii. AMS.010653.X – Walgreens#13679
 - lxiv. CDS.027412.MD – Karen Joy Ortenberg
 - lxv. CDS.033956.MD – Fatai Gbolade Adamson
 - lxvi. CPT.005428 – Annette Dequeant Thompson
 - lxvii. CDS.039817.MD – Geetika Dembla
 - lxviii. AMS.010611.X – Walgreen Pharmacy #07083
 - lxix. CPT.008906.DDS – Shamelle LaQuan Harris
 - lxx. CPT.007293 – Kimberly Renee Johnson
 - lxxi. CDS.029182.DDS – Tahisa Patric Colbert
 - lxxii. CDS.037279.APN – Delana M. Martinez
 - lxxiii. CDS.028341.MD – Antoinette Theresa Harvey-Fields

NOTE: Pursuant to the Open Meetings Law at La. R.S. 42:16, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.

- lxxiv. CDS.034855.APN – Luberta M. Brown
- lxxv. CDS.032773.RES – Karen Stokes
- lxxvi. CDS.042532.DVM – Neal Joseph Hebert
- lxxvii. CDS.024955.DVM – Martin J. Sanchez
- lxxviii. CDS.036125.MD – Richard S. Kuebler
- lxxix. CDS.038041.MD – Erin T. Mariano MD
- lxxx. CDS.016851.DVM – Lisa S. Brabham
- lxxxi. CDS.034825.APN – Barbara B. Maxwell
- lxxxii. CDS.024917.MD – James David Hammond
- lxxxiii. CDS.025785.MD – Lolita Carmen Gonzales
- lxxxiv. CDS.032961.OD – Andre Long
- lxxxv. CDS.041800.DDS – Joshua S. Brandner
- lxxxvi. CDS.020345.MD – Moises Yoselevitz
- lxxxvii. CDS.032856.MD – Jeryl Breaux
- lxxxviii. CDS.042454.APN – Shelly Kaye Dupin
- lxxxix. CDS.039895.MD – Abhishek Agarwal
 - xc. CDS.038344.MD – Anshuman Jyoti
 - xc. CDS.042579.MD – Claude Y. Bundrick
 - xcii. CDS.018231.MD – Michael Leon Wheelis

7. Adjourn

NOTE: Pursuant to the Open Meetings Law at La. R.S. 42:16, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.

Title: Reinstatement Committee

Policy No. I.B.5.a

Approved: 08-05-2009

Revised:

-
1. The statutory authority for the Reinstatement Committee is RS 37:1249.
 2. The regulatory authority for the Reinstatement Committee is LAC 46:LIII.109.
 3. Current regulations indicate the expiration date of licenses issued by the Board.
 - a. The pharmacist license expires December 31 of each year. (LAC 46:LIII.505.A.4)
 - b. The pharmacy technician certificate expires June 30 of each year. (LAC 46:LIII.807.D)
 - c. The controlled dangerous substance (CDS) license expires one year after the date of issue. (LAC 46:LIII.2707.A.6)
 4. Applications for licensure renewal placed in possession of authorized mail carriers, or received in the Board office, after the expiration date shall be referred to the Reinstatement Committee for its consideration.
 - a. For credentials lapsed less than one year, the Executive Director may exercise administrative discretion in the approval of the reinstatement application.
 - b. For credentials lapsed more than one year, the Executive Director shall consult with the committee chair to determine the necessity for the personal appearance of a reinstatement applicant.
 - c. For credentials (other than CDS licenses) lapsed five years or more, the Executive Director committee chair in consultation with the President shall have the discretion to notice the applicant to appear before the committee.
 - d. For CDS credentials lapsed five years or more, the Executive Director shall consult with the committee chair, and further, shall notify the applicant's primary licensing agency and the U. S. Drug Enforcement Administration of the applicant's lapse and reinstatement.
 5. The applicant shall submit the following items to the Board office no later than 30 days prior to any Administrative Hearing:
 - a. properly completed application for renewal;
 - b. copies of continuing pharmacy (cpe) education certificates submitted in support of CPE requirements;
 - c. report of criminal background check, provided, however, that the non-receipt of said report shall not serve to automatically delay the consideration of the application by the committee;
 - d. administrative hearing fee of \$250, (RS 37:1184.a.ix);
 - e. reinstatement fee of \$200, (RS 37:1184.b.iii);
 - f. any unpaid fees imposed by prior Board orders; and

Title: Reinstatement Committee

Policy No. I.B.5.a

Approved: 08-05-2009

Revised:



- g. any other fees incurred through non-renewal. The fee for credentials lapsed in excess of one year shall include the renewal fee and the delinquent fee in effect for each intervening year.
6. The committee will determine the conditions under which it will recommend to the Board the approval or denial of the application for renewal. The committee's recommendation may include the successful completion of the Multistate Pharmacy Jurisprudence Examination (MPJE), additional supervised practical experience, additional continuing pharmacy education, or any other measures the committee may deem necessary.
7. All correspondence and/or communications relative to applicants shall be coordinated through the Board office.

DRAFT

Title: Reinstatement Committee

Policy No. I.B.5.a

Approved: 08-05-2009

Revised:

Revision History

- 02-10-2000 Original policy approved.
- 04-26-2000 Added the following:
- 4a. For licenses lapsed less than one year, the Executive Director may exercise administrative discretion in the approval of the reinstatement application.
 - 4b. For licenses lapsed more than one year, the Executive Director shall consult with the committee chair to determine the necessity for the personal appearance of a reinstatement applicant.
- 05-05-2004 Updated regulatory citations in Articles 2, 3.2, and 3.b
Technical corrections in Articles 3.b, 4.a, and 4.b ('credentials' for 'licenses').
Added Article 4.c.
Deleted Article 5.f.ii, due to deletion of enabling regulation.
- 02-21-2008 Added Article 5.c.
- 08-05-2009 Added Article 3.c.
Amended Article 4.c to insert 'other than CDS licenses' after credentials
Added Article 4.d



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Tripartite Committee

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Regulation Revision Committee

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.

- 55 access prescription monitoring information.
- 56 5. Upon receipt of information that an authorized user no longer possesses authority to prescribe or
- 57 dispense controlled substances, the program shall terminate the user’s credentials to access
- 58 prescription monitoring information. If or when the user’s authority to prescribe or dispense
- 59 controlled substances is reinstated, the program may reinstate the user’s credentials to access
- 60 prescription monitoring information.
- 61 6. Prescribers and dispensers approved for access shall be responsible for the enabling and/or
- 62 disabling of access privileges for their delegates, as well as the supervision of their activities.
- 63

64 AUTHORITY NOTE: Promulgated by R.S. 40:1011.

65 HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 33:1347
66 (July 2007), amended LR

67
68 **§2921. Methods of Access to Prescription Monitoring Information**

- 69 A. Prescribers and dispensers as well as their delegates, once properly registered, may solicit prescription
- 70 monitoring information from the program concerning their patients, or for verifying their prescription
- 71 records. The program may require such users to certify the legitimacy of their inquiry prior to
- 72 furnishing the requested information.

73 ...

74
75 AUTHORITY NOTE: Promulgated in accordance with R.S. 40:1011.

76 HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 33:1347
77 (July 2007), amended LR 39:315 (February 2013), amended LR

78
79 **§2923. Unlawful Use or Disclosure of Prescription Monitoring Information**

- 80 A. If the program receives evidence of inappropriate or unlawful use or disclosure of prescription
- 81 monitoring information by an authorized user or his delegate, the program shall refer that user to the
- 82 appropriate professional licensing, certification, or regulatory agency for administrative sanctions as
- 83 deemed appropriate by that agency.

84
85 AUTHORITY NOTE: Promulgated in accordance with R.S. 40:1011.

86 HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 33:1348
87 (July 2007), amended LR

88

Louisiana Administrative Code

Title 46 – Professional and Occupational Standards

Part LIII – Pharmacists

Chapter 29. Prescription Monitoring Program

Subchapter A. General Operations

§2901. Definitions

A. As used in this Chapter, the following terms shall have the meaning ascribed to them unless the context clearly indicates otherwise:

...

Dispenser – a person authorized by this state to dispense or distribute to the ultimate user any controlled substance or drug monitored by the program, but shall not include any of the following:

a. – d. ...

~~e. – a veterinarian who dispenses negligible amounts of controlled substances or drugs of concern, as identified by rule~~

...

AUTHORITY NOTE: Promulgated in accordance with R.S. 40:1011.

HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 33:1345 (July 2007), amended LR 36:755 (April 2010), effective September 1, 2010, amended LR 39:314 (February 2013), amended LR

...

§2909. Advisory Council

A. The advisory council shall consist of the following members, each of whom may appoint a designee:

1-4. ...

~~5. – the president of the Louisiana State Board of Veterinary Medicine;~~

6-25...

~~26. – the president of the Louisiana Veterinary Medical Association~~

...

AUTHORITY NOTE: Promulgated in accordance with R.S. 40:1005.

HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 33:1346 (July 2007), amended LR 39:314 (February 2013), amended LR

1 HLS 14-
 2 Regular Session, 2014
 3 House / Senate Bill No. _____
 4 By Representative / Senator _____
 5

6 CONTROLLED SUBSTANCES: Adds new drugs to Schedules II, III, and IV.

7

8 AN ACT

9

10 To amend and reenact R.S. 40:964, relative to the composition of various schedules of controlled
 11 substances.

12 Be it enacted by the Legislature of Louisiana:

13 Section 1. R.S. 40:964 is hereby amended and reenacted to read as follows:

14 §964. Composition of schedules

	*	*	*
--	---	---	---

16 Schedule II

	*	*	*
--	---	---	---

18 E. Immediate Precursors

	*	*	*
--	---	---	---

20 (3) Immediate precursor to fentanyl:

21 (a) 4-anilino-N-phenethyl-4-piperidine (ANPP)

	*	*	*
--	---	---	---

23 Schedule III

	*	*	*
--	---	---	---

24

1
2
3
4
5
6
7
8
9
10
11

B. Depressants

* * *

(15) Perampanel

* * *

Schedule IV

* * *

D. Stimulants

* * *

(13) Lorcaserin

* * *

1 HLS 14-
 2 Regular Session, 2014
 3 House / Senate Bill No. _____
 4 By Representative / Senator _____

5

6 CONTROLLED SUBSTANCES: Amends the frequency of reporting prescription transactions to
 7 the state prescription monitoring program.

8

9 AN ACT

10

11 To amend and reenact R.S. 40:1006, relative to the reporting of prescription monitoring
 12 information.

13 Be it enacted by the Legislature of Louisiana:

14 Section 1. R.S. 40:1006 is hereby amended and reenacted to read as follows:

15 §1006. Reporting of prescription monitoring information

16 * * *

17 B. Each dispenser shall submit the required information in accordance with
 18 transmission methods and frequency established by the board. ~~Each eligible~~
 19 ~~prescription transaction shall be reported as soon as possible but in no event~~
 20 ~~more than seven days after the date of dispensing.~~

21 * * *

22



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Executive Committee

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



NOTICE IS HEREBY GIVEN that a meeting of the Executive Committee has been ordered and called for the late afternoon of Tuesday, February 11, 2014 [to follow the meeting of the Impairment Committee] at the Board office, for the purpose to wit:

AGENDA

NOTE: This agenda is tentative until 24 hours in advance of the meeting, at which time the most recent revision becomes official.

Revised 02-05-2014

1. Call to Order
2. Quorum Call
3. Call for Additional Agenda Items
4. Opportunity for Public Comment
5. Review of Contracts & Agreements
6. Review of Administrative Operations
7. Review of *Policy No. I.A.2 – Declaratory Statements & Advisory Opinions*
8. Adjourn

NOTE: Pursuant to the Open Meetings Law at La. R.S. 42:16, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.

Louisiana Board of Pharmacy
Executive Committee

<u>Contractor - Purpose of Contract</u>	<u>FY 12-13 Actual</u>	<u>FY 13-14 YTD</u>	<u>FY 14-15 Contract</u>
Accounting - General Russell F. Champagne Kolder, Champagne, Slaven, LLC Certified Public Accountants 113 East Bridge Street Breaux Bridge, LA 70517	16,699	12,466	25,000
Legal - Prosecuting Attorney Celia R. Cangelosi PO Box 3036 Baton Rouge, LA 70821-3036	2,586	12,675	80,000
Legal - Counsel to Hearing Officer E. Wade Shows Shows, Cali & Berthelot 644 St. Ferdinand Baton Rouge, LA 70802	20,482	8,079	40,000
Testing & Information Systems - Licensure Information System Iron Data Corporation 4515 Falls of Neuse Rd, Suite 250 Raleigh, NC 27609	104,849	63,746	75,000
Testing & Information Systems - Network Support Services Essential Solutions, LLC 343 Third Street, Suite 400 Baton Rouge, LA 70801	26,690	20,968	40,000
Testing & Information Systems - Prescription Monitoring Program Optimum Technology, Inc. 100 Campus View Blvd, Ste 380 Columbus, OH43235	110,500**	0	100,000

** Previous Vendor - Health Information Designs (HID)

Louisiana Board of Pharmacy
Executive Committee

<u>Contractor - Purpose of Contract</u>	FY 11-12 <u>Actual</u>	FY 12-13 <u>YTD</u>	FY 13-14 <u>Contract</u>
Publication Services - Board Newsletter NABP Foundation 1600 Feehanville Drive Mount Prospect, IL 60056	31,217	16,471	2,000
Examination Services - Pharmacists NABP 1600 Feehanville Drive Mount Prospect, IL 60056	0	0	0
Examination Services - Technicians PTCB 2215 Constitution Ave., NW Washington, DC 20202	0	0	0



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Prescription Monitoring Program

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Prescription Monitoring Program


Board Meeting
February 12, 2014

Joe Fontenot, R.Ph. Assistant Executive Director
Danielle C. Meadors, Administrative Assistant

Number of Eligible Transactions Reported to the PMP

Total Reported as of
December 31, 2013


68,073,313




Practitioner Access

(as of December 31, 2013)

Prescribers – Total
Authorized 4,009



Dispensers – Total
Authorized 2,575



Total Number of Practitioners with Access – 6,584

Practitioner Access


(as of December 31, 2013)

Prescriber Category	Prescribers possessing CDS license	Prescribers with PMP Access	Percentage with PMP Access
Physicians (MD)	11,621	2,771	23.8%
Physicians' Assistants (PA)	424	120	28.3%
Dentists (DDS)	2,084	366	17.6%
APRNs	1,307	482	36.9%
Medical Psychologists (MP)	78	37	47.4%
Optometrists (OD)	308	11	3.5%
Podiatrists (DPM)	130	16	12.3%
Totals:	15,952	3,803	23.8%

Louisiana Licensed Pharmacists	Number of Louisiana licensed Pharmacists	Pharmacists with PMP Access	Percentage with PMP Access
Pharmacists (RPh)	7,826	2,562	32.7%

Practitioner Queries – 2013


Overall Query total = 1,224,343



Practitioner Queries


(01/01/2009 through 12/31/2013)

Overall Query total = 3,527,377



Board and Regulatory Agencies

Profile Views by Boards & Regulatory Agencies Total = **6,794**
(01/01/2009 through 12/31/2013)



Law Enforcement Access and Requests

Number of Law Enforcement
Requests Processed = **4,794**
(01/01/2009 through 12/31/2013)

2009	2010	2011	2012	2013
680	889	1,230	845	1,150

Requests for Exemption from PMP Reporting

February 12, 2014

In accordance with LA.R.S:40.4.X-A.1006.C. The board may issue a waiver to a dispenser who is unable to submit prescription information by electronic means. The waiver shall state the format and frequency with which the dispenser shall submit the required information. The board may issue an exemption from the reporting requirement to a dispenser whose practice activities are inconsistent with the intent of the program. The board may rescind any previously issued exemption without the need for an informal or formal hearing.

Permit	Type	Name	Scope of Practice	DEA	City	State
6809	OS	One Stop Pharmacy	Compounding Pharmacy	No	St. Petersburg	FL

Staff Recommendation: Not to approve.

Permit	Type	Name	Scope of Practice	DEA	City	State
5933	OS	Critical Care Systems	Sterile Compounding	Yes	Houston	TX
6443	OS	Critical Care Systems	Parenteral Pharmacy	Yes	Mobile	AL
6767	OS	Direct Pharmacy Source	Retail Pharmacy	Yes	Sunrise	FL
6776	OS	Alliance Allergy Solutions	Compounding (Sublingual Allergy Drops)	No	Birmingham	AL
6790	OS	ASL Pharmacy	Topical Sinus Medications	Yes	Camarillo	CA
6812	OS	Infuserve America	IV Lyme Disease Treatment	Yes	St. Petersburg	FL
4881	HOS	Teche Regional Medical Center Pharmacy	Inpatient Hospital Pharmacy	Yes	Morgan City	LA
6781	HOS	LifeCare Specialty Hospital of North Louisiana	Inpatient Hospital Pharmacy	Yes	Ruston	LA

Staff Recommendation

Approve the proposed waivers conditioned upon execution of the standard Consent Agreement:

WAIVER TO PRESCRIPTION MONITORING PROGRAM REPORTING REQUIREMENTS
CONSENT AGREEMENT

WHEREAS, in order to facilitate the pharmacy's request for a waiver to the reporting requirements to the Louisiana Board of Pharmacy's Prescription Monitoring Program (PMP) as required by law, the Pharmacy indicated below agrees to the following terms:

- (1) The Pharmacy shall not be authorized to dispense any controlled dangerous substances (CDS) or *drugs of concern*, with the exception of hospital inpatient dispensing, as identified by the Louisiana Board of Pharmacy (Board) by regulation.
- (2) Upon the first instance of receipt of evidence by the Board indicating the Pharmacy dispensed CDS or drugs of concern, the Pharmacy agrees to the following sanction:
The Pharmacy agrees to pay a fine of \$5,000.00 and reimburse the Board \$250.00 in administrative hearing costs, with total payment due the Board of \$5,250.00, due by certified check or money order within 30 days of notice of this prohibited activity.
- (3) Upon the second instance of receipt of evidence indicating the Pharmacy dispensed CDS or drugs of concern, the Pharmacy agrees to pay the above sanction, the termination of this waiver and the resumption of its reporting to the PMP.
- (4) The Pharmacy shall post a copy of this agreement adjacent or attached to its pharmacy permit.

By signing this Consent Agreement, Respondent agrees that the Board has jurisdiction in this matter and waives all rights to informal conference, to Notice of Hearing, to a formal Administrative Hearing, and to judicial review of this Consent Agreement.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Report of General Counsel

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Report of Executive Director

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



February 12, 2014

Agenda Item 10-L: Report of Executive Director

1. Meeting Activity
2. Reports
3. Examinations
4. Operations
5. State Activities
6. National Activities
7. International Activities

1. **Meeting Activity**

In addition to Board and committee meetings, I have also participated in or attended the following meetings since the last Board meeting.

Jan. 21 La. House of Representatives Cmte on Criminal Justice (HSR-1)

2. **Reports** (all in the Boardroom Library)

A. Census Reports

1. Compliance Division – Practitioner Recovery Program & Discipline
2. Credentials Division – CDS & Pharmacy Programs

B. Credentials Division Production Reports

1. Licensure Activity Report [new credentials in previous quarter]
2. Application Activity Report [pending applications count]

C. Exceptions Report

1. PIC in Multiple Locations
2. Resurrected Credentials / Special Work Permits

3. **Examinations**

- A. MPJE – the results for the third trimester of 2013 are posted.
- B. NAPLEX – the results for the third trimester of 2013 are posted.
- C. PARE – first test administered in office on Jan. 31, 2014.
- D. PTCB – the results for the second half of 2013 are posted.

4. **Operations**

A. Credentials Division

We opened the renewal cycles for pharmacists and pharmacies on November 1 and closed them on December 31.

- Of the 7,864 pharmacists noticed, 7,500 renewed timely – and of that number, 93.5% did so online.

- Of the 1,841 pharmacies noticed, 1,694 renewed timely – and of that number, 89.9% did so online.
- Of the 1,383 pharmacies holding CDS licenses noticed, 1,383 renewed timely – and of that number, 92.4% did so online.

During the November 2013 Board meeting, the Executive Committee requested staff consultation with the National Association of Boards of Pharmacy (NABP) for assistance in the inspection of non-resident pharmacies. On our approach to NABP, they advised us of a new program designed to assist state boards in regulating nonresident pharmacies. The Verified Pharmacy Program (VPP) was developed to provide an information sharing network for the boards of pharmacy to use in sharing critical inspection and licensing data with other boards. Similar to the Electronic Licensure Transfer Program for pharmacists, VPP also facilitates the nonresident pharmacy licensure transfer process. To assist your understanding of this new program, I have posted NABP's Fact Sheet about the program in the Boardroom Library. I encourage your review of these materials to learn more about the program.

To address our board's needs to appropriately regulate our nonresident pharmacies, I recommend the Board consider requiring our nonresident pharmacies to obtain a VPP e-Profile number prior to applying for a new pharmacy permit and prior to renewing their existing pharmacy permit. In the event you decide to move in that direction, you may wish to consider whether you wish to provide any delayed enforcement discretion for such a requirement. We currently have approximately 400 nonresident pharmacy permits in active status, and further, have approximately 60 applications for nonresident pharmacy permits in various stages of processing.

B. Compliance Division

Our 5 pharmacist compliance officers are responsible for inspecting all the pharmacies and other facilities holding controlled substances (CDS). The census reports available for this meeting reflects just over 1,400 pharmacies within the state, as well as approximately 800 various types of facilities for CDS visits, including hospitals, distributors, ambulatory surgical centers, etc.

In addition to their routine site visits, the compliance officers are also responsible for investigating complaints filed with the Board. We began the fiscal year with 178 cases pending from the prior fiscal year. To date we have entered 313 new cases and closed 319, leaving 172 cases pending at this time. Of the 319 cases closed to date this fiscal year, 182 (57%) were disposed of through staff activities and the balance through committee and Board action.

5. **State Activities**

A. 2014 Louisiana Legislature

The initial report for this year's session was posted in the Boardroom Library.

B. Board of Nursing

Pursuant to the board's direction with respect to the petition from the home infusion provider at the pharmacy board's August 2013 meeting, we met with the nursing board leadership to review the request and supporting documentation. We planned the research necessary to obtain information relevant to the request. We met again to review the results of the research. As you may know, the Board of Nursing has a new Executive Director and we have paused the progress of our efforts to give her an opportunity to engage in the project.

6. **National Activities**

A. National Association of Boards of Pharmacy (NABP)

For your planning purposes, the 2014 meeting will be held in Phoenix, AZ and the 2015 meeting will be held in New Orleans, LA. This conference is one of the three meetings for which your travel expenses are eligible for reimbursement, subject to the

limitations itemized in the Board's travel policy as well as the state's travel policy in PPM-49.

B. NABP-AACP District 6 Annual Meeting

For your planning purposes, the 2014 meeting will be held in Whitefish, MT on September 21-24. This conference is one of the three meetings for which your travel expenses are eligible for reimbursement, subject to the limitations itemized in the Board's travel policy as well as the state's travel policy in PPM-49.

C. MALTAGON

The 2014 conference is scheduled to be hosted by the Florida Board of Pharmacy this fall. As soon as we have confirmed details, we will forward that information to you. This conference is one of the three meetings for which your travel expenses are eligible for reimbursement, subject to the limitations itemized in the Board's travel policy as well as the state's travel policy in PPM-49.

7. *International Activities*

A. International Pharmaceutical Federation (FIP)

Thailand is scheduled to host the 2014 World Congress in Bangkok on August 30 – September 4. Due to recent political events in that country, the FIP Bureau has scheduled a meeting this month to consider potential changes to their plans.

B. World Health Professions Alliance (WHPA)

WHPA was formed in 1999 and includes the International Council of Nurses, International Pharmaceutical Federation, World Confederation for Physical Therapy, World Dental Federation, and World Medical Association. The alliance facilitates collaboration among the health professions and major stakeholders, including national governments and the World Health Organization.

In 2008, the WHPA instituted the World Health Professions Regulation Conference. The conference participants discuss different models of health professional regulation, regulatory body governance and performance, as well as trade in services and implications for regulation. The second conference in the series was held in 2010, and the third conference in the series will be held on May 17-18, 2014 in Geneva, Switzerland. The objectives for the 2014 conference are to evaluate the challenges facing health professional regulation, review the evolution of competence based approaches to regulatory functions, and identify and promote best practices in regulatory governance and performance.

Respectfully submitted,
Malcolm J. Broussard
Executive Director



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Compliance Division Census Report

February 12, 2014

Practitioner Recovery Program

- Probation Completion Report

02-11-2014	PST.014439 – Kenneth Ray Richard
02-11-2014	CPT.007340 – Laura Elizabeth Lyons
02-11-2014	PST.016890 – James Claude McGee

- Active Probation 50 Pharmacist
 2 Pharmacy intern
 3 Technician
- Active Suspension 41 Pharmacist
 2 Pharmacy intern
 12 Technician
 4 Technician candidate

Disciplinary Restrictions

- Probation Completion Report

12-15-2013	PST.016189 – Melinda Hill Jones
01-01-2014	PHY.006070 – The Compounding Corner
01-01-2014	PST.016625 – Kristian Raymond Hahn
01-01-2014	PHY.003693 – Medic's Compounding Lab
01-01-2014	PST.014279 – David Stanley Burch
01-01-2014	PST.009123 – Eugene John McKeon
01-01-2014	CPT.007615 – Catherine Joette Pearson

- Active Probation 26 Pharmacist
 5 Technician
 2 Technician candidate
 10 Pharmacy permit (+ 2 on restriction, w/o probation)
 5 CDS-PHY license
 1 CDS-DIS license
- Active Suspension 41 Pharmacist
 1 Pharmacy intern
 56 Technician
 14 Technician candidate
 13 Pharmacy permit
 1 CDS-PHY license
 26 CDS license for practitioners

Louisiana Board of Pharmacy
 Credentials Division
 Pharmacy Program

		<u>06/30/05</u>	<u>06/30/06</u>	<u>06/30/07</u>	<u>06/30/08</u>	<u>06/30/09</u>	<u>06/30/10</u>	<u>06/30/11</u>	<u>06/30/12</u>	<u>06/30/13</u>	<u>02/05/14</u>
PST-VI	LA	0	0	0	0	0	0	12	10	9	14
	NR	0	0	0	0	0	0	9	10	15	9
	Total	0	0	0	0	0	0	21	20	24	23
PST-GVI	LA	0	0	0	0	0	0	0	6	13	11
	NR	0	0	0	0	0	0	0	0	3	4
	Total	0	6	16	15						
PST-M	LA	0	0	0	0	0	0	3	5	3	1
	NR	0	0	0	0	0	0	11	11	11	13
	Total	0	0	0	0	0	0	14	16	14	14
PST-G	LA	0	0	0	0	0	0	158	157	164	143
	NR	0	0	0	0	0	0	30	35	32	28
	Total	0	0	0	0	0	0	188	192	196	171
PST	LA	4,532	4,460	4,522	4,612	4,750	4,860	4,654	4,933	4,981	5,139
	NR	1,686	1,915	1,975	1,964	2,029	2,098	2,079	2,212	2,527	2,354
	Total	6,218	6,375	6,497	6,576	6,779	6,958	6,733	7,145	7,508	7,493
	PST	6,218	6,375	6,497	6,576	6,779	6,958	6,935	7,353	7,758	7,716
PNT	LA	1,154	980	1,079	1,074	1,035	965	907	938	942	992
	NR	0	109	117	67	84	153	137	128	128	125
	Total	1,154	1,089	1,196	1,141	1,119	1,118	1,044	1,066	1,070	1,117
PNT-FPG	Total	0	0	0	0	0	0	5	0	3	6
	PNT	1,154	1,089	1,196	1,141	1,119	1,118	1,049	1,066	1,073	1,123
CPT	LA	4,455	4,552	4,587	4,780	4,733	5,363	5,720	5,509	5,751	6,280
	NR	0	163	152	144	109	144	145	120	112	125
	Total	4,455	4,715	4,739	4,924	4,842	5,507	5,865	5,629	5,863	6,405
CPT-M	Total	0	0	0	0	0	0	1	0	1	1
	CPT	4,455	4,715	4,739	4,924	4,842	5,507	5,866	5,629	5,864	6,406
PTC	LA	1,074	1,081	1,389	1,446	1,510	1,679	1,574	1,665	1,658	1,799
	NR	0	32	32	23	32	35	35	39	37	32
	PTC	1,074	1,113	1,421	1,469	1,542	1,714	1,609	1,704	1,695	1,831
PHY	CH	12	12	12	11	12	14	12	12	12	12
	HOS	181	167	164	167	167	165	151	154	158	162
	HOX	0	0	0	0	0	0	19	18	14	12
	IN	36	35	36	37	37	27	14	10	12	11
	INX	0	0	0	0	0	0	11	14	13	13
	IR	729	681	620	588	592	587	570	568	558	574
	IRX	0	0	0	0	0	0	21	19	17	13
	NR	200	226	240	250	256	286	318	361	387	396
	NRN	0	0	0	0	0	0	0	0	0	9
	NU	13	17	16	16	16	16	15	15	15	15
	PEN	0	0	0	0	0	0	0	0	0	0
	PEX	0	0	0	0	0	0	0	0	1	2
	RC	473	430	491	534	545	562	576	587	597	613
	PHY	1,644	1,568	1,579	1,603	1,625	1,657	1,707	1,758	1,784	1,832
AMS	AMS	174	173	212	255	306	361	55	64	349	89
	AMS-X	0	0	0	0	0	0	301	302	289	360
	AMS	174	173	212	255	306	361	356	366	638	449
EDK	EDK	471	428	412	439	388	503	417	435	421	467
	EDK-X	0	0	0	0	0	0	13	13	10	10
	EDK	471	428	412	439	388	503	430	448	431	477
DME	LA								223	160	228
	NR									218	204
	DME									378	432
CDTM										41	41
MAR										1,617	1,833
SWP							58	78		126	43
TOTAL										21,405	22,183

Louisiana Board of Pharmacy
 Credentials Division
 CDS Program

<i>Classification</i>	<u>06/30/07</u>	<u>06/30/08</u>	<u>06/30/09</u>	<u>06/30/10</u>	<u>06/30/11</u>	<u>06/30/12</u>	<u>06/30/13</u>	<u>02/05/14</u>
ACS Animal Control Shelter	0	0	0	1	1	1	1	1
AMS Automated Medication Sys	0	0	0	0	0	0	0	15
AMX Automated Medication Sys - Exempt	0	0	0	0	0	0	0	1
APN APRN	346	479	607	758	889	1,015	1,103	1,323
ASC Ambulatory Surgical Ctr	94	101	106	113	90	88	85	87
CRX Correctional Ctr - Exempt	0	0	0	0	7	6	5	5
DDS Dentist	2,090	2,177	2,267	2,363	2,027	2,048	1,902	2,084
DET Drug Detection / Canine	20	20	20	22	14	12	10	9
DEX Drug Detection / Canine - Exempt								1
DIS Distributor	285	322	363	400	279	288	273	320
DPM Podiatrist	147	153	161	165	139	136	118	132
DVM Veterinarian	870	936	1,000	1,065	922	901	852	990
DYS Dialysis Ctr	63	63	63	63	6	4	3	4
EMC Emergency Medical Ctr	17	17	17	18	14	16	17	18
EMS Emergency Medical Service	57	58	63	66	54	50	45	48
ETC Animal Euthanasia Tech - Cert	31	39	44	49	16	7	6	4
ETL Animal Euthanasia Tech - Lead	0	0	0	0	12	20	21	23
HOS Hospital	369	387	405	438	280	267	263	279
HOX Hospital - Exempt	0	0	0	0	12	14	5	6
LAB Laboratory	13	14	14	15	8	6	7	7
LAX Laboratory - Exempt	0	0	0	0	4	5	5	5
MD Physician	13,195	13,876	14,599	15,269	12,362	11,727	10,698	11,657
MDT Physician on Telemedicine	0	0	0	0	0	0	0	1
MED Medical Clinic	73	78	88	102	77	81	68	72
MEX Medical Clinic - Exempt	0	0	0	0	3	5	14	11
MFR Manufacturer	36	43	52	58	48	50	45	48
MIS Miscellaneous	74	73	58	59	11	10	9	10
MIX Miscellaneous - Exempt	0	0	0	0	9	4	3	3
MP Medical Psychologist	37	44	50	58	65	67	69	78
OD Optometrist	230	253	269	278	275	287	279	309
PA Physician Assistant	170	194	232	272	294	326	344	428
PHX Pharmacy - Exempt	0	0	0	0	50	47	41	33
PHY Pharmacy	0	0	0	0	1,307	1,318	1,329	1,341
REP Sales Representative	57	65	66	88	29	20	7	5
RES Researcher	100	110	119	156	109	110	98	107
RHC Rural Health Clinic	19	20	21	23	17	12	11	12
SAC Substance Abuse Clinic	14	14	14	17	7	9	9	9
SAX Subst. Abuse Clinc - Exempt	0	0	0	0	0	0	0	0
Total	18,407	19,536	20,698	21,916	19,437	18,957	17,745	19,486

Total Credentials Under Management

Pharmacy	16,056	16,407	16,601	17,818	18,260	18,625	21,405	22,183
CDS	<u>18,407</u>	<u>19,536</u>	<u>20,698</u>	<u>21,916</u>	<u>19,437</u>	<u>18,957</u>	<u>17,745</u>	<u>19,486</u>
Total	34,463	35,943	37,299	39,734	37,697	37,582	39,150	41,669

Louisiana Board of Pharmacy
Census Report

<i>Type of Credential</i>	<u>3/17/1995</u>	<u>6/30/1996</u>	<u>3/19/1997</u>	<u>6/30/1998</u>	<u>6/30/1999</u>	<u>6/30/2000</u>	<u>6/30/2001</u>	<u>6/30/2002</u>	<u>6/30/2003</u>	<u>6/30/2004</u>	<u>6/30/2005</u>
Pharmacists											
In-state	3,642	3,660	4,143	4,247	4,269	4,830	3,887	4,386	4,435	4,486	4,532
Out-of-state	377	446	1,339	1,435	1,421	944	1,901	1,453	1,455	1,484	1,686
TOTAL	4,019	4,106	5,482	5,682	5,690	5,774	5,788	5,839	5,890	5,970	6,218
Pharmacy Interns											
In-state											
Out-of-state											
TOTAL							957	976	929	995	1,154
Pharmacy Technicians											
In-state											
Out-of-state											
TOTAL							3,216	3,453	3,505	4,114	4,455
Pharmacy Technician Candidates											
In-state											
Out-of-state											
TOTAL							2,896	2,372	1,336	1,069	1,074
Pharmacy Permits											
IR	651	634	636	609	621	585	584	576	573	633	729
RC	464	473	471	493	505	520	528	535	541	555	473
H	177	174	171	175	172	171	171	174	179	181	181
IN	46	45	38	39	19		17	18	19	27	36
NU	9	10	10	9	10		12	14	13	13	13
CH	4	4	4	7	4		8	9	11	12	12
PEN											
OS	122	152	168	175	216	223	262	313	353	339	200
PE	78	104	102	120	102			95	94	0	
CO	13	12	12	12	12		12	13	13	0	
TOTAL	1,564	1,608	1,612	1,639	1,668	1,663	1,717	1,771	1,818	1,760	1,644
Equipment Permits											
AMS							0	109	136	158	174
EDK							468	461	474	444	471

Louisiana Board of Pharmacy
Census Report

<i>Type of Credential</i>	<u>6/30/2006</u>	<u>6/30/2007</u>	<u>6/30/2008</u>	<u>6/30/2009</u>	<u>6/30/2010</u>	<u>6/30/2011</u>	<u>6/30/2012</u>	<u>6/30/2013</u>	2/5/2014
Pharmacists									
In-state	4,460	4,522	4,612	4,750	4,860	5,000	5,095	5,170	5,303
Out-of-state	1,915	1,975	1,964	2,029	2,098	2,179	2,258	2,588	2,413
TOTAL	6,375	6,497	6,576	6,779	6,958	7,179	7,353	7,758	7,716
Pharmacy Interns									
In-state	980	1,079	1,074	1,035	965	917	938	945	996
Out-of-state	109	117	67	84	153	137	128	128	127
TOTAL	1,089	1,196	1,141	1,119	1,118	1,054	1,066	1,073	1,123
Pharmacy Technicians									
In-state	4,552	4,587	4,780	4,733	5,363	5,722	5,509	5,752	6,281
Out-of-state	163	152	144	109	144	145	120	112	125
TOTAL	4,715	4,739	4,924	4,842	5,507	5,867	5,629	5,864	6406
Pharmacy Technician Candidates									
In-state	1,081	1,389	1,446	1,510	1,679	1,574	1,665	1,658	1,799
Out-of-state	32	32	23	32	35	35	39	31	32
TOTAL	1,113	1,421	1,469	1,542	1,714	1,609	1,704	1,695	1,831
Pharmacy Permits									
IR	681	620	588	592	587	591	587	575	587
RC	430	491	534	545	562	576	587	597	613
H	167	164	167	167	165	170	172	172	174
IN	35	36	37	37	27	25	24	25	24
NU	17	16	16	16	16	15	15	15	15
CH	12	12	11	12	14	12	12	12	12
PEN								1	2
NR	226	240	250	256	286	318	361	387	405
TOTAL	1,568	1,579	1,603	1,625	1,657	1,707	1,758	1,784	1,832
Equipment Permits									
AMS	173	212	255	306	361	356	366	638	449
EDK	428	412	439	388	503	430	448	431	477
DME							223	378	432
Special Activity								41	41
CDTM								41	41
MAR								1,617	1833
Special Work Permit						58	78	126	43

Louisiana Board of Pharmacy
CDS Program - Census Report

<i>Classification</i>	<u>8/1/2006</u>	<u>6/30/2007</u>	<u>6/30/2008</u>	<u>6/30/2009</u>	<u>6/30/2010</u>	<u>6/30/2011</u>	<u>6/30/2012</u>	<u>6/30/2013</u>	<u>2/5/2014</u>
ACS Animal Control Shelter	0	0	0	0	1	1	1	1	1
AMS Automated Medication System	0	0	0	0	0	0	0	0	16
APN Advanced Practice Registered Nurse	220	346	479	607	758	889	1,015	1,103	1,323
ASC Ambulatory Surgical Center	94	94	101	106	113	90	88	85	87
CRX Correctional Center	0	0	0	0	0	7	6	5	5
DDS Dentist	2,009	2,090	2,177	2,267	2,363	2,027	2,048	1,902	2,084
DET Drug Detection Canine	19	20	20	20	22	14	12	10	10
DIS Distributor	236	285	322	363	400	279	288	273	320
DPM Podiatrist	146	147	153	161	165	139	136	118	132
DVM Veterinarian	817	870	936	1,000	1,065	922	901	852	990
DYS Dialysis Center	58	63	63	63	63	6	4	3	4
EMC Emergency Medical Center	17	17	17	17	18	14	16	17	18
EMS Emergency Medical Service	56	57	58	63	66	54	50	45	48
ETC Animal Euthanasia Tech - Cert	29	31	39	44	49	28	27	27	27
HOS Hospital	350	369	387	405	438	292	281	268	285
LAB Analytical Laboratory	13	13	14	14	15	12	11	12	12
MD Physician	12,754	13,195	13,876	14,599	15,269	12,362	11,727	10,698	11,657
MDT Physician on Telemedicine	0	0	0	0	0	0	0	0	1
MED Medical Clinic	65	73	78	88	102	80	86	82	83
MFR Manufacturer	31	36	43	52	58	48	50	45	48
MIS Other	80	74	73	58	59	20	14	12	13
MP Medical Psychologist	30	37	44	50	58	65	67	69	78
OD Optometrist	196	230	253	269	278	275	287	279	309
PA Physician's Assistant	153	170	194	232	272	294	326	344	428
PHY Pharmacy	0	0	0	0	0	1357	1,365	1,370	1,374
REP Sales Representative	54	57	65	66	88	29	20	7	5
RES Researcher	91	100	110	119	156	109	110	98	107
RHC Rural Health Clinic	15	19	20	21	23	17	12	11	12
SAC Substance Abuse Clinic	14	14	14	14	17	7	9	9	9
TOTAL	17,547	18,407	19,502	20,663	21,916	19,437	18,957	17,745	19,486

Total Credentials Under Board Management

Pharmacy Program	15,461	16,056	16,407	16,601	17,818	18,260	18,625	21,405	22,183
CDS Program	<u>17,547</u>	<u>18,407</u>	<u>19,536</u>	<u>20,698</u>	<u>21,916</u>	<u>19,437</u>	<u>18,957</u>	<u>17,745</u>	<u>19,486</u>
TOTAL	33,008	34,463	35,943	37,299	39,734	37,697	37,582	39,150	41,669

New Credentials Issued
FYE 2014 ~ 2nd Quarter
October 1, 2013 - December 2013

Prefix	Subcategory	CredentialType	Total
AMS		Automated Medication System	13
AMS	X	Automated Medication System - Exempt	30
Prefix Totals			43
CDS	AMS	CDS License - Automated Medication System	4
CDS	APN	CDS License - APRN	62
CDS	ASC	CDS License - Ambulatory Surgical Center	1
CDS	DDS	CDS License - Dentist	7
CDS	DIS	CDS License - Distributor	24
CDS	DPM	CDS License - Podiatrist	3
CDS	DVM	CDS License - Veterinarian	16
CDS	HOS	CDS License - Hospital	8
CDS	MD	CDS License - Physician	95
CDS	MED	CDS License - Medical Clinic	2
CDS	MFR	CDS License - Manufacturer	2
CDS	MP	CDS License - Medical Psychologist	2
CDS	OD	CDS License - Optometrist	5
CDS	PA	CDS License - Physician Assistant	20
CDS	PHY	CDS License - Pharmacy	23
CDS	RES	CDS License - Researcher	2
Prefix Totals			276
CDTM		Collaborative Drug Therapy Management (V)	2
CPT		Certified Pharmacy Technician	122
DME		Durable Medical Equipment (DME) Provider	25
EDK		Emergency Drug Kit	21
MA		Medication Administration (V)	83
PHY	HOS	Pharmacy - Hospital Inpatient	7
PHY	IR	Pharmacy - Community ~ Independent	13
PHY	OS	Pharmacy - Nonresident	17
PHY	RC	Pharmacy - Community ~ Chain	8
Prefix Totals			45
PIC		Pharmacist-in-Charge (V)	11
PMP	CDS	PMP - CDS Credential	129
PMP	PST	PMP - Pharmacist	31
Prefix Totals			160
PNT		Pharmacy Intern	121
PNT	FPG	Pharmacy Intern - Foreign Pharmacy Graduate	1
Prefix Totals			122
PST		Pharmacist	56
PTC		Pharmacy Technician Candidate	321
SWP		Special Work Permit	10
Grand Totals			1297

Pending Applications

PHARMACY CREDENTIALS

Prefix	Subcat.	CredentialType	08/18/12	12/07/12	02/26/13	05/02/13	08/02/13	10/14/13	02/05/14
AMS		Automated Medication System	1	1	1	2	4	5	3
CPT		Certified Pharmacy Technician	78	95	83	62	69	49	55
DME		Durable Medical Equipment	1	2			4	11	14
EDK		Emergency Drug Kit		2	2	2	1	1	
PHY	CH	Pharmacy - Charitable							
PHY	HOS	Pharmacy - Hospital Inpatient	3	3	4	6	8	11	5
PHY	IN	Pharmacy - Institutional	2					1	1
PHY	IR	Pharmacy - Community ~ Independent	17	28	19	15	13	18	18
PHY	NR	Pharmacy - Nonresident	30	41	47	45	39	41	59
PHY	NU	Pharmacy - Nuclear							
PHY	PEN	Pharmacy - Penal			1	1	1	1	
PHY	RC	Pharmacy - Community ~ Chain	4	5	3	4	5	8	7
PIC		Pharmacist-in-Charge	1		1		2	1	1
PNT	FPG	Pharmacy Intern - Foreign Graduate					2	1	1
PNT		Pharmacy Intern	86	91	44	34	66	100	36
PST		Pharmacist	260	218	247	284	335	267	239
PTC		Pharmacy Technician Candidate	377	432	342	375	334	387	346
Subtotal			860	918	794	830	883	902	785

CDS CREDENTIALS

Prefix	Subcat.	CredentialType	08/18/12	12/07/12	02/26/13	02/26/13	08/02/13	10/14/13	02/05/14
CDS	ACS	CDS - Animal Control Shelter							
CDS	AMS	CDS - Automated Medication System						2	1
CDS	APN	CDS - APRN	12	14	12	20	17	22	30
CDS	ASC	CDS - Ambulatory Surgical Center	1	3	1	2	3	2	1
CDS	CRX	CDS - Correctional Center	1						
CDS	DDS	CDS - Dentist	6			1	2	1	2
CDS	DET	CDS - Drug Detection / Canine	2	2	2	2			3
CDS	DIS	CDS - Distributor	5	4	6	3	3	3	5
CDS	DPM	CDS - Podiatrist	1						
CDS	DVM	CDS - Veterinarian		1			1		
CDS	DYS	CDS - Dialysis Center							
CDS	EMC	CDS - Emergency Medical Center			1	1			
CDS	EMS	CDS - Emergency Medical Service			1	1	2	3	3
CDS	ETC	CDS - Animal Euthanasia Tech, Certified	2	1	2	2	1		
CDS	ETL	CDS - Animal Euthanasia Tech, Lead						1	
CDS	HOS	CDS - Hospital	3	2	4	4	11	11	7
CDS	HOX	CDS - Hospital - Exempt							
CDS	LAB	CDS - Laboratory							
CDS	MD	CDS - Physician	35	13	12	13	15	14	16
CDS	MED	CDS - Medical Clinic	2	4	4	2	2	4	5
CDS	MEX	CDS - Medical Clinic - Exempt				1	1	1	
CDS	MFR	CDS - Manufacturer							1
CDS	MIS	CDS - Miscellaneous / Other	1	1	1	2			
CDS	MP	CDS - Medical Psychologist							
CDS	OD	CDS - Optometrist	1	1	1	1		1	1
CDS	PA	CDS - Physician Assistant	4	3	3	3	7	7	5
CDS	PHY	CDS - Pharmacy	24	32	21	18	15	23	21
CDS	PHX	CDS - Pharmacy - Exempt							
CDS	REP	CDS - Sales Representative							
CDS	RES	CDS - Researcher	3	4	3	2			1
CDS	RHC	CDS - Rural Health Clinic							
CDS	SAC	CDS - Substance Abuse Clinic	2	2	2	2			
Subtotal			105	87	76	80	80	95	102

OTHER CREDENTIALS

Prefix	Subcat.	CredentialType	08/18/12	12/07/12	02/26/13	02/26/13	08/02/13	10/14/13	02/05/14
CDTM		Collaborative Drug Therapy Management	2	5					
LB		Law Book	2	1					1
MA		Medication Administration	24	20	23	25	15	7	9
PMP		PMP - CDS Credential	236	240	272	289	182	226	307
PMP		PMP - MIS Credential						44	
PMP		PMP - PST Credential	65	50	66	53	42		50
SWP		Special Work Permit		50	58	58	35	34	48
Subtotal			329	366	419	425	274	311	415

TOTAL

1294 1371 1289 1335 1237 1308 1302



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Multistate Pharmacy Jurisprudence Examination (MPJE™)

September 1 – December 31, 2013

School Reports
Interpretation of Scores
Frequency Distribution of Scaled Scores
Cumulative Record (since January 2000)

February 12, 2014

Multistate Pharmacy Jurisprudence Examination (MPJE™)

This computer adaptive competency assessment is administered by the National Association of Boards of Pharmacy (NABP). The examination blueprint is designed to assess the applicant's competency in federal and state laws relative to pharmacy practice and is therefore specific for a given state. The examination is administered via an open window process; applicants may schedule the examination at a local testing center at any time following approval by the state board and receipt of an Authorization to Test (ATT) document from NABP. Individual scores are available to applicants via secure web posting approximately 7-10 days following the examination. Summary reports are provided to the state boards on a calendar trimester basis.

Table of Contents

Current Trimester Report for ULM School of Pharmacy	03
Cumulative Report (since January 2000) for ULM School of Pharmacy	09
Current Trimester Report for Xavier College of Pharmacy	13
Cumulative Report (since January 2000) for Xavier College of Pharmacy	21



**Multistate Pharmacy Jurisprudence Examination® (MPJE) ®
School Summary Report**

Test Window: September 1, 2013 - December 31, 2013

School Name: University Louisiana Monroe

This MPJE score report consists of two levels of scores: school-aggregated scores and individual candidate scores. Summary information is provided separately for first-time examinees from ACPE schools/colleges and for all examinees, regardless of repeater status and/or the educational institution. Tables 1 and 2 contain school-specific as well as national pass rate information.

Table 1 First Time Test Takers

School 1: Examinees testing in same state as respective college

School 2: Examinees testing in different states than respective college

	Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation
School 1	1	100.00	82.00	
School 2	27	96.30	83.19	4.51
State	118	87.29	81.08	5.62
National	4138	90.04	81.22	5.45

Candidates who did not answer enough questions to receive a score are reflected in pass rate data as a fail but are not included in mean scaled score data.

Table 2 All Test Takers

	Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation
School 1	2	100.00	80.50	2.12
School 2	28	92.86	82.79	4.90
State	142	85.21	80.43	5.62
National	5379	87.01	80.52	5.55

Candidates who did not answer enough questions to receive a score are reflected in pass rate data as a fail but are not included in mean scaled score data.

**Multistate Pharmacy Jurisprudence Examination® (MPJE)®
Candidate Summary Report**

Test Window: September 1, 2013 - December 31, 2013

	Pass/Fail	Total Scaled Score	Test Date	Graduation Date	First Attempt	State
1	Pass	77	11/19/2013	05/11/2013	Y	ME
2	Pass	79	09/28/2013	05/11/2013	N	LA
3	Pass	80	09/19/2013	05/11/2013	Y	TX
4	Pass	81	09/03/2013	05/11/2013	Y	TX
5	Pass	84	12/19/2013	05/19/2012	Y	MS
6	Pass	82	09/07/2013	05/21/2011	Y	NV
7	Pass	84	09/28/2013	05/22/2010	Y	FL
8	Fail	72	10/04/2013	05/19/2007	N	MA
9	Pass	83	11/13/2013	05/21/2005	Y	TX
10	Pass	88	10/30/2013	05/01/2005	Y	MD
11	Pass	86	09/16/2013	05/01/2005	Y	OR
12	Pass	90	09/03/2013	05/01/2005	Y	NE
13	Pass	90	12/09/2013	12/01/1998	Y	TX
14	Pass	77	09/30/2013	12/01/1998	Y	NE
15	Pass	83	12/23/2013	05/18/1996	Y	IL
16	Pass	86	11/21/2013	12/15/1995	Y	MD
17	Pass	77	10/29/2013	05/20/1995	Y	WA
18	Pass	86	10/28/2013	05/20/1995	Y	NH
19	Pass	82	12/16/2013	05/15/1995	Y	LA
20	Pass	85	09/05/2013	12/19/1992	Y	TX
21	Pass	82	09/03/2013	08/15/1992	Y	TX
22	Pass	79	11/05/2013	12/21/1991	Y	MD
23	Pass	85	11/01/2013	05/17/1991	Y	MS
24	Pass	79	11/15/2013	12/15/1990	Y	WY
25	Pass	84	11/02/2013	12/19/1982	Y	NC
26	Pass	89	10/10/2013	12/19/1982	Y	OK
27	Fail	73	09/23/2013	12/01/1978	Y	TN
28	Pass	89	12/12/2013	12/17/1977	Y	MD
29	Pass	88	11/12/2013	12/17/1977	Y	TN
30	Pass	79	11/26/2013	07/01/1960	Y	TX

National Statistics for All Candidates

Mean Scaled Score: 80.52
Standard Deviation: 5.55
Range: 58 - 100
Passing Rate (%): 87.01

National Statistics for First-Time Candidates

Mean Scaled Score: 81.22
Standard Deviation: 5.45
Range: 60 - 100
Passing Rate (%): 90.04

The following tables are scaled score frequency distributions for MPJE® candidates.

Candidates who did not answer enough questions to receive a score are not reflected in the frequency distributions.

National Frequency Distribution of Scaled Scores

Based on Total Tests Administered (N = 5379)

Test Window: September 1, 2013 - December 31, 2013

Scaled Score	Frequency	Cumulative Percent of the Upper Limit of the Interval
0 - 4	0	0.0%
5 - 9	0	0.0%
10 - 14	0	0.0%
15 - 19	0	0.0%
20 - 24	0	0.0%
25 - 29	0	0.0%
30 - 34	0	0.0%
35 - 39	0	0.0%
40 - 44	0	0.0%
45 - 49	0	0.0%
50 - 54	0	0.0%
55 - 59	3	0.1%
60 - 64	12	0.3%
65 - 69	117	2.5%
70 - 74	564	12.9%
75 - 79	1611	42.9%
80 - 84	1845	77.2%
85 - 89	936	94.6%
90 - 94	246	99.2%
95 - 100	42	100.0%

National Frequency Distribution of Scaled Scores
Based on First-Time Candidates from ACPE-Accredited Programs (N = 4138)

Test Window: September 1, 2013 - December 31, 2013

Scaled Score	Frequency	Cumulative Percent of the Upper Limit of the Interval
0 - 4	0	0.0%
5 - 9	0	0.0%
10 - 14	0	0.0%
15 - 19	0	0.0%
20 - 24	0	0.0%
25 - 29	0	0.0%
30 - 34	0	0.0%
35 - 39	0	0.0%
40 - 44	0	0.0%
45 - 49	0	0.0%
50 - 54	0	0.0%
55 - 59	0	0.0%
60 - 64	6	0.1%
65 - 69	66	1.7%
70 - 74	338	9.9%
75 - 79	1149	37.7%
80 - 84	1477	73.4%
85 - 89	835	93.6%
90 - 94	224	99.0%
95 - 100	41	100.0%

Multistate Pharmacy Jurisprudence Examination (MPJE)

University of Louisiana at Monroe

	2000		2001		2002		2003	
	<u>Jan - Jun</u>	<u>Jul - Dec</u>						
TOTAL CANDIDATE GROUP								
No. of Candidates	125	82	100	57	59	123	77	119
School Average Score:	83.27	82.76	80.84	81.37	80.17	80.41	78.57	80.04
State Average Score:	81.64	80.49	80.64	80.32	80.34	79.41	77.32	78.87
National Average Score:	82.24	81.75	82.25	81.51	90.78	79.85	79.92	79.33
School Pass Rate:	94.40	91.46	90.00	91.23	88.14	88.62	77.92	88.24
State Pass Rate:	89.89	86.25	87.84	90.00	92.00	85.98	72.88	84.67
National Pass Rate:	91.37	90.50	91.22	90.54	90.78	84.93	84.52	82.61
FIRST-TIME CANDIDATE GROUP								
No. of Candidates	117	78	92	51	55	111	59	110
School Average Score:	83.67	83.14	80.89	81.78	80.22	80.58	79.31	80.22
State Average Score:	82.14	80.97	80.67	80.51	80.30	79.41	77.69	79.23
National Average Score:	82.55	82.05	82.59	81.86	82.08	80.19	80.34	79.76
School Pass Rate:	96.58	93.59	90.22	90.20	89.09	88.29	81.36	88.18
State Pass Rate:	92.59	87.32	88.06	89.77	91.49	86.32	75.00	86.55
National Pass Rate:	92.57	91.37	92.45	91.75	92.15	86.45	86.58	84.67

Multistate Pharmacy Jurisprudence Examination (MPJE)

University of Louisiana at Monroe

	2004		2005		2006		2007	
	<u>Jan - Jun</u>	<u>Jul - Dec</u>						
TOTAL CANDIDATE GROUP								
No. of Candidates	62	110	59	146	68	111	50	151
School Average Score:	79.39	80.79	79.25	80.50	80.43	81.92	80.20	81.62
State Average Score:	78.58	80.03	80.50	80.03	80.01	81.34	80.15	81.47
National Average Score:	80.10	79.83	80.39	80.04	80.68	80.42	81.26	81.14
School Pass Rate:	91.94	91.82	89.83	87.67	88.24	92.79	90.00	92.05
State Pass Rate:	86.90	92.55	90.55	87.03	91.09	92.39	87.18	90.39
National Pass Rate:	85.63	84.75	86.57	85.69	87.25	87.82	89.38	89.78
FIRST-TIME CANDIDATE GROUP								
No. of Candidates	52	104	55	132	60	102	43	140
School Average Score:	79.73	80.96	79.33	80.66	80.80	82.14	81.05	81.83
State Average Score:	79.04	80.11	80.71	80.29	80.24	81.52	80.59	81.84
National Average Score:	80.58	80.25	80.80	80.44	81.09	80.80	81.72	81.51
School Pass Rate:	92.31	92.31	89.09	87.12	91.67	94.12	95.35	93.57
State Pass Rate:	90.14	92.53	91.38	88.69	92.31	93.53	91.18	92.49
National Pass Rate:	88.16	86.87	88.51	87.51	89.41	89.34	91.43	91.24

Multistate Pharmacy Jurisprudence Examination (MPJE)


University of Louisiana at Monroe

	2008		2009			2010			2011		
	<u>Jan - Jun</u>	<u>Jul - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>
TOTAL CANDIDATE GROUP											
No. of Candidates	61	137	42	120	36	38	104	35	5	71	12
Mean Scaled Score - School	81.26	81.99	80.95	82.58	80.75	81.47	82.14	81.89	82.60	82.73	83.83
Mean Scaled Score - State	81.33	81.34	79.57	81.69	80.35	81.37	80.88	81.64		81.01	80.41
Mean Scaled Score - National	81.59	81.27	80.29	82.39	80.25	80.45	82.51	80.57	80.27	82.23	80.46
School Pass Rate:	96.72	91.97	88.10	95.00	86.11	94.74	90.38	91.43	100.00	97.18	100.00
State Pass Rate:	91.75	91.05	81.03	94.52	85.92	90.00	92.64	95.79		89.91	90.99
National Pass Rate:	90.31	89.92	86.23	93.74	87.04	89.09	94.83	89.35	86.43	92.17	86.24
FIRST-TIME CANDIDATE GROUP											
No. of Candidates	58	127	37	117	34	34	96	30	5	66	11
Mean Scaled Score - School	81.52	82.13	81.30	82.56	81.09	82.12	82.67	82.33	82.60	83.08	84.18
Mean Scaled Score - State	81.53	81.62	79.69	81.76	80.98	82.07	80.93	82.07		81.52	81.14
Mean Scaled Score - National	81.97	81.57	80.75	82.58	80.63	80.82	82.67	80.94	81.17	82.86	81.76
School Pass Rate:	96.55	91.34	89.19	94.87	88.24	97.06	93.75	93.33	100.00	100.00	100.00
State Pass Rate:	92.31	91.95	80.77	94.34	89.66	93.44	92.92	97.56		94.06	94.32
National Pass Rate:	91.82	91.16	88.45	94.30	88.68	90.64	95.50	90.79	92.24	96.05	94.00

Multistate Pharmacy Jurisprudence Examination (MPJE)

University of Louisiana at Monroe

	2012			2013			2014			2015		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>
TOTAL CANDIDATE GROUP												
No. of Candidates	4	126	87	47	94	30						
<i>* testing in same/different state</i>		72 / 54	11 / 34	11 / 36	40 / 54	2 / 28						
Mean Scale Score - School *	82.25	82.44/82.70	80.09/79.85	81.45/84.03	82.50/82.59	80.50/82.79						
<i>* testing in same/different state</i>												
Mean Scaled Score - State	81.18	80.91	79.62	81.33	80.82	80.43						
Mean Scaled Score - National	80.41	82.43	80.55	80.92	82.50	80.52						
School Pass Rate: *	100.00	97.22/90.74	90.91/85.29	100/97.22	95.00/98.15	100 / 92.86						
<i>* testing in same/different state</i>												
State Pass Rate:	90.41	90.69	81.61	93.98	90.51	85.21						
National Pass Rate:	84.54	92.76	86.85	87.18	92.98	87.01						
FIRST-TIME CANDIDATE GROUP												
No. of Candidates	4	124	70	44	93	28						
<i>* testing in same/different state</i>		72 / 52	10 / 29	10 / 34	39 / 54	1 / 27						
Mean Scaled Score - School *	82.25	82.44/83.02	80.62/79.90	81.80/84.26	82.77/82.59	82.00/83.19						
<i>* testing in same/different state</i>												
Mean Scaled Score - State	81.75	81.03	80.21	81.90	81.03	81.08						
Mean Scaled Score - National	81.44	82.75	81.26	81.78	82.76	81.22						
School Pass Rate: *	100.00	97.22/92.31	89.66/90.00	100.00/97.06	97.44/98.15	100 / 96.30						
<i>* testing in same/different state</i>												
State Pass Rate:	93.22	91.03	85.71	97.22	91.88	87.29						
National Pass Rate:	89.13	93.94	89.60	91.08	93.95	90.04						



**Multistate Pharmacy Jurisprudence Examination® (MPJE) ®
School Summary Report**

Test Window: September 1, 2013 - December 31, 2013

School Name: Xavier University of Louisiana

This MPJE score report consists of two levels of scores: school-aggregated scores and individual candidate scores. Summary information is provided separately for first-time examinees from ACPE schools/colleges and for all examinees, regardless of repeater status and/or the educational institution. Tables 1 and 2 contain school-specific as well as national pass rate information.

Table 1 First Time Test Takers

School 1: Examinees testing in same state as respective college

School 2: Examinees testing in different states than respective college

	Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation
School 1	31	67.74	77.03	4.93
School 2	55	74.55	78.85	5.57
State	118	87.29	81.08	5.62
National	4138	90.04	81.22	5.45

Candidates who did not answer enough questions to receive a score are reflected in pass rate data as a fail but are not included in mean scaled score data.

Table 2 All Test Takers

	Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation
School 1	46	71.74	77.33	4.79
School 2	69	76.81	78.72	5.52
State	142	85.21	80.43	5.62
National	5379	87.01	80.52	5.55

Candidates who did not answer enough questions to receive a score are reflected in pass rate data as a fail but are not included in mean scaled score data.

**Multistate Pharmacy Jurisprudence Examination® (MPJE)®
Candidate Summary Report**

Test Window: September 1, 2013 - December 31, 2013

	Pass/Fail	Total Scaled Score	Test Date	Graduation Date	First Attempt	State
1	Pass	81	11/19/2013	08/03/2013	Y	LA
2	Pass	90	10/28/2013	08/03/2013	Y	LA
3	Pass	79	10/11/2013	08/03/2013	Y	MS
4	Pass	83	11/06/2013	08/02/2013	N	LA
5	Fail	74	09/30/2013	08/02/2013	Y	LA
6	Pass	76	11/26/2013	06/29/2013	Y	MS
7	Pass	79	11/17/2013	06/29/2013	Y	MS
8	Pass	78	11/04/2013	06/29/2013	N	LA
9	Pass	88	10/29/2013	06/29/2013	Y	TX
10	Pass	81	10/23/2013	06/29/2013	N	TX
11	Pass	79	10/15/2013	06/29/2013	Y	TX
12	Pass	80	10/12/2013	06/29/2013	Y	LA
13	Pass	79	10/02/2013	06/29/2013	Y	LA
14	Fail	71	09/24/2013	06/29/2013	Y	LA
15	Pass	77	09/20/2013	06/29/2013	Y	LA
16	Fail	73	09/17/2013	06/29/2013	Y	TX
17	Pass	81	09/16/2013	06/29/2013	Y	LA
18	Pass	79	09/16/2013	06/29/2013	Y	LA
19	Pass	78	09/14/2013	06/29/2013	Y	LA
20	Pass	83	09/07/2013	06/29/2013	Y	LA
21	Pass	82	12/06/2013	06/28/2013	N	TX
22	Fail	69	11/25/2013	06/28/2013	Y	LA
23	Pass	76	10/21/2013	06/28/2013	N	LA
24	Fail	71	10/17/2013	06/28/2013	Y	TX
25	Pass	82	09/24/2013	06/28/2013	N	LA
26	Fail	73	09/18/2013	06/28/2013	Y	LA
27	Pass	76	09/04/2013	06/28/2013	Y	TX
28	Pass	78	10/01/2013	05/13/2013	N	LA
29	Pass	80	12/30/2013	05/11/2013	Y	LA
30	Pass	80	12/23/2013	05/11/2013	Y	MI
31	Pass	79	12/23/2013	05/11/2013	N	LA
32	Pass	78	12/18/2013	05/11/2013	N	IL
33	Pass	80	12/05/2013	05/11/2013	N	TX
34	Pass	83	11/26/2013	05/11/2013	N	TX
35	Pass	91	11/18/2013	05/11/2013	Y	MS
36	Fail	71	11/16/2013	05/11/2013	Y	MS
37	Fail	70	11/16/2013	05/11/2013	Y	GA
38	Pass	77	11/15/2013	05/11/2013	Y	LA
39	Pass	89	11/11/2013	05/11/2013	Y	TX
40	Pass	86	11/07/2013	05/11/2013	Y	LA
41	Pass	81	11/06/2013	05/11/2013	N	LA
42	Pass	75	11/05/2013	05/11/2013	Y	LA
43	Fail	74	11/05/2013	05/11/2013	N	LA
44	Fail	72	11/04/2013	05/11/2013	Y	MS

**Multistate Pharmacy Jurisprudence Examination® (MPJE)®
Candidate Summary Report**

	Pass/Fail	Total Scaled Score	Test Date	Graduation Date	First Attempt	State
45	Pass	77	10/19/2013	05/11/2013	N	AL
46	Pass	81	10/12/2013	05/11/2013	N	TX
47	Fail	72	10/11/2013	05/11/2013	Y	TX
48	Pass	78	10/11/2013	05/11/2013	Y	TX
49	Pass	83	10/10/2013	05/11/2013	Y	MS
50	Fail	74	10/08/2013	05/11/2013	Y	LA
51	Pass	82	10/05/2013	05/11/2013	Y	TN
52	Pass	79	10/04/2013	05/11/2013	Y	TX
53	Pass	77	10/03/2013	05/11/2013	Y	LA
54	Pass	77	10/02/2013	05/11/2013	N	LA
55	Pass	75	10/01/2013	05/11/2013	Y	LA
56	Fail	74	10/01/2013	05/11/2013	Y	LA
57	Pass	86	09/30/2013	05/11/2013	Y	TX
58	Pass	75	09/27/2013	05/11/2013	Y	LA
59	Pass	78	09/27/2013	05/11/2013	Y	MS
60	Pass	76	09/25/2013	05/11/2013	N	LA
61	Fail	68	09/25/2013	05/11/2013	Y	TN
62	Pass	84	09/24/2013	05/11/2013	N	MS
63	Fail	73	09/23/2013	05/11/2013	Y	LA
64	Fail	73	09/23/2013	05/11/2013	Y	LA
65	Pass	78	09/23/2013	05/11/2013	N	AL
66	Fail	70	09/21/2013	05/11/2013	Y	LA
67	Pass	80	09/20/2013	05/11/2013	Y	NY
68	Pass	87	09/18/2013	05/11/2013	N	LA
69	Pass	78	09/17/2013	05/11/2013	N	LA
70	Fail	69	09/14/2013	05/11/2013	Y	AL
71	Pass	75	09/09/2013	05/11/2013	Y	TX
72	Pass	85	09/09/2013	05/11/2013	Y	LA
73	Pass	84	09/09/2013	05/11/2013	Y	DE
74	Pass	81	09/07/2013	05/11/2013	Y	AL
75	Pass	78	09/05/2013	05/11/2013	Y	LA
76	Pass	77	09/03/2013	05/11/2013	Y	LA
77	Pass	85	09/03/2013	05/11/2013	Y	AZ
78	Fail	69	12/30/2013	05/12/2012	N	TX
79	Fail	72	12/07/2013	05/12/2012	Y	WA
80	Fail	74	10/29/2013	05/12/2012	Y	TX
81	Pass	80	10/10/2013	05/12/2012	Y	TX
82	Fail	68	12/09/2013	05/07/2011	N	LA
83	Pass	86	09/03/2013	05/07/2011	Y	MA
84	Pass	82	12/11/2013	05/08/2010	N	AL
85	Pass	81	12/10/2013	05/08/2010	Y	FL
86	Pass	83	10/18/2013	05/08/2010	Y	AK
87	Pass	78	10/22/2013	08/01/2009	Y	LA
88	Pass	82	10/17/2013	05/09/2009	Y	TX

**Multistate Pharmacy Jurisprudence Examination® (MPJE)®
Candidate Summary Report**

	Pass/Fail	Total Scaled Score	Test Date	Graduation Date	First Attempt	State
89	Pass	76	11/04/2013	05/10/2008	Y	MD
90	Pass	88	12/30/2013	05/12/2007	Y	TX
91	Pass	77	12/11/2013	12/19/2006	N	TX
92	Fail	64	10/12/2013	12/19/2006	N	TX
93	Fail	70	09/07/2013	12/19/2006	Y	TX
94	Pass	85	09/10/2013	05/20/2006	Y	TX
95	Pass	80	10/16/2013	05/01/2003	Y	TX
96	Fail	68	11/20/2013	08/31/2002	Y	LA
97	Fail	73	09/27/2013	05/01/2002	Y	TX
98	Pass	82	11/13/2013	05/01/2001	Y	NC
99	Pass	78	12/30/2013	08/01/2000	Y	LA
100	Pass	82	09/12/2013	08/01/2000	Y	MS
101	Pass	78	11/27/2013	05/01/1999	Y	NJ
102	Pass	80	11/22/2013	05/01/1999	Y	MO
103	Pass	79	09/20/2013	05/01/1999	Y	MA
104	Pass	81	09/11/2013	05/01/1999	Y	MD
105	Fail	74	09/07/2013	12/30/1996	Y	TX
106	Fail	74	11/18/2013	05/11/1996	Y	NC
107	Pass	79	11/27/2013	05/10/1989	N	AZ
108	Pass	76	10/25/2013	05/10/1989	Y	ID
109	Pass	80	10/18/2013	05/10/1989	Y	WY
110	Pass	78	10/02/2013	05/10/1989	Y	OR
111	Pass	78	09/30/2013	05/10/1989	Y	WA
112	Pass	90	11/13/2013	05/18/1986	Y	MS
113	Pass	81	12/09/2013	05/05/1984	Y	TX
114	Pass	80	10/25/2013	05/20/1973	N	LA
115	Fail	72	09/14/2013	05/20/1973	N	LA

National Statistics for All Candidates

Mean Scaled Score: 80.52
Standard Deviation: 5.55
Range: 58 - 100
Passing Rate (%): 87.01

National Statistics for First-Time Candidates

Mean Scaled Score: 81.22
Standard Deviation: 5.45
Range: 60 - 100
Passing Rate (%): 90.04

The following tables are scaled score frequency distributions for MPJE® candidates.

Candidates who did not answer enough questions to receive a score are not reflected in the frequency distributions.

National Frequency Distribution of Scaled Scores

Based on Total Tests Administered (N = 5379)

Test Window: September 1, 2013 - December 31, 2013

Scaled Score	Frequency	Cumulative Percent of the Upper Limit of the Interval
0 - 4	0	0.0%
5 - 9	0	0.0%
10 - 14	0	0.0%
15 - 19	0	0.0%
20 - 24	0	0.0%
25 - 29	0	0.0%
30 - 34	0	0.0%
35 - 39	0	0.0%
40 - 44	0	0.0%
45 - 49	0	0.0%
50 - 54	0	0.0%
55 - 59	3	0.1%
60 - 64	12	0.3%
65 - 69	117	2.5%
70 - 74	564	12.9%
75 - 79	1611	42.9%
80 - 84	1845	77.2%
85 - 89	936	94.6%
90 - 94	246	99.2%
95 - 100	42	100.0%

National Frequency Distribution of Scaled Scores
Based on First-Time Candidates from ACPE-Accredited Programs (N = 4138)

Test Window: September 1, 2013 - December 31, 2013

Scaled Score	Frequency	Cumulative Percent of the Upper Limit of the Interval
0 - 4	0	0.0%
5 - 9	0	0.0%
10 - 14	0	0.0%
15 - 19	0	0.0%
20 - 24	0	0.0%
25 - 29	0	0.0%
30 - 34	0	0.0%
35 - 39	0	0.0%
40 - 44	0	0.0%
45 - 49	0	0.0%
50 - 54	0	0.0%
55 - 59	0	0.0%
60 - 64	6	0.1%
65 - 69	66	1.7%
70 - 74	338	9.9%
75 - 79	1149	37.7%
80 - 84	1477	73.4%
85 - 89	835	93.6%
90 - 94	224	99.0%
95 - 100	41	100.0%

Multistate Pharmacy Jurisprudence Examination (MPJE)

Xavier College of Pharmacy

	2000		2001		2002		2003	
	<u>Jan - Jun</u>	<u>Jul - Dec</u>						
TOTAL CANDIDATE GROUP								
No. of Candidates	25	94	53	126	43	122	71	158
School Average Score:	78.92	78.90	77.43	79.86	79.12	78.18	76.75	77.99
State Average Score:	81.64	80.49	80.64	80.32	80.34	79.41	77.32	78.87
National Average Score:	82.24	81.75	82.25	81.51	81.72	79.85	79.92	79.33
School Pass Rate:	80.00	80.85	69.81	88.10	81.40	77.05	67.61	75.95
State Pass Rate:	89.89	86.25	87.84	90.00	92.00	85.98	72.88	84.67
National Pass Rate:	91.37	90.50	91.22	90.54	90.78	84.93	84.52	82.61
FIRST-TIME CANDIDATE GROUP								
No. of Candidates	23	86	38	107	38	102	53	122
School Average Score:	79.04	79.01	77.58	79.92	79.58	78.18	77.04	78.48
State Average Score:	82.14	80.97	80.67	80.51	80.30	79.41	77.69	79.23
National Average Score:	82.55	82.05	82.59	81.86	82.08	80.19	80.34	79.76
School Pass Rate:	78.26	80.23	71.05	86.92	86.84	78.43	71.70	78.69
State Pass Rate:	92.59	87.32	88.06	89.77	91.49	86.32	75.00	86.55
National Pass Rate:	92.57	91.37	92.45	91.75	92.15	86.45	86.58	84.67

Multistate Pharmacy Jurisprudence Examination (MPJE)

Xavier College of Pharmacy

	2004		2005		2006		2007	
	<u>Jan - Jun</u>	<u>Jul - Dec</u>						
TOTAL CANDIDATE GROUP								
No. of Candidates	66	123	82	135	139	181	77	169
School Average Score:	77.36	78.64	78.06	78.96	79.04	79.82	78.47	79.76
State Average Score:	78.58	80.03	80.50	80.03	80.01	81.34	80.15	81.47
National Average Score:	80.10	79.83	80.39	80.04	80.68	80.42	81.26	81.14
School Pass Rate:	78.79	80.49	76.83	82.22	87.77	86.19	77.92	87.57
State Pass Rate:	86.90	92.55	90.55	87.03	91.09	92.39	87.18	90.39
National Pass Rate:	85.63	84.75	86.57	85.69	87.25	87.82	89.38	89.78
FIRST-TIME CANDIDATE GROUP								
No. of Candidates	56	101	63	121	121	156	62	154
School Average Score:	77.73	79.19	78.57	79.36	79.14	80.27	79.47	80.03
State Average Score:	79.04	80.11	80.71	80.29	80.24	81.52	80.59	81.84
National Average Score:	80.58	80.25	80.80	80.44	81.09	80.80	81.72	81.51
School Pass Rate:	80.36	84.16	79.37	85.12	87.60	89.10	85.48	88.96
State Pass Rate:	90.14	92.53	91.38	88.69	92.31	93.53	91.18	92.49
National Pass Rate:	88.16	86.87	88.51	87.51	89.41	89.34	91.43	91.24

Multistate Pharmacy Jurisprudence Examination (MPJE)

Xavier College of Pharmacy

	2008		2009			2010			2011		
	<u>Jan - Jun</u>	<u>Jul - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>
TOTAL CANDIDATE GROUP											
No. of Candidates	55	208	63	162	68	42	160	83	10	77	44
Mean Scaled Score - School	78.25	79.49	78.03	80.20	78.10	78.93	79.89	78.17	76.50	79.32	78.93
Mean Scaled Score - State	81.33	81.34	79.57	81.69	80.35	81.37	80.88	81.64		81.01	80.41
Mean Scaled Score - National	81.59	81.27	80.29	82.39	80.25	80.45	82.51	80.57	80.27	82.23	80.46
School Pass Rate:	80	83.17	74.60	88.27	77.94	80.95	88.75	78.31	70.00	81.82	81.82
State Pass Rate:	91.75	91.05	81.03	94.52	85.92	90.00	92.64	95.79		89.91	90.99
National Pass Rate:	90.31	89.92	86.23	93.74	87.04	89.08	94.83	89.35	86.43	92.17	86.24
FIRST-TIME CANDIDATE GROUP											
No. of Candidates	45	181	44	150	47	32	157	61	7	67	29
Mean Scaled Score - School	79.02	79.71	78.55	80.35	78.79	79.66	79.95	78.48	78.14	79.84	80.14
Mean Scaled Score - State	81.53	81.62	79.69	81.76	80.98	82.07	80.93	82.07		81.52	81.14
Mean Scaled Score - National	81.97	81.57	80.75	82.58	80.63	80.82	82.67	80.94	81.17	82.86	81.76
School Pass Rate:	88.89	85.64	79.55	88.67	82.98	84.38	89.17	78.69	85.71	86.57	89.66
State Pass Rate:	92.31	91.95	80.77	94.34	89.66	93.44	92.92	97.56		94.06	94.32
National Pass Rate:	91.82	91.16	88.45	94.30	88.68	90.64	95.50	90.89	92.24	96.05	94.00

Multistate Pharmacy Jurisprudence Examination (MPJE)

Xavier College of Pharmacy

	2012			2013			2014			2015		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>
TOTAL CANDIDATE GROUP												
No. of Candidates	13	181	87	53	188	115						
* <i>testing in same/different state</i>		94 / 87	23 / 65	6 / 47	95 / 93	46 / 69						
Mean Scaled Score - School *	79.69	79.27/78.48	76.96/79.95	78.17/79.09	79.46/79.55	77.33/78.72						
* <i>testing in same/different state</i>												
Mean Scaled Score - State	81.18	80.91	79.62	81.33	80.82	80.43						
Mean Scaled Score - National	80.41	82.43	80.55	80.92	82.50	80.52						
School Pass Rate: *	84.62	84.04/81.61	60.87/86.15	83.33/76.60	85.26/81.72	71.74/76.81						
* <i>testing in same/different state</i>												
State Pass Rate:	90.41	90.69	81.61	93.98	90.51	85.21						
National Pass Rate:	84.54	92.76	86.85	87.18	92.98	87.01						
FIRST-TIME CANDIDATE GROUP												
No. of Candidates	9	163	70	43	171	86						
* <i>testing in same/different state</i>		87 / 76	11 / 54	3 / 40	89 / 82	31 / 55						
Mean Scaled Score - School *	79.78	79.34/78.70	77.55/80.57	81.33/79.38	79.66/79.94	77.03/78.85						
* <i>testing in same/different state</i>												
Mean Scaled Score - State	81.75	81.03	80.21	81.90	81.03	81.08						
Mean Scaled Score - National	81.44	82.75	81.26	81.78	82.76	81.22						
School Pass Rate: *	88.89	83.91/84.24	63.64/87.04	100 / 77.50	87.64/82.93	67.74/74.55						
* <i>testing in same/different state</i>												
State Pass Rate:	93.22	91.03	85.71	97.22	91.88	87.29						
National Pass Rate:	89.13	93.94	89.60	91.08	93.95	90.04						



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



North American Pharmacist Licensure Examination (NAPLEX™)

September 1 – December 31, 2013

School Reports
Interpretation of Scores
Frequency Distribution of Scaled Scores
Cumulative Record (since January 2000)


February 12, 2014

North American Pharmacist Licensure Examination (NAPLEX™)

This computer adaptive competency assessment is administered by the National Association of Boards of Pharmacy (NABP). The examination blueprint is designed to assess the applicant's competency in basic pharmacy practice and is recognized by pharmacy regulatory authorities in all of the states and territories within the USA. The examination is administered via an open window process; applicants may schedule the examination at a local testing center at any time following approval by the state board and receipt of an Authorization to Test (ATT) document from NABP. Individual scores are available to applicants via secure web posting approximately 7-10 days following the examination. Summary reports are provided to the state boards on a calendar trimester basis.

Table of Contents

Current Trimester Report for ULM College of Pharmacy	03
Cumulative Report (since January 2000) for ULM College of Pharmacy	10
Current Trimester Report for Xavier College of Pharmacy	14
Cumulative Report (since January 2000) for Xavier College of Pharmacy	21



**North American Pharmacist Licensure Examination® (NAPLEX) ®
School Summary Report**

Test Window: September 1, 2013 - December 31, 2013

School Name: University Louisiana Monroe

This NAPLEX score report consists of two levels of scores: school-aggregated scores and individual candidate scores. Summary information is provided separately for first-time examinees from ACPE schools/colleges and for all examinees, regardless of repeater status and/or the educational institution.

Tables 1 and 2 contain school-specific as well as national pass rate information and mean area scores for each of the three main NAPLEX competency areas:

- Assess Pharmacotherapy to Assure Safe and Effective Therapeutic Outcomes (56%),
- Assess Safe and Accurate Preparation and Dispensing of Medications (33%), and
- Assess, Recommend and Provide Health Care Information that Promotes Public Health (11%).

Table 1 First-Time Candidates, ACPE-Accredited Programs Only

	Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation	Area 1 Scaled Score Mean	Standard Deviation	Area 2 Scaled Score Mean	Standard Deviation	Area 3 Scaled Score Mean	Standard Deviation
School	4	100.00	92.00	8.87	11.75	0.50	11.75	1.50	11.00	0.82
State	24	83.33	88.33	12.72	11.63	1.01	11.38	1.10	11.54	1.50
National	1049	84.46	92.69	18.21	11.99	1.24	11.74	1.39	12.11	1.71

Candidates who did not answer enough questions to receive a score are reflected in pass rate data as a fail but are not included in mean scaled score data.

Table 2 All Candidates

	Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation	Area 1 Scaled Score Mean	Standard Deviation	Area 2 Scaled Score Mean	Standard Deviation	Area 3 Scaled Score Mean	Standard Deviation
School	7	100.00	88.43	8.79	11.29	0.76	11.57	1.27	11.14	0.69
State	33	81.82	86.88	14.87	11.48	1.06	11.39	1.12	11.61	1.75
National	1864	75.91	87.03	19.70	11.64	1.28	11.45	1.42	11.59	1.80

Candidates who did not answer enough questions to receive a score are reflected in pass rate data as a fail but are not included in mean scaled score data.

Interpretation and Uses of Candidate Scores

At the candidate level, two sets of scores are produced: an overall, composite scaled score and individual area scores. Only overall scores are used to make pass/fail decisions. Area scores are intended to provide insight into areas of strength and weakness and can be used as a tool for self-assessment and subsequent remediation.

Area scores are numerical performance indicators for each of the three main competency areas of the NAPLEX. There are a total of three area scores, one per main competency area. Area scores are always reported on a scale of [6, 18], where a score of 6 is the lowest possible score and a score of 18 is the highest possible score. This reporting scale does not have a number-correct interpretation. In other words, a score of 6 does not mean that the candidate answered 6 questions correctly. Instead, area scores are computed from ability estimates that are created for sets of items that map to each of the three content areas.

Reference Tables 3 and 4 contain summative data for all first-time test takers from ACPE-accredited programs (2012). In table 3, scaled scores were ordered and divided into four equi-sized bins for the computation of quartile values. The column labeled "Top (1st) Quartile" applies to the highest scoring group of examinees. The column labeled "Bottom (4th) Quartile" applies to the lowest scoring group. Table 4 contains similar information but is based on pass/fail status of examinees.

**Reference Table 3 NAPLEX
Mean Area Score Summary (2012) by Quartiles**

	Top (1st) Quartile	2nd Quartile	3rd Quartile	Bottom (4th) Quartile
Mean Area 1 Scaled Score	13.82	12.91	12.22	11.29
Mean Area 2 Scaled Score	13.83	12.83	12.18	11.22
Mean Area 3 Scaled Score	14.33	13.34	12.74	11.86
Mean Overall Scaled Score	119.72	109.26	100.15	84.05
Scaled Score Range	[114, 137]	[105, 113]	[95, 104]	[10, 94]
# Examinees per bin	3,171	3,172	3,171	3,171

In the quartile table (above), the mean overall scaled score for the bottom quartile is 84.05 which is greater than the NAPLEX passing threshold of 75. Because the set of overall scaled scores is not normally distributed, the scores and subsequent interpretations should be evaluated carefully.

**Reference Table 4 NAPLEX
Mean Area Score Summary (2012) by Pass/Fail Status**

	Pass	Fail
Mean Area 1 Scaled Score	12.64	10.26
Mean Area 2 Scaled Score	12.60	10.25
Mean Area 3 Scaled Score	13.15	10.81
Mean Overall Scaled Score	104.72	64.05
Scaled Score Range	[75, 137]	[10, 74]
# Examinees per bin	12,243	443

**Table 5 North American Pharmacist Licensure Examination® (NAPLEX)®
Candidate Summary Report**

Test Window: September 1, 2013 - December 31, 2013

Candidate	Pass/Fail	Total Scaled Score	Area 1 Scaled Score	Area 2 Scaled Score	Area 3 Scaled Score	Test Date	Graduation Date	First Attempt
1	Pass	81	10	12	11	11/05/2013	05/11/2013	N
2	Pass	92	11	12	12	11/02/2013	05/11/2013	N
3	Pass	78	11	10	11	10/10/2013	05/11/2013	N
4	Pass	87	12	10	12	09/27/2013	05/11/2013	Y
5	Pass	103	12	13	11	09/11/2013	05/11/2013	Y
6	Pass	83	11	11	10	09/07/2013	05/11/2013	Y
7	Pass	95	12	13	11	09/23/2013	05/13/1978	Y

National Statistics for All NAPLEX Candidates

Mean Scaled Score: 87.03
Standard Deviation: 19.70
Range: 0 - 133
Passing Rate (%): 75.91

National Statistics for First-Time NAPLEX Candidates

Mean Scaled Score: 92.69
Standard Deviation: 18.21
Range: 22 - 133
Passing Rate (%): 84.46

The following tables are scaled score frequency distributions for NAPLEX candidates. Candidates who did not answer enough questions to receive a score are not reflected in the frequency distributions.

**National Frequency Distribution of Scaled Scores
Based on Total Tests Administered (N = 1864)**

Test Window: September 1, 2013 - December 31, 2013

Scaled Score	Frequency	Cumulative Percent of the Upper Limit of the Interval
0 - 4	2	0.1%
5 - 9	0	0.1%
10 - 14	0	0.1%
15 - 19	2	0.2%
20 - 24	4	0.4%
25 - 29	7	0.8%
30 - 34	7	1.2%
35 - 39	16	2.0%
40 - 44	15	2.9%
45 - 49	21	4.0%
50 - 54	31	5.7%
55 - 59	45	8.1%
60 - 64	87	12.8%
65 - 69	91	17.7%
70 - 74	114	23.8%
75 - 79	158	32.3%
80 - 84	187	42.4%
85 - 89	176	51.9%
90 - 94	214	63.4%
95 - 99	178	73.0%
100 - 104	132	80.1%
105 - 109	137	87.5%
110 - 114	109	93.3%
115 - 119	70	97.1%
120 - 124	34	98.9%
125 - 129	18	99.9%
130 - 134	2	100.0%
135 - 139	0	100.0%
140 - 144	0	100.0%
145 - 150	0	100.0%

National Frequency Distribution of Scaled Scores
Based on First-Time Candidates from ACPE-Accredited Programs (N = 1049)

Test Window: September 1, 2013 - December 31, 2013

Scaled Score	Frequency	Cumulative Percent of the Upper Limit of the Interval
0 - 4	0	0.0%
5 - 9	0	0.0%
10 - 14	0	0.0%
15 - 19	0	0.0%
20 - 24	2	0.2%
25 - 29	2	0.4%
30 - 34	1	0.5%
35 - 39	4	0.9%
40 - 44	4	1.2%
45 - 49	7	1.9%
50 - 54	9	2.8%
55 - 59	13	4.0%
60 - 64	34	7.3%
65 - 69	38	10.9%
70 - 74	46	15.3%
75 - 79	66	21.6%
80 - 84	95	30.7%
85 - 89	86	38.9%
90 - 94	125	50.9%
95 - 99	115	61.9%
100 - 104	101	71.5%
105 - 109	105	81.5%
110 - 114	86	89.8%
115 - 119	58	95.3%
120 - 124	31	98.3%
125 - 129	16	99.8%
130 - 134	2	100.0%
135 - 139	0	100.0%
140 - 144	0	100.0%
145 - 150	0	100.0%

North American Pharmacist Licensure Examination (NAPLEX)

University of Louisiana at Monroe

	2000			2001			2002			2003		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>
TOTAL CANDIDATE GROUP												
No. of Candidates	76	47	18	40	30	10	13	62	27	10	70	24
School Average Score:	96.51	91.62	88.61	88.93	87.30	87.00	82.85	100.24	89.56	78.40	101.44	92.50
State Average Score:	96.75	88.52	86.05	84.66	93.82	82.05	75.50	101.46	87.48	77.50	99.40	87.33
National Average Score:	91.78	99.86	91.21	90.25	101.70	90.50	90.81	101.21	90.02	91.50	101.40	89.40
School Pass Rate:	96.05	82.98	88.89	85.00	90.00	90.00	84.62	85.48	77.78	60.00	95.71	87.50
State Pass Rate:	92.50	78.57	77.27	75.86	89.29	70.00	50.00	85.90	70.37	62.50	94.90	80.00
National Pass Rate:	82.95	92.05	83.04	81.07	94.38	83.69	81.52	93.76	81.73	82.77	93.84	79.55
FIRST-TIME CANDIDATE GROUP												
No. of Candidates	71	33	9	37	20	6	13	61	20	2	64	16
School Average Score:	97.13	96.00	94.00	88.32	86.90	90.67	82.85	100.44	92.80	73.50	102.69	98.56
State Average Score:	97.49	93.61	87.77	88.78	95.92	85.93	81.89	103.71	91.15	74.00	100.41	92.38
National Average Score:	96.51	101.85	96.48	94.54	103.35	94.22	95.13	103.00	94.62	97.39	103.38	95.88
School Pass Rate:	95.77	96.97	100.00	83.78	85.00	100.00	84.62	85.25	75.00	50.00	96.88	100.00
State Pass Rate:	94.59	93.18	84.62	83.33	91.84	73.33	77.78	90.28	70.00	66.67	95.65	90.48
National Pass Rate:	91.44	95.44	91.39	87.91	96.75	90.10	89.27	96.74	88.52	91.47	96.54	89.64

North American Pharmacist Licensure Examination (NAPLEX)

University of Louisiana at Monroe

	2004			2005			2006			2007		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>
TOTAL CANDIDATE GROUP												
No. of Candidates	3	64	18	9	72	17	2	60	10	3	90	23
School Average Score:	85.67	105.30	94.83	82.67	104.17	101.65	98.00	113.17	95.80	107.67	117.27	101.57
State Average Score:	81.33	103.47	96.71	95.00	101.77	92.50	86.67	111.87	96.07	88.00	117.29	94.73
National Average Score:	92.13	102.16	91.70	91.32	104.85	87.72	86.89	107.02	93.18	89.95	113.33	94.18
School Pass Rate:	100.00	96.88	94.44	88.89	90.28	94.12	100.00	93.33	80.00	100.00	95.56	78.26
State Pass Rate:	83.33	96.12	100.00	100.00	87.83	78.57	77.78	89.17	79.31	63.64	95.52	74.51
National Pass Rate:	83.22	95.11	84.79	82.88	89.15	71.73	68.82	90.52	77.07	71.38	94.47	78.76
FIRST-TIME CANDIDATE GROUP												
No. of Candidates	2	58	17	5	70	11	2	58	4	3	89	19
School Average Score:	87.00	107.34	93.47	81.40	105.09	110.09	98.00	114.59	125.00	107.67	117.66	103.05
State Average Score:	84.00	105.61	99.73	101.50	103.64	98.94	93.33	112.95	95.41	103.40	118.18	95.00
National Average Score:	100.14	104.14	96.60	98.84	107.67	95.89	97.18	110.34	99.96	102.16	116.00	102.19
School Pass Rate:	100.00	100.00	94.12	80.00	91.43	100.00	100.00	94.83	100.00	100.00	95.51	78.95
State Pass Rate:	100.00	100.00	100.00	100.00	90.09	88.89	100.00	90.38	70.59	100.00	96.69	76.74
National Pass Rate:	95.07	97.38	92.22	91.31	92.86	82.12	81.12	94.49	84.74	84.09	97.23	88.12

North American Pharmacist Licensure Examination (NAPLEX)


University of Louisiana at Monroe

	2008			2009			2010			2011		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>
TOTAL CANDIDATE GROUP												
No. of Candidates	11	98	12	6	91	8	3	67	6	2	91	9
Mean Scaled Score - School	94.73	106.39	93.83	97.83	113.84	77.25	98.00	99.97	93.17	67.50	97.40	87.22
Mean Scaled Score - State	93.70	103.31	95.41	94.80	108.26	84.32	83.15	94.22	80.13		99.66	85.27
Mean Scaled Score - National	96.76	112.08	96.61	93.72	112.51	93.62	84.75	101.11	84.90	83.97	103.27	88.08
School Pass Rate:	90.91	92.86	83.33	83.33	95.60	50.00	100.00	95.52	100.00	0.00	89.01	77.78
State Pass Rate:	90.00	90.34	82.76	80.00	92.64	63.16	61.54	83.24	65.00		90.81	73.17
National Pass Rate:	83.11	95.48	81.96	76.40	95.03	78.20	65.07	92.39	72.20	67.85	94.16	76.57
FIRST-TIME CANDIDATE GROUP												
No. of Candidates	3	97	5	3	88	3	0	67	2	1	87	3
Mean Scaled Score - School	110.33	106.76	95.80	93.00	115.34	78.33	0.00	99.97	97.00	62.00	99.39	84.67
Mean Scaled Score - State	96.00	104.42	95.82	86.00	108.80	84.10	92.00	94.46	90.75		100.88	83.70
Mean Scaled Score - National	106.63	114.11	103.62	106.27	114.65	102.87	100.12	103.06	94.26	96.99	105.03	96.71
School Pass Rate:	100.00	93.81	80.00	66.67	96.59	33.33	0.00	95.52	100.00	0.00	93.10	66.67
State Pass Rate:	83.33	92.35	82.35	57.14	93.04	60.00	66.67	84.15	83.33		93.18	74.07
National Pass Rate:	92.24	97.44	90.66	90.76	97.50	89.51	88.38	95.31	86.71	87.50	96.57	89.24

North American Pharmacist Licensure Examination (NAPLEX)

University of Louisiana at Monroe

	2012			2013			2014			2015		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>
TOTAL CANDIDATE GROUP												
No. of Candidates	6	80	17	3	40	7						
Mean Scaled Score - School	75.33	97.14	85.41	92.00	100.45	88.43						
Mean Scaled Score - State	81.25	98.42	86.95	77.25	98.66	86.88						
Mean Scaled Score - National	83.15	102.81	88.15	80.17	102.78	87.03						
School Pass Rate:	83.33	92.50	82.35	100.00	90.00	100.00						
State Pass Rate:	68.75	93.82	76.19	55.56	92.95	81.82						
National Pass Rate:	68.33	95.21	77.86	61.07	94.65	75.91						
FIRST-TIME CANDIDATE GROUP												
No. of Candidates	2	80	9	3	38	4						
Mean Scaled Score - School	49.50	97.14	87.11	92.00	101.68	92.00						
Mean Scaled Score - State	84.00	99.47	91.00	80.75	99.30	88.33						
Mean Scaled Score - National	94.87	104.13	95.75	92.48	104.02	92.69						
School Pass Rate:	50.00	92.50	77.78	100.00	92.11	100.00						
State Pass Rate:	75.00	95.35	72.73	75.00	94.08	83.33						
National Pass Rate:	87.69	97.19	90.14	85.14	96.57	84.46						



**North American Pharmacist Licensure Examination® (NAPLEX) ®
School Summary Report**

Test Window: September 1, 2013 - December 31, 2013

School Name: Xavier University of Louisiana

This NAPLEX score report consists of two levels of scores: school-aggregated scores and individual candidate scores. Summary information is provided separately for first-time examinees from ACPE schools/colleges and for all examinees, regardless of repeater status and/or the educational institution.

Tables 1 and 2 contain school-specific as well as national pass rate information and mean area scores for each of the three main NAPLEX competency areas:

- Assess Pharmacotherapy to Assure Safe and Effective Therapeutic Outcomes (56%),
- Assess Safe and Accurate Preparation and Dispensing of Medications (33%), and
- Assess, Recommend and Provide Health Care Information that Promotes Public Health (11%).

Table 1 First-Time Candidates, ACPE-Accredited Programs Only

Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation	Area 1 Scaled Score Mean	Standard Deviation	Area 2 Scaled Score Mean	Standard Deviation	Area 3 Scaled Score Mean	Standard Deviation	
School	29	68.97	82.76	14.71	11.41	1.09	11.00	1.20	11.10	1.35
State	24	83.33	88.33	12.72	11.63	1.01	11.38	1.10	11.54	1.50
National	1049	84.46	92.69	18.21	11.99	1.24	11.74	1.39	12.11	1.71

Candidates who did not answer enough questions to receive a score are reflected in pass rate data as a fail but are not included in mean scaled score data.

Table 2 All Candidates

Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation	Area 1 Scaled Score Mean	Standard Deviation	Area 2 Scaled Score Mean	Standard Deviation	Area 3 Scaled Score Mean	Standard Deviation	
School	43	65.12	81.47	14.39	11.30	1.04	10.91	1.15	10.98	1.37
State	33	81.82	86.88	14.87	11.48	1.06	11.39	1.12	11.61	1.75
National	1864	75.91	87.03	19.70	11.64	1.28	11.45	1.42	11.59	1.80

Candidates who did not answer enough questions to receive a score are reflected in pass rate data as a fail but are not included in mean scaled score data.

Interpretation and Uses of Candidate Scores

At the candidate level, two sets of scores are produced: an overall, composite scaled score and individual area scores. Only overall scores are used to make pass/fail decisions. Area scores are intended to provide insight into areas of strength and weakness and can be used as a tool for self-assessment and subsequent remediation.

Area scores are numerical performance indicators for each of the three main competency areas of the NAPLEX. There are a total of three area scores, one per main competency area. Area scores are always reported on a scale of [6, 18], where a score of 6 is the lowest possible score and a score of 18 is the highest possible score. This reporting scale does not have a number-correct interpretation. In other words, a score of 6 does not mean that the candidate answered 6 questions correctly. Instead, area scores are computed from ability estimates that are created for sets of items that map to each of the three content areas.

Reference Tables 3 and 4 contain summative data for all first-time test takers from ACPE-accredited programs (2012). In table 3, scaled scores were ordered and divided into four equi-sized bins for the computation of quartile values. The column labeled "Top (1st) Quartile" applies to the highest scoring group of examinees. The column labeled "Bottom (4th) Quartile" applies to the lowest scoring group. Table 4 contains similar information but is based on pass/fail status of examinees.

**Reference Table 3 NAPLEX
Mean Area Score Summary (2012) by Quartiles**

	Top (1st) Quartile	2nd Quartile	3rd Quartile	Bottom (4th) Quartile
Mean Area 1 Scaled Score	13.82	12.91	12.22	11.29
Mean Area 2 Scaled Score	13.83	12.83	12.18	11.22
Mean Area 3 Scaled Score	14.33	13.34	12.74	11.86
Mean Overall Scaled Score	119.72	109.26	100.15	84.05
Scaled Score Range	[114, 137]	[105, 113]	[95, 104]	[10, 94]
# Examinees per bin	3,171	3,172	3,171	3,171

In the quartile table (above), the mean overall scaled score for the bottom quartile is 84.05 which is greater than the NAPLEX passing threshold of 75. Because the set of overall scaled scores is not normally distributed, the scores and subsequent interpretations should be evaluated carefully.

**Reference Table 4 NAPLEX
Mean Area Score Summary (2012) by Pass/Fail Status**

	Pass	Fail
Mean Area 1 Scaled Score	12.64	10.26
Mean Area 2 Scaled Score	12.60	10.25
Mean Area 3 Scaled Score	13.15	10.81
Mean Overall Scaled Score	104.72	64.05
Scaled Score Range	[75, 137]	[10, 74]
# Examinees per bin	12,243	443

**Table 5 North American Pharmacist Licensure Examination® (NAPLEX) ®
Candidate Summary Report**

Test Window: September 1, 2013 - December 31, 2013

Candidate	Pass/Fail	Total Scaled Score	Area 1 Scaled Score	Area 2 Scaled Score	Area 3 Scaled Score	Test Date	Graduation Date	First Attempt
1	Pass	89	11	11	13	10/08/2013	08/03/2013	Y
2	Pass	91	13	10	11	09/17/2013	08/03/2013	Y
3	Pass	114	14	13	12	09/04/2013	08/02/2013	Y
4	Fail	65	10	11	11	10/01/2013	06/29/2013	Y
5	Fail	59	11	8	11	09/27/2013	06/29/2013	Y
6	Fail	73	11	11	11	09/16/2013	06/29/2013	Y
7	Pass	78	11	11	10	09/10/2013	06/29/2013	Y
8	Pass	92	12	11	10	09/09/2013	06/29/2013	Y
9	Pass	96	12	10	14	09/03/2013	06/29/2013	Y
10	Pass	112	13	13	12	09/03/2013	06/29/2013	Y
11	Fail	74	12	9	10	12/17/2013	06/28/2013	N
12	Fail	57	10	9	9	11/02/2013	06/28/2013	Y
13	Pass	79	11	11	9	10/18/2013	06/28/2013	Y
14	Pass	103	13	13	10	09/10/2013	06/28/2013	Y
15	Fail	71	11	10	12	09/07/2013	06/28/2013	Y
16	Pass	92	12	12	13	09/23/2013	05/13/2013	Y
17	Pass	75	11	10	9	12/19/2013	05/11/2013	N
18	Pass	90	12	11	11	12/10/2013	05/11/2013	N
19	Fail	73	10	11	12	11/26/2013	05/11/2013	N
20	Fail	73	12	10	9	11/19/2013	05/11/2013	N
21	Pass	92	11	12	12	11/17/2013	05/11/2013	Y
22	Fail	51	10	9	8	11/12/2013	05/11/2013	N
23	Pass	97	12	12	11	11/07/2013	05/11/2013	N
24	Pass	99	12	12	12	11/06/2013	05/11/2013	N
25	Pass	98	12	12	11	10/30/2013	05/11/2013	N
26	Pass	85	11	11	13	10/17/2013	05/11/2013	N
27	Pass	78	11	11	10	10/09/2013	05/11/2013	N
28	Pass	87	12	11	11	10/04/2013	05/11/2013	Y
29	Pass	83	11	11	12	10/01/2013	05/11/2013	Y
30	Fail	66	10	10	10	09/27/2013	05/11/2013	Y
31	Fail	65	11	9	10	09/27/2013	05/11/2013	Y
32	Fail	65	10	10	9	09/20/2013	05/11/2013	Y
33	Pass	84	13	11	12	09/18/2013	05/11/2013	Y
34	Pass	93	12	12	10	09/11/2013	05/11/2013	Y
35	Pass	81	10	12	13	09/10/2013	05/11/2013	Y
36	Pass	83	12	11	10	09/07/2013	05/11/2013	Y
37	Pass	95	12	12	13	09/07/2013	05/11/2013	Y
38	Pass	89	11	12	11	09/03/2013	05/11/2013	Y
39	Fail	68	10	11	10	09/03/2013	05/11/2013	Y
40	Pass	78	11	11	11	09/03/2013	05/11/2013	Y
41	Pass	78	10	12	12	12/27/2013	05/12/2012	N
42	Fail	64	10	10	10	10/16/2013	05/12/2012	N
43	Fail	68	10	10	12	11/08/2013	05/07/2011	N

National Statistics for All NAPLEX Candidates

Mean Scaled Score: 87.03
Standard Deviation: 19.70
Range: 0 - 133
Passing Rate (%): 75.91

National Statistics for First-Time NAPLEX Candidates

Mean Scaled Score: 92.69
Standard Deviation: 18.21
Range: 22 - 133
Passing Rate (%): 84.46

The following tables are scaled score frequency distributions for NAPLEX candidates. Candidates who did not answer enough questions to receive a score are not reflected in the frequency distributions.

**National Frequency Distribution of Scaled Scores
Based on Total Tests Administered (N = 1864)**

Test Window: September 1, 2013 - December 31, 2013

Scaled Score	Frequency	Cumulative Percent of the Upper Limit of the Interval
0 - 4	2	0.1%
5 - 9	0	0.1%
10 - 14	0	0.1%
15 - 19	2	0.2%
20 - 24	4	0.4%
25 - 29	7	0.8%
30 - 34	7	1.2%
35 - 39	16	2.0%
40 - 44	15	2.9%
45 - 49	21	4.0%
50 - 54	31	5.7%
55 - 59	45	8.1%
60 - 64	87	12.8%
65 - 69	91	17.7%
70 - 74	114	23.8%
75 - 79	158	32.3%
80 - 84	187	42.4%
85 - 89	176	51.9%
90 - 94	214	63.4%
95 - 99	178	73.0%
100 - 104	132	80.1%
105 - 109	137	87.5%
110 - 114	109	93.3%
115 - 119	70	97.1%
120 - 124	34	98.9%
125 - 129	18	99.9%
130 - 134	2	100.0%
135 - 139	0	100.0%
140 - 144	0	100.0%
145 - 150	0	100.0%

National Frequency Distribution of Scaled Scores
Based on First-Time Candidates from ACPE-Accredited Programs (N = 1049)

Test Window: September 1, 2013 - December 31, 2013

Scaled Score	Frequency	Cumulative Percent of the Upper Limit of the Interval
0 - 4	0	0.0%
5 - 9	0	0.0%
10 - 14	0	0.0%
15 - 19	0	0.0%
20 - 24	2	0.2%
25 - 29	2	0.4%
30 - 34	1	0.5%
35 - 39	4	0.9%
40 - 44	4	1.2%
45 - 49	7	1.9%
50 - 54	9	2.8%
55 - 59	13	4.0%
60 - 64	34	7.3%
65 - 69	38	10.9%
70 - 74	46	15.3%
75 - 79	66	21.6%
80 - 84	95	30.7%
85 - 89	86	38.9%
90 - 94	125	50.9%
95 - 99	115	61.9%
100 - 104	101	71.5%
105 - 109	105	81.5%
110 - 114	86	89.8%
115 - 119	58	95.3%
120 - 124	31	98.3%
125 - 129	16	99.8%
130 - 134	2	100.0%
135 - 139	0	100.0%
140 - 144	0	100.0%
145 - 150	0	100.0%

North American Pharmacist Licensure Examination (NAPLEX)

Xavier College of Pharmacy

	2000			2001			2002			2003		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>
TOTAL CANDIDATE GROUP												
No. of Candidates	10	80	43	28	85	40	22	69	48	19	90	40
School Average Score:	77.60	87.99	81.67	76.50	93.14	85.15	76.00	93.23	86.98	79.42	94.46	84.33
State Average Score:	96.75	88.52	86.05	84.66	93.82	82.05	75.50	101.46	87.48	77.50	99.40	87.33
National Average Score:	91.78	99.86	91.21	90.25	101.70	83.69	90.81	101.21	90.02	91.50	101.40	89.40
School Pass Rate:	60.00	77.50	62.79	57.14	85.88	82.50	54.55	79.71	85.42	68.42	90.00	75.00
State Pass Rate:	92.50	78.57	77.27	75.86	89.29	70.00	50.00	85.90	70.37	62.50	94.90	80.00
National Pass Rate:	82.95	92.05	83.04	81.07	94.38	83.69	81.52	93.76	81.73	82.77	93.84	79.55
FIRST-TIME CANDIDATE GROUP												
No. of Candidates	1	77	23	10	74	29	8	63	40	8	83	26
School Average Score:	95.00	88.19	82.13	74.80	95.92	86.48	80.63	95.00	88.60	87.75	95.34	88.04
State Average Score:	97.49	93.61	87.77	88.78	95.92	85.93	81.89	103.71	91.15	74.00	100.41	92.38
National Average Score:	96.51	101.85	96.48	94.54	103.35	94.22	95.13	103.00	94.62	97.39	103.38	95.88
School Pass Rate:	100.00	77.92	65.22	50.00	90.54	82.76	75.00	84.13	90.00	87.50	90.36	80.77
State Pass Rate:	94.59	93.18	84.62	83.33	91.84	73.33	77.78	90.28	70.00	66.67	95.65	90.48
National Pass Rate:	91.44	95.44	91.39	87.91	96.75	90.10	89.27	96.74	88.52	91.47	96.54	89.64

North American Pharmacist Licensure Examination (NAPLEX)

Xavier College of Pharmacy

	2004			2005			2006			2007		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>
TOTAL CANDIDATE GROUP												
No. of Candidates	10	82	19	6	95	30	20	94	48	17	81	56
School Average Score:	76.40	98.99	91.68	83.00	98.92	73.07	72.15	106.20	92.81	74.18	109.07	86.77
State Average Score:	81.33	103.47	96.71	95.00	101.77	92.50	86.67	111.87	96.07	88.00	117.29	94.73
National Average Score:	92.13	102.16	91.70	91.32	104.85	87.72	86.89	107.02	93.18	89.95	113.33	94.18
School Pass Rate:	70.00	96.34	84.21	83.33	86.32	56.67	50.00	82.98	77.08	52.94	83.95	64.29
State Pass Rate:	83.33	96.12	100.00	100.00	87.83	78.57	77.78	89.17	79.31	63.64	95.52	74.51
National Pass Rate:	83.22	95.11	84.79	82.88	89.15	71.73	68.82	90.52	77.07	71.38	94.47	78.76
FIRST-TIME CANDIDATE GROUP												
No. of Candidates	2	79	10	3	90	19	5	87	31	3	68	46
School Average Score:	72.50	100.06	98.80	85.00	101.34	79.79	69.40	109.32	93.10	94.67	114.60	90.50
State Average Score:	84.00	105.61	99.73	101.50	103.64	98.94	93.33	112.95	95.41	103.40	118.18	95.00
National Average Score:	100.14	104.14	96.60	98.84	107.67	95.89	97.18	110.34	99.96	102.16	116.00	102.19
School Pass Rate:	50.00	98.73	100.00	66.67	88.89	68.42	40.00	86.21	77.42	100.00	92.65	71.74
State Pass Rate:	100.00	100.00	100.00	100.00	90.09	88.89	100.00	90.38	70.59	100.00	96.69	76.74
National Pass Rate:	95.07	97.38	92.22	91.31	92.86	82.12	81.12	94.49	84.74	84.09	97.23	88.12

North American Pharmacist Licensure Examination (NAPLEX)

Xavier College of Pharmacy

	2008			2009			2010			2011		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>
TOTAL CANDIDATE GROUP												
No. of Candidates	22	138	55	18	138	28	19	148	52	25	124	45
Mean Scaled Score - School	81.36	96.77	89.82	80.33	97.59	86.96	73.63	89.73	77.15	76.00	99.13	85.04
Mean Scaled Score - State	93.70	103.31	95.41	94.80	108.26	84.32	83.15	94.22	80.13		99.66	85.27
Mean Scaled Score - National	96.76	112.08	96.61	93.72	112.51	93.62	84.75	101.11	84.90	83.97	103.27	88.08
School Pass Rate:	68.18	81.88	76.36	61.11	83.33	71.43	42.11	75.00	59.62	64.00	87.10	75.56
State Pass Rate:	90.00	90.34	82.76	80.00	92.64	63.16	61.54	83.24	65.00		90.81	73.17
National Pass Rate:	83.11	95.48	81.96	76.40	95.03	78.20	65.07	92.39	72.20	67.85	94.16	76.57
FIRST-TIME CANDIDATE GROUP												
No. of Candidates	5	124	36	6	127	12	6	143	16	6	115	33
Mean Scaled Score - School	85.40	98.77	92.47	81.00	99.77	83.33	79.83	90.78	84.00	61.00	101.95	85.45
Mean Scaled Score - State	96.00	104.42	95.82	86.00	108.80	84.10	92.00	94.46	90.75		100.88	83.70
Mean Scaled Score - National	106.63	114.11	103.62	106.27	114.65	102.87	100.12	103.06	94.26	96.99	105.03	96.71
School Pass Rate:	80.00	84.68	80.56	50.00	86.61	66.67	50.00	76.92	75.00	16.67	92.17	81.82
State Pass Rate:	83.33	92.35	82.35	57.14	93.04	60.00	66.67	84.15	83.33		93.18	74.07
National Pass Rate:	92.24	97.44	90.66	90.76	97.50	89.51	88.38	95.31	86.71	87.50	96.57	89.24

North American Pharmacist Licensure Examination (NAPLEX)

Xavier College of Pharmacy

	2012			2013			2014			2015		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>
TOTAL CANDIDATE GROUP												
No. of Candidates	13	120	21	10	136	43						
Mean Scaled Score - School	76.69	95.13	83.24	68.67	95.13	81.47						
Mean Scaled Score - State	81.25	98.42	86.95	77.25	98.66	86.88						
Mean Scaled Score - National	83.15	102.81	88.15	80.17	102.78	87.03						
School Pass Rate:	46.15	90.00	61.90	40.00	86.03	65.12						
State Pass Rate:	68.75	93.82	76.19	55.56	92.95	81.82						
National Pass Rate:	68.33	95.21	77.86	61.07	94.65	75.91						
FIRST-TIME CANDIDATE GROUP												
No. of Candidates	3	111	12	1	131	29						
Mean Scaled Score - School	84.67	97.71	95.58	47.00	96.65	82.76						
Mean Scaled Score - State	84.00	99.47	91.00	80.75	99.30	88.33						
Mean Scaled Score - National	94.87	104.13	95.75	92.48	104.02	92.69						
School Pass Rate:	66.67	93.69	91.67	0.00	89.31	68.97						
State Pass Rate:	75.00	95.35	72.73	75.00	94.08	83.33						
National Pass Rate:	87.69	97.19	90.14	85.14	96.57	84.46						



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



Pharmacy Technician Certification Examination (PTCE™)

July 1 – December 31, 2013

Cumulative Record (since January 2000)

February 12, 2014

Pharmacy Technician Certification Examination (PTCE™)

This computer adaptive competency assessment is administered by the Pharmacy Technician Certification Board (PTCB). The examination blueprint is designed to assess the applicant's competency in basic pharmacy practice and is recognized by pharmacy regulatory authorities in most of the states and territories within the USA. The examination is administered via an open window process; applicants may schedule the examination at a designated testing center at any time following approval by PTCB and receipt of an Authorization to Test (ATT) document from PTCB. Individual scores are available to applicants immediately after the test; certificates are mailed to the applicant within 30 days following the examination. Summary reports are provided to the state boards on a semi-annual basis.

Table of Contents

Cumulative Report (since January 2000)

03

Louisiana Board of Pharmacy

Pharmacy Technician Certification Board (PTCB) Examination

	1995-1999									
<u>National Data</u>	<u>Data</u>	<u>3/25/2000</u>	<u>7/22/2000</u>	<u>11/18/2000</u>	<u>3/10/2001</u>	<u>7/14/2001</u>	<u>11/10/2001</u>	<u>3/16/2002</u>	<u>7/27/2002</u>	<u>11/16/2002</u>
No. of Candidates Attempting	58,382	8,101	12,317	12,941	8,442	12,057	10,608	8,874	13,399	11,521
No. of Candidates Passing	47,973	6,206	10,006	9,520	6,116	9,799	8,354	7,072	10,681	9,164
Passing Score										
Average Score										
Pass Rate	82%	77%	81%	74%	72%	81%	79%	80%	80%	80%
Louisiana Data										
No. of Candidates Attempting	514	141	346	327	187	310	324	269	383	308
No. of Candidates Passing	390	92	271	221	125	227	228	184	269	213
Average Score										
Pass Rate	76%	65%	78%	68%	67%	73%	70%	68%	70%	69%
<hr/>										
	2000-2002									
<u>National Data</u>	<u>Data</u>	<u>3/29/2003</u>	<u>7/26/2003</u>	<u>11/15/2003</u>	<u>3/20/2004</u>	<u>7/17/2004</u>	<u>11/13/2004</u>	<u>3/19/2005</u>	<u>7/23/2005</u>	<u>11/19/2005</u>
No. of Candidates Attempting	98,260	12,147	14,162	13,401	11,508	15,942	13,795	13,673	18,250	14,068
No. of Candidates Passing	76,918	9,506	11,720	11,006	9,100	12,196	10,818	11,009	14,246	10,583
Passing Score										650
Average Score										702
Pass Rate	78%	78%	83%	82%	79%	77%	78%	81%	78%	75%
Louisiana Data										
No. of Candidates Attempting	2,595	385	384	351	285	382	290	337	488	216
No. of Candidates Passing	1,830	294	286	271	211	281	214	274	351	167
Average Score										688
Pass Rate	71%	76%	74%	77%	74%	74%	74%	81%	72%	77%

Louisiana Board of Pharmacy

Pharmacy Technician Certification Board (PTCB) Examination

	2000-2005 Data	3/11/2006	7/22/2006	9/9/2006	11/18/2006	2000-2006 Data	2/5/2007 3/9/2007	4/24/2007 5/25/2007	8/27/2007 9/28/2007	11/26/2007 12/31/2007
National Data										
No. of Candidates Attempting	225,206	12,383	18,992	3,029	15,285	274,895	8,768	10,730	14,666	10,881
No. of Candidates Passing	177,102	8,559	12,609	2,006	9,145	209,421	6,034	7,487	10,497	7,472
Passing Score		650	650	650	650	650	650	650	650	650
Average Score		688	683	683	668					
Pass Rate	79%	69%	66%	66%	60%	76%	69%	70%	72%	69%
Louisiana Data										
No. of Candidates Attempting	5,713	288	420	59	312	6,792	216	306	266	207
No. of Candidates Passing	4,179	181	239	37	137	4,773	133	196	177	121
Average Score		673	664	685	641					
Pass Rate	73%	63%	57%	63%	44%	70%	62%	64%	67%	58%
<hr/>										
	2000-2007 Data	2/4/2008 3/14/2008	4/28/2008 6/20/2008	8/18/2008 10/10/2008	11/10/2008 12/19/2008	2000-2008 Data	1/1/2009 3/31/2009	4/1/2009 6/30/2009	7/1/2009 9/30/2009	10/1/2009 12/31/2009
National Data										
No. of Candidates Attempting	319,940	7,547	14,291	16,385	11,792	369,955	13,087	8,424	13,735	10,674
No. of Candidates Passing	240,911	5,165	10,155	11,781	7,770	275,782	9,141	6,363	10,067	7,682
Passing Score	650	650	650	650	650	650	650	650	650	650
Average Score										
Pass Rate	75%	68%	72%	72%	66%	75%	70%	76%	73%	72%
Louisiana Data										
No. of Candidates Attempting	7,787	128	392	304	215	8,826	301	260	238	218
No. of Candidates Passing	5,400	72	233	182	118	6,005	184	196	166	137
Average Score										
Pass Rate	69%	56%	59%	60%	55%	68%	61%	75%	70%	63%

Louisiana Board of Pharmacy

Pharmacy Technician Certification Board (PTCB) Examination

	2000-2009 Data	1/1/2010 3/31/2010	4/1/2010 6/30/2010	7/1/2010 9/30/2010	10/1/2010 12/31/2010	2000-2010 Data	1/1/2011 3/31/2011	4/1/2011 6/30/2011	7/1/2011 9/30/2011	10/1/2011 12/31/2011
National Data										
No. of Candidates Attempting	415,875	11,611	15,033	16,025	12,774	471,318	11,219	14,026	12,356	14,031
No. of Candidates Passing	309,035	8,521	11,216	12,349	9,275	350,396	8,366	10,472	9,565	10,826
Passing Score	650	650	650	650	650	650	650	650	650	650
Average Score										
Pass Rate	74%	73%	75%	77%	73%	74%	75%	75%	77%	77%
Louisiana Data										
No. of Candidates Attempting	9,843	217	421	320	268	11,069	247	437	268	257
No. of Candidates Passing	6,688	121	287	219	166	7,481	161	306	182	168
Average Score										
Pass Rate	68%	56%	68%	68%	62%	68%	65%	70%	68%	65%
<hr/>										
	2000-2011 Data	1/1/2012 3/31/2012	4/1/2012 6/30/2012	7/1/2012 9/30/2012	10/1/2012 12/31/2012	2000-2012 Data	Changed to semi-annual reports 1/1/2013 to 6/30/2013		7/1/2013 to 12/31/2013	
National Data										
No. of Candidates Attempting	522,950	11,851	14,356	14,375	11,180	574,712	25,448		28,797	
No. of Candidates Passing	389,625	9,232	11,044	10,982	8,471	429,354	19,581		21,745	
Passing Score	650	650	650	650	650	650	650		650	
Average Score										
Pass Rate	75%	78%	77%	76%	76%	75%	77%		76%	
Louisiana Data										
No. of Candidates Attempting	12,278	246	368	329	239	13,460	622		537	
No. of Candidates Passing	8,298	158	269	226	168	9,119	412		351	
Average Score										
Pass Rate	68%	64%	73%	69%	70%	68%	66%		65%	

HB 62 Pugh Health & Welfare
Provides relative to pharmacy record audits.
01-23-2014 Prefiled and referred to committee.

This measure seeks to amend the insurance law relative to audits of pharmacy records by third party payors.

HB 99 H. Burns Health & Welfare
Authorizes certain entities to supply and administer epinephrine auto-injectors.
02-05-2014 Prefiled and referred to committee.

This measure seeks to allow prescribers to issue prescriptions for epinephrine auto-injectors in the name of certain organizations and to allow dispensers to dispense such prescriptions to certain organizations and to allow certain individuals in those organizations to administer epinephrine auto-injectors to persons who appear to have need for the medication.

HB 103 Foil Administration of Criminal Justice
Increases penalties for distribution of narcotic Schedule I controlled substances.
02-05-2014 Prefiled and referred to committee.

This measure seeks to amend the existing criminal penalties for unlawful distribution of narcotic drugs listed in Schedule I. Since we include the controlled substance law in the pharmacy law book, passage of this bill will require an update in the pharmacy law book.

Resolutions

Concurrent Resolutions

Study Resolutions

Concurrent Study Resolutions

Senate

Bills

SB 9 Amedee Judiciary-C
Increases penalties for manufacture, distribution, or possession with intent to distribute heroin.
01-22-2014 Prefiled and referred to committee.

This measure seeks to increase the period of incarceration for heroin convictions, from not less than 5 nor more than 50, to a term of not less than 10 nor more than 99, years. Since we include the controlled substance law in the pharmacy law book, passage of this bill will require an update of the law book.

Resolutions

Concurrent Resolutions

Study Resolutions

Concurrent Study Resolutions



NABP Verified Pharmacy Program™

Providing a vital resource for the boards of pharmacy for use when making licensure and registration determinations.

In the wake of the New England Compounding Center (NECC) tragedy, member state boards of pharmacy spoke out very clearly about the need to build regulatory uniformity among the states and enhance the services offered by the National Association of Boards of Pharmacy® (NABP®). Due to the strength and leadership of its member boards, NABP had a strong foundation to rapidly build and deploy services to assist member boards in their charge to protect the public health. Building from a wide range of existing services – including license verification; the Electronic Licensure Transfer Program®; NABP Clearinghouse, which includes disciplinary information; accreditation; and inspection services – NABP developed the Verified Pharmacy Program™ (VPP™) to assist member boards in enhancing the licensure processes they already have in place.

What Is VPP?

VPP, or the Verified Pharmacy Program, is an inspection service and information sharing network the boards of pharmacy may use to share critical inspection and licensing data with their fellow boards. Similar to the Electronic Licensure Transfer Program for pharmacists, VPP also facilitates what could be described as the nonresident pharmacy licensure transfer process.



What Is VPP Meant to Accomplish?

VPP creates e-Profiles for each pharmacy and links these facility e-Profiles to key personnel e-Profiles, including those of the pharmacist-in-charge (PIC) in the state of domicile as well as any nonresident PICs.

The program is meant to enhance what the state boards of pharmacy are already doing in terms of determining qualifications for pharmacy licensure and ensure that the boards have complete and accurate information for making licensure decisions on nonresident pharmacies.

What Does Recognizing and/or Requiring VPP Mean for the Boards?

The boards can recognize VPP and/or require that nonresident pharmacies apply through VPP when seeking to obtain or renew licensure. If an e-Profile for the applicant does not already exist, one will be created and applicable alerts pertaining to that facility's disciplinary and inspection history will automatically be pushed to the board of pharmacy. Additionally, participating boards will have access to the e-Profiles and will have the capability to search for facilities by a variety of categories. The boards also have the ability to attach their own inspection reports and other documentation to the e-Profiles.

Recognizing and/or requiring VPP does not necessarily mean that the board is requiring that an inspection be conducted by NABP. When a VPP application from a pharmacy is received, NABP reviews and verifies the data submitted by the pharmacy. This includes any recent inspection reports, if available. Should an applicant submit a "qualified" inspection report and/or already have a qualified inspection report attached to the pharmacy e-Profile through the Inspection Clearinghouse, that pharmacy will not require a new inspection and all qualifying information will be pushed directly to the state board of pharmacy where the pharmacy is seeking licensure. In addition, the information will be provided to any other states where the pharmacy holds a license in order to provide supplemental data for the states to utilize when making licensing decisions.

If the applicant is found to not have a "qualified" inspection, an inspection will be scheduled through NABP. All VPP inspections are conducted by licensed pharmacists.

NABP provides all data directly to the applicable state boards of pharmacy and does not render any judgment on an applicant, as this authority is left to the state boards.



What Is a “Qualified” Inspection and What Inspection Forms Are Available?

A qualified inspection is one that has been conducted within the past 18-24 months, if the facility provides routine retail pharmacy services, or within the past 12 months if it provides compounding services, and includes the appropriate modules of inspection standards depending on the services provided.

The simple presence of an inspection by the state of domicile does not necessarily mean the nonresident facility meets nonresident states’ requirements. Further, if a facility has been performing sterile compounding, it is possible that it may not have been subjected to a thorough compliance inspection by a properly trained inspector in many years, if ever.



NABP recently convened a task force to compile licensure standards that are consistent across the states with the purpose of structuring a uniform inspection form. Drawing from the expertise provided during the task force meeting, this form is under development and will assist in further defining a qualified inspection. The form will continue to evolve to meet the states’ needs. In addition, NABP has worked to develop uniform compounding inspection forms using elements of several different states’ inspection forms that inspect to United States Pharmacopeia Chapter <795> and Chapter <797> as a minimum standard for compounding. These will also evolve to further meet the needs identified by the member boards of pharmacy.

NABP is also exploring the possibility of forming specialized working groups to develop inspection form modules based on the varying types of pharmacy services.

The uniform, qualified inspections can also be coupled with self-reported facility information in order to identify sterile compounding facilities.

What Are the Fees for VPP?

If recognizing and/or requiring VPP, and the board has the ability to pass the costs of an inspection along to the applicant/licensee, the board can direct nonresident pharmacies to NABP to begin the application process.

VPP applicants pay fees dependent on the type of pharmacy:

- Routine Retail: \$1,995
- Nonsterile Compounding or Large Mail Order: \$2,500
- Sterile Compounding or Institutional: \$3,000

If an applicant already has a resident state inspection deemed qualified through NABP processes, the applicant is refunded all but a \$500 processing fee. Pharmacies seeking licensure in multiple states will likely experience savings in inspection fees by avoiding costs associated with multiple state inspections.

For those states that must bear the costs of the inspections, NABP still recommends that states send their applicants through the VPP process and subsidize the inspection fee for the applicants. The Association may be able to work with the board on a discounted inspection fee.

The fees were developed based on estimates of NABP’s costs of performing inspections and other processing functions and are not intended to generate excess revenue. Any excess revenue will be used to support member boards of pharmacy through programs and services including, but not limited to, additional compliance training, the development of uniform inspection forms, and the development of other technology and tools to perform inspections.

For more information or to apply for VPP, visit www.nabp.net/programs/licensure/verified-pharmacy-program.

Or contact VPP staff via phone at 847/391-4406 or via e-mail at vpp@nabp.net.



National Association of Boards of Pharmacy
1600 Feehanville Drive, Mount Prospect, IL 60056
(P) 847/391-4406 • (F) 847/391-4502 • www.nabp.net



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ Facsimile 225.925.6499
www.pharmacy.la.gov ~ E-mail: info@pharmacy.la.gov



February 12, 2014

Agenda Item 11: Announcements

Feb. 25	Regulation Revision & Application Review Committees
Mar. 4	Mardi Gras Day – <i>Board office closed</i>
Mar. 10	Louisiana Legislature convenes
Mar. 12-13	Violations Committee
Mar. 20-21	MPJE Item Development Workshop – Mount Prospect, IL
Mar. 28-31	APhA Annual Meeting – Orlando, FL
April 9	Louisiana Pharmacy Congress Prescription Monitoring Program Advisory Council
April 18	Good Friday – <i>Board office closed</i>
April 26-29	NACDS Annual Meeting – Scottsdale, AZ
May 6	Reinstatement, Impairment, & Executive Committees
May 7	Reciprocity Committee & Board Meeting
May 8	Administrative Hearing
May 17-18	WHPA Regulation Conference – Geneva, CH
May 17-20	NABP Annual Meeting – Phoenix, AZ
May 22-24	LSHP Annual Meeting – New Orleans, LA
May 26	Memorial Day – <i>Board office closed</i>
May 31 – June 4	ASHP Summer Meeting – Las Vegas, NV

Remaining Board Meetings in Calendar Year 2014:

May 6-8
August 12-14
November 12-14